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It is well established that renal allograft recipients have an increased incidence of viral
warts and premalignant and malignant cutaneous lesions, and the risk of their
development increases in proportion to duration of graft survival. It has been
postulated that, in addition to the effects of prolonged immunosuppression and
previous sun exposure, human papillomaviruses may also contribute to the
carcinogenic process. In this study, the prevalence of human papillomavirus DNA was
examined in a range of premaligant and malignant cutaneous tumours from 52
immunosuppressed patients (49 renal allograft recipients plus 3 cardiac allograft
recipients) and 83 immunocompetent patients using Southern hybridisation analysis as
a low stringency screening method and type specific polymerase chain reaction (PCR)
assays for 8 human papillomavirus types. The combined results for renal allograft
recipients showed that human papillomavirus was detectable in 71% of viral warts,
43% of premaligant keratoses, 42% of intraepidermal carcinomas, 51% of invasive
squamous cell carcinomas and 14% of uninvolved skin specimens. The prevalence of
human papillomavirus DNA was significantly greater in squamous cell carcinomas
(p<0.02 x2 test) and intraepidermal carcinomas (p=0.05 %2 test) than in uninvolved
skin from renal allograft recipients. In immunocompetent patients, the pattern of
human papillomavirus prevalence was 100% for viral warts, 15% for keratoses, 20%
for intraepidermal carcinomas, 27% for squamous cell carcinomas and 8% for
uninvolved skin. No single human papillomavirus type predominated in tumour
specimens from either group. More tumours were found to contain human
papillomavirus DNA by Southern hybridisation analysis than by type specific PCR
indicating the presence of human papillomavirus types other than 1, 2, 5, 6, 8, 11, 16
and 18 in some tumours. This was confirmed in a small number of lesions found to be
human papillomavirus positive by Southern Hybridisation analysis that were further
typed by restriction digestion analysis. However, "low risk" human papillomavirus
types 1, 2 and 6 as well as "high cancer risk" types 5 and 16 were specifically detected
by PCR in a small number of neoplasms. These data suggest that multiple human
papillomavirus types may contribute to cutaneous neoplasia in renal allograft recipients
and that they appear to act early in the carcinogenic process, possibly by functioning as
tumour promotors via stimulation of cell proliferation.
This study also employed immunocytochemical techniques to investigate the
prevalence and localisation of accumulated p53 in over 200 cutaneous biopsies
(including 56 squamous cell carcinomas) from renal allograft recipients and
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immunocompetent controls. In renal allograft recipients, accumulated p53 was present
in 24% of uninvolved skin samples, 14% of viral warts, 41% of pre-malignant
keratoses, 65% of intraepidermal carcinomas, and 56% of squamous cell carcinomas
(intraepidermal carcinomas differed significantly from keratoses (p<0.05) and
squamous cell carcinoma and intraepidermal carcinoma differed significantly from
uninvolved skin (p<0.005) and viral warts (p<0.01)). A similar trend was revealed in
immunocompetent patients (an older, chronically sun-exposed population) but with
lower prevalence of p53 immunoreactivity: 25% of uninvolved skin samples, 0% of
viral warts, 25% of keratoses, 53% of intraepidermal carcinomas and 53% of
squamous cell carcinomas. These differences were not statistically significant.
Morphologically, p53 immunoreactivity strongly associated with areas of epidermal
dysplasia and the abundance of staining correlated positively with the severity of
dysplasia. These data suggest that p53 plays a critical role in skin carcinogenesis and is
associated with progression to the pre-invasive state. However, the prevalence of
accumulated p53 was similar in intraepidermal carcinomas and squamous cell
carcinomas indicating that other genetic events must occur prior to the development of
the invasive state. Single strand conformational polymorphism analysis (exons 5 to 8)
was used to determine the frequency of mutated p53 in 28 malignancies with varying
degrees of immunopositivity. p53 mutations were found in 5/9 (56%) malignancies
with p53 staining in >50 % of cells reducing to 1/6 (17%) where 10-50% of cells were
positively stained and none where <10% of cells were stained. These data imply that
factors other than p53 gene mutation play a part in the accumulation of p53 in skin
cancers. No correlation was observed between stabilised p53 and the presence of
human papillomavirus DNA in any of the lesions and p53 mutations were detected in
human papillomavirus positive (including human papillomavirus 5 and 16) and human
papillomavirus negative cancers. On the basis of the findings of this study, a model of






1: CUTANEOUS NEOPLASIA IN RENAL ALLOGRAFT RECIPIENTS
It is now well established that immunosuppressed allograft recipients are at an
increased risk of developing certain types of cancer (Sheil et al, 1985; Alloub et al,
1989; Barrett et al, 1993). Kaposi's sarcoma, non-Hodgkin's lymphoma and carcinoma
of the cervix, vulva and perineum, are especially prevalent. However, the most
common cancer occurring in renal allograft recipients (RARs) is squamous cell
carcinoma (SCC) of the skin (Hoxtell et al, 1977; Blohme & Larko, 1984; Sheil et al,
1985; Shuttleworth et al, 1987; McLelland et al, 1988; Hartevelt et al, 1990). Viral
warts (VWs) and SCC precursor lesions are also more prevalent in transplant patients
and form a continuous spectrum of cutaneous disease. Ultraviolet (UV) radiation and
immunosuppression are known to be important in the aetiology of SCCs in RARs and
there is evidence to suggest that human papillomaviruses (HPVs) may also play a
significant role. However, the biological mechanisms by which these aetiological
agents contribute to the neoplastic process of RARs, and their associated genetic
events, have yet to be elucidated.
1.1 EPIDEMIOLOGY AND PATHOGENESIS OF CUTANEOUS NEOPLASIA IN RARS
The development of SCCs in RARs is a serious clinical problem and is proving to be
one of the major long term complications of renal transplantation. The incidence
increases logarithmically with the duration of immunosuppression and is highest in
Caucasian transplant patients living in tropical or subtropical climates. In a large series
reported from Southern Australia, 25% ofRARs surviving 9.9 years and 50% of those
surviving 20 years developed SCCs (Dyall-Smith et al, 1991), whereas in South East
Scotland Barr et al (1989) found 2% of RARs with a graft life of 5 years or less and
13% of patients with a graft life of 5 to 22 years were affected by cutaneous SCCs. In
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one other study from the Netherlands, the overall risk of developing a first skin cancer
increased from 10% after 10 years to 40% after 20 years of graft survival (Hartevelt et
al, 1990). Squamous cell carcinomas from RARs tend to be more aggressive, have a
higher potential for local recurrence and metastasise more frequently than those from
age-matched, immunocompetent controls (Hoxtell et al, 1977; Benton et al, 1992;
Blohme & Larko, 1984; Hartevelt et al, 1990; Sheil et al,1985). In some series, 13% of
SCC from RARs have been reported to metastasise and deaths from cutaneous SCCs
were 10 times higher than expected in these patients (Rowe et al, 1992). Some RARs
exhibit multiple skin cancers which may recur soon after surgery, presumably because
of the widespread dysplastic change which is evident in the sun-exposed skin of these
patients (Figure 1.1A) (Benton et al, 1992). Atypical histological features, such as an
overall verrucous architecture, hyperkeratosis and perinuclear halo formation, which
are usually associated with viral infection, are often observed in SCCs from RARs
indicating a possible viral contribution (Figure 1.1B) (Blessing et al, 1989). Basal cell
carcinomas (BCCs) are also observed in RARs, however, the increase in SCCs with
immunosuppression is significantly greater than BCCs. Indeed, the ratio of BCCs to
SCCs is reversed in RARs from the 3:1 to 7:1 seen in the immunocompetent
population to 1:1.2 to 1:3 in immunosuppressed patients (Rudlinger et al, 1986; Barr
et al, 1989; Hartevelt et al, 1990; Benton et al, 1992).
Squamous cell carcinomas are commonly preceded by the development of VWs in
RARs. In contrast to such lesions from immunocompetent patients (ICPs), VWs may
be extensive, intractable and cause severe morbidity in allograft recipients (Figure
1.2A) (Rudlinger et al, 1986; Rudlinger & Grob, 1989; Bunney et al, 1992; Benton et
al, 1992). As with skin cancer, they are more prevalent in patients with high sun
exposure and usually occur on sun exposed body sites (Boyle et al, 1984; Shuttleworth
et al, 1987). Although the incidence increases with the duration of immunosuppression
(eg. Barr et al, (1989) reported a 77% incidence of VWs in patients with graft survival
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of 5 to 22 years), VWs may appear just months after transplantation and are a
recognised risk factor for skin cancer development (Mclelland et al, 1988; Barr et al,
1989; Blessing et al, 1989). Many of the warts observed in RARs have a typical clinical
appearance. However, those arising on sun exposed body sites are often atypical and
may be difficult to distinguish from pre-malignant keratoses or SCCs on clinical
grounds alone (Bunney et al, 1992; Ledo, 1992). These VWs may also show unusual
histopathological features including epithelial dysplasia and the typical papuliferous
architecture associated with HPV infection (Figure 1.1B and C) (Blessing et al, 1989;
Barr et al, 1989).
Actinic keratoses, which are the most common precursor lesions to intraepidermal
carcinomas (IECs) and SCCs, are also more prevalent in RARs and are often
widespread, involving both sun exposed and covered areas (Blohme & Larko, 1984;
Shuttleworth et al, 1987; Mclelland et al, 1988; Marks et al, 1988 and 1992; Dodson et
al, 1991; Kwa et al, 1992; Bouwes Bavinck et al, 1993a). It is in such areas of
widespread keratoses that SCCs frequently arise (Figure 1.1 A). Histologically, actinic
keratoses from RARs often have a papillomatous (viral) architecture and show more
severe epidermal dysplasia (sometimes approximating that seen in IEC) as compared to
similar lesions from ICPs (Figure 1.1D). (Blessing et al, 1989; Hardie et al, 1980).
Intraepidermal carcinomas (Bowen's disease) have a long latency period in ICPs and
only a small proportion of patients go on to develop frankly invasive SCC (Braverman,
1991; Johnson et al, 1992; Kwa et al, 1992). By contrast, IECs from RARs are much
more aggressive and undergo accelerated progression to SCC (Blohme & Larko,
1984; Mclelland et al, 1988; Shuttleworth et al, 1987; Bouwes Bavinck et al, 1993a).
Anogenital cancer is also a major clinical problem and a more frequent cause of death
than skin cancer in transplant patients (Rudlinger et al, 1986; Halpert et al, 1986;
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Figure 1.1. (A) Severe actinic damage with warts, keratoses and several foci of
squamous cell carcinoma on the scalp of a 45-year-old man who had received a renal
transplant 20 years previously. (B) Invasive squamous cell carcinoma (right) showing
an overall verrucous architecture and hyperkeratosis, in continuity with typical fronds
of a viral wart (left). (C) High power (x40) of B showing perinuclear haleo-formation
(which is a typical cytological feature of viral infection) along side severely dysplastic
cells (D) Extensive keratoses and warts arising in a background of sun damaged skin
on the dorsum of the hand of a male allograft recipient. Although many of these lesions
showed dysplasia, none were malignant.
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Figure 1.1;- Clinical AndHistological FeaturesOf Cutaneous Lesions
FromRenalAllograft Recipients
Alloub et al, 1989). In one study from the South East of Scotland, a significantly
increased prevalence of cervical intraepithelial neoplasia was found in RARs (49%)
compared with a control group of patients (10%) (Alloub et al, 1989). The detection
of HPV 16 and 18 was also more common in RARs. Some of the long standing
allograft recipients included in Alloub's series developed invasive SCC of the cervix,
vulva and anal canal, as well as intraepithelial neoplasia and anogenital warts.
1.2 :■ AETIOPATHOGENF.SIS OF CUTANEOUS NEOPLASIA IN RARS
Both host and environmental factors have been implicated in the development of skin
cancer in RARs. Age, skin type and HLA class I and II antigens are all considered to
influence host susceptibility to skin cancer while solar radiation, immunosuppressive
therapy and viral infection are believed to be the most important environmental risk
factors.
1.2.1 Host Factors
The high incidence of skin neoplasia among fair skinned RARs, especially those of
Irish, Scottish and English descent, suggests that host skin pigmentation strongly
influences susceptibility to the development of SCCs and VWs in RARs (Mclelland et
al, 1988; Dyall-Smith et al, 1991; Bouwes Bavinck et al, 1993a). A correlation between
age and incidence of skin neoplasia has also been demonstrated (Blohme & Larko,
1984). However, this is probably more strongly linked to the number of years on
immunosuppressive therapy and the cumulative level of UV exposure.
The major histocompatability complex (MHC) contains a large number of polymorphic
genes that encode the class I (HLA-A,B,C) and II (HLA-Dr,Dq,Dp) antigens which
play an important role in the cellular immune response to viral and tumour antigens
(Browning & Bodmer, 1992). HLA associated susceptibility exists for several kinds of
viral related malignancies including Kaposi's sarcoma (HLA-Dr5), Burkit's lymphoma
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(HLA-A1.-B12 and -Dr7) and cervical carcinoma (HLA-Dqw3) (Jones et al, 1980;
Scorza et al, 1986; Wank & Thomssen, 1991). A negative association between HLA-
All and carcinoma of the cervix has also been reported (Wank & Thomssen, 1991). It
has recently been demonstrated that HLA-A11 has a protective effect against skin
cancer in RARs whereas HLA-Dr7, HLA-B27 and HLA-Dqw2 are associated with an
increased risk of developing SCCs (Bouwes Bavinck et al, 1991a and b and 1993b;
Glover et al, 1993). Furthermore, HLA-DR homozygosity and HLA-B mismatching
are significantly associated with an increased risk of SCC in RARs (Bouwes Bavinck et
al, 1991a). These data indicate that there may be an inherited susceptibility to skin
cancer development involving genes in the class I and II regions of MHC. Recent
studies have also demonstrated that susceptibility to the immunosuppressive effects of
UYB radiation may be genetically determined (Yoshikawa et al, 1990).
1.2.2 Environmental Factors: Solar Radiation
The association between human skin cancer and sun exposure has been recognised
since the 19th century. The preferential localisation of cutaneous neoplasia on sun
exposed skin and the increase in incidence nearer the equator, strongly suggest an
important role for sunlight in the pathogenesis of skin disorders in RARs (Boyle et al,
1984; Dyall-Smith et al, 1991; Shuttleworth et al, 1987; Hartevelt et al, 1990).
Indeed, numerous studies have demonstrated a highly significant association between
sun exposure and skin cancer in both RARs and ICPs (Vitalliano & Urbach, 1980;
Marks, 1992; Johnson et al, 1992; Kwa et al, 1992). Cumulative lifetime exposure to
UV radiation has been shown to be important in the development of skin cancers,
whereas the development of keratotic skin lesions (including VWs) is thought to be
connected with recent episodes of sun burn (Bowes Bavinck et al, 1993a). Solar
radiation may enhance the development of cutaneous neoplasia by two distinct
mechanisms: as a direct carcinogen and as an immunosuppressant (Kripke, 1984;
Brash et al, 1991; Yoshikawa et al, 1990; Streilein, 1991). Although UVB light (290
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to 320 nm) is the most carcinogenic wavelength, its effects are augmented by UVA
light (320 to 400 nm) which acts as a co-carcinogen. The carcinogenic effects ofUV
radiation result directly from the absorption of UV light by DNA. The UV induced
photoproducts (principally cyclobutane pyrimidine dimers and 6-4 pyrimidine-
pyrimidone photoproducts) are potentially mutagenic if located within oncogenes or
tumour suppressor genes (McGregor et al, 1991; Brash et al, 1991).
Epidermal Langerhans cells play a critical role in initiating the local immune response
against virally infected cells and skin cancers (Streilein, 1991; Baadsgaard, 1991; Cruz
& Bergstresser, 1989). Low doses of UVB have been shown to deplete mouse
epidermis of the surface markers on Langerhans cells and reduce the total number of
these cells (Aberer et al, 1981; Stingl et al, 1981). Most murine tumours induced by
UV radiation are highly immunogenic and are rejected when transplanted into normal
syngeneic mice. However, when such tumours are transplanted into UV irradiated
mice, the tumours grow progressively (Fisher & Kripke, 1977). This unresponsiveness
is due to the appearance of antigen specific suppressor T lymphocytes (and thus
systemic immunosuppression) following high doses ofUV radiation (Ullrich & Kripke,
1984). Urocanic acid is a major UV absorbing component of the stratum corneum
which undergoes a trans to cis isomerization on absorption of UV. The induction of
cis-urocanic acid is also associated with systemic immunosuppression of UV irradiated
mice (Noonan & De Fabo, 1992). Although most of these studies have been carried
out on experimental animals, more recent data suggests that UV radiation can alter
immune function in humans in a similar fashion (Baadsgaard, 1991).
1.2.3 Environmental Factors: Immunosuppression
Epidermodysplasia verruciformis (EV) is a rare inherited skin disorder which is
associated with specific defects of the cell mediated immune response and the life-long
presence of multiple, persistent VWs (Fuchs & Pfister, 1990). In addition, 30%-50%
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of EV patients develop cutaneous SCCs (Orth et al, 1979; Pfister et al, 1983a; Orth,
1986). Viral warts and skin cancers are also more prevalent in patients with other
genetically determined conditions associated with defects of the immune system
(Briggaman & Wheeler, 1979; Barnett et al, 1983). Similarly, HPV infection is a
common occurrence in therapeutically immunosuppressed, non-transplant patients
(Benton et al, 1992). These data provide circumstantial but compelling evidence that
immunosuppression plays a major role in the neoplastic process of RARs. Further
evidence that immunosuppression is contributing to the development of at least VWs
in RARs comes from the observation that extensive VWs may resolve rapidly when
graft rejection occurs and immunosuppressive drugs are withdrawn (Figure 1.2A and
B) (Benton et al, 1992). It is presently unknown whether a similar reversal of the
malignant process occurs following graft rejection, although, limited data suggests that
the development of cutaneous cancers may at least slow down (Benton et al, 1992).
The increased incidence of both VWs and skin cancers in RARs and other
immunosuppressed patients suggests that immunosuppression may contribute to
cutaneous carcinogenesis by allowing persistence of viral infection.
1.2.4 Environmental Factors: Viral Infection
Renal allograft recipients have a marked increase in malignancies that may be
associated with viral infection such as carcinoma of the cervix (HPV), B-cell
lymphoma (Epstein Barr virus (EBV)), and Kaposi's sarcoma (EBV) (Birkeland, 1983;
Sheil et al, 1985; Alloub et al, 1989; Penn, 1991; Barrett et al, 1993). Although there is
a strong association between the number of warts and the occurrence of SCCs in
RARs (skin cancers having the histological appearance of a viral associated lesion) it
has not yet been clarified whether viral infection is also contributing to the










































1.3 MOLECULAR EVENTS ASSOCIATED WITH CUTANEOUS CARCINOGENESIS
1.3.1 Genetic Abnormalities In Cutaneous Neoplasia
The ras gene family is made up of three closely related genes (Ha-ras, Ki-ras and N-
ras) which encode membrane bound proteins with intrinsic GTPase activity.
Transforming ras mutations, mainly in codons 12, 13 and 61, appear to be common
events in a large variety of human tumours. Although the majority of reports suggest
that ras gene mutations are rare events in skin carcinogenesis (Campbell et al, 1993c;
Mukhtar & Bickers, 1993), Ha-ras codon 12 mutations have been demonstrated in
46% of cutaneous SCCs in one series (Pierceall et al, 1991b).
DNA aneuploidy has been found in 25% to 80% of cutaneous SCCs (Frentz & Moller,
1983; Newton et al, 1987; Randall et al, 1990). Actinic keratoses and IECs may also
be aneuploid but they demonstrate intralesional variation in chromosome number (or
DNA index) suggesting origin from multiple cell clones with varying DNA content
(Frentz & Moller, 1983). In contrast, SCC cell populations demonstrate little or no
variation in aneuploid number/DNA index which supports origin from one cell clone
(Frentz & Moller, 1983; Newton et al, 1987). Consequently, it has been proposed that
selection and dominance of a single cell clone in epidermal pre-cancers is associated
with the emergence of tumour invasion (Kwa et al, 1992).
1.3.2 p53 And Cutaneous Carcinogenesis
One of the putative major biological roles for p53 is to prevent replication of genomes
that have suffered DNA damage through induction of growth arrest and/or apoptosis
in response to cell injury (Lane et al, 1992 and 1993). It therefore seems likely that p53
may play an important role in the skin where epidermal keratinocytes are continually
exposed to the damaging effects of UV radiation. Although p53 mutations have been
extensively investigated in a wide range of human cancers, the role of p53 in cutaneous
carcinogenesis of RARs and ICPs has yet to be elucidated. The biological and
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biochemical properties of p53 and its role in cancer development will be discussed in
Section 3 of the introduction.
1.3.3 Mouse Model Of Skin Carcinogenesis
Information regarding the cellular and genetic mechanisms involved in the initiation
and progression of human cutaneous neoplasia is presently limited. However, a number
of the genetic events associated with different stages of the mouse 2-step model of
cutaneous carcinogenesis have been characterised. This model provides a useful
comparison in the interpretation of data derived from investigations into human skin
cancer.
Initial treatment of mouse skin with a subcarcinogenic dose of a carcinogen such as
dimethylebenzanthracene (DMBA), induces a population of initiated cells. Subsequent
treatment with a non-carcinogenic promoting agents (such as phorbol esters)
selectively expands the population of initiated cells and benign papillomas develop
within three months. A proportion of these lesions spontaneously progress to
malignant carcinomas. Therefore, this system possesses at least three well defined
stages: initiation, promotion and progression (Yuspa et al, 1986 and 1991; Bowden &
Krieg, 1991; Burns et al, 1991).
Initiation occurs rapidly, is irreversible and is commonly caused by mutagens.
Although initiated cells persist throughout the lifetime of the animal, they do not
develop into tumours without further treatment. Point mutation and/or amplification of
the c-Ha-ras oncogene has been demonstrated in more than 90% of DMBA initiated
mouse tumours (Quintanilla et al, 1986). This mutation is found in both papillomas and
carcinomas suggesting that c-Ha-ra.s activation occurs early in tumour development
(Balmain et al, 1984; Harper et al, 1987; Burns et al, 1991).
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Tumour promotion in mouse skin is a complex process in which many of the
biochemical changes are reversible (Hennings et al, 1984). Several applications of
tumour promoter are usually required before papillomas form and in some cases,
papillomas will regress when the promoter is withdrawn (dependent papillomas)
(Hennings et al, 1984; Yuspa et al, 1985). The phorbol ester class of tumour
promoters were traditionally used in mouse skin carcinogenesis protocols and are
therefore the most extensively characterised (Scribner et al, 1983; Hennings & Yuspa,
1985; Fujiki et al, 1991). Phorbol esters activate protein kinase C and have the ability
to stimulate the proliferation of some epidermal cells and induce differentiation of
others (Hartley et al, 1985 and 1987). The net result of this heterogeneous response to
promoting agents is the expansion of the proliferative population of cells at the
expense of the differentiating population with each promoter exposure. Initiated cells
are resistant to differentiation induced by phorbol esters and are therefore at a growth
advantage (Kulesz-Martin et al, 1983; Hennings et al, 1984). Based on this data, it has
been proposed that phorbol ester-mediated promotion involves changes in the growth
and maturation kinetics of the skin, which leads to selective clonal expansion of
initiated cells and papilloma formation.
Malignant conversion is a relatively rare event that occurs late in the mouse model of
carcinogenesis (Bowden & Kreig, 1991). In vivo, it is often a variable process that is
preceded by progressive dysplastic changes. The introduction of certain oncogenes
(such as neu) into papilloma cell lines accentuate the dysplastic epidermal changes in
the resultant tumours in vivo but these tumours do not convert to malignancy (Dotto
et al, 1988). Several lines of evidence suggest that a single genetic change is sufficient
to cause malignant conversion in mouse skin carcinogenesis. Activating mutations in
the proto-oncogene c-fos and the tumour suppressor gene p53 have been closely
linked with this stage (Greenhalgh et al, 1990; Kemp et al, 1993).
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1,3,4 Human Skin CarQinpggn^i? Anfl RAR$
The spectrum of cutaneous neoplasia observed in RARs, which progresses from benign
VWs through increasing severities of dysplasia to invasive SCCs, makes this an ideal
model in which to investigate the role of viruses, oncogenes and tumour suppressor
genes at different stages of human skin carcinogenesis. Investigation of the putative
roles of HPV and p53 in cutaneous carcinogenesis of RARs forms the basis of this
thesis and these will be considered in more detail in the subsequent sections.
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2: PAPILLOMAVIRUSES AND CANCER
2.1 Virion Properties And Classification
Papillomaviruses (PVs) are a genus of DNA viruses that specifically infect squamous
epithelia, inducing cellular proliferation and subsequently tumours of the skin or
mucosa. Although these tumours, called papillomas or warts, are often benign, certain
members of the PV family are associated with the development of malignant tumours
(Arends et al, 1990; Chang, 1990; Quan & May, 1991; Howley, 1991).
Papillomavirus virions are made up of a central core of closed circular, double stranded
DNA of approximately 8 Kb, encapsulated in an outer protein shell of 72 capsomeres.
Unlike some other DNA viruses they have no outer envelope. They are classified
according to the host species they infect and their degree of nucleic acid homology
with known PV types, as measured by hybridisation in the liquid phase (de Villiers,
1989). For a PV to be recognised as an independent type, the nucleotide sequence of
its E6, E7 and LI open reading frames (ORFs) must share less than 90% sequence
homology to sequences of other PV types (Van Ranst et al, 1994). Over 70
independent HPV types have been identified to date which can be grouped according
to the site of their associated lesions (Table 1.1).
2.2 Human Papillomavirus Infection
Direct access to the basal layer of differentiating epithelium is thought to be necessary
for a productive HPV infection to be established (Schneider, 1993). This occurs most
commonly through microlacerations or by direct contact with basal cells at the
transformation zone of the cervical squamo-columnar junction. The productive life
cycle of the virus is highly dependent on the environment provided by differentiating
keratinocytes and there is evidence that HPV can modify this keratinocyte maturation
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Table 1.1:- Human Papillomavirus Types Grouped According To The
Site Oe Thf.tr Associated Lesions
Site Group HPV Type
Skin Al 1




EV B I 5*, 8*, 9, 12, 14#, 17#>
19, 20#-25, 36-38, 46, 47,
49
B II 50
Mucosa And CI 6, 11, 13, 44
Specialised Skin CII 16*, 31#








Classification of the first 50 HPV types (except HPV 40 and 48) by site of infection
and overall DNA sequence homology (Arends et al, 1990). The sites of viral infection
are A = skin; B = skin of epidermodysplasia verruciformis (EV) patients; C = various
mucosa and specialised skin (cervix, vulva, anogenital region, upper respiratory tract
and digestive tract). * = HPV types strongly associated with malignant tumours;
# = HPV types suggested to have malignant potential or cloned from a cancer.
(Bedell et al, 1991). Early viral genes are expressed in the lower epithelial layers and
regulate viral DNA synthesis, whereas the expression of capsid proteins and packaging
of viral genomes is limited to the most highly differentiated upper layers (Sterling et al,
1990; Bedell et al, 1991; Meyers et al, 1992). Infectious viral particles may be released
through expression of the viral E4 protein which has been shown to destabilise the
intracellular cytokeratin network (Doorbar et al, 1991). Understanding of the
pathogenesis of PV infection has been limited by the inability to propagate these
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viruses in tissue culture. However, a collagen raft culture system containing cells
derived from an HPV31b infected high grade epithelial dysplasia, has recently allowed
the production ofHPV 31 b viral particles in the upper epithelial layers (Meyers et al,
1992). HPV 11 and 16 viral particles have also been produced using mouse xenograft
systems (Kreider et al, 1987; Sterling et al, 1990). More data on the synthesis and
assembly of virions and viral interactions with differentiating keratinocytes can be
expected from studies using these and other experimental systems.
2.3 PAPILLOMAVIRUSES AND CANCER
The role ofPV in the aetiology of epithelial neoplasias was first demonstrated in early
studies of the cottontail rabbit PV (CRPV) where 25% of CRPV-induced skin tumours
in domestic rabbits progressed to malignancy (Lancaster & Olson, 1982). The first
association of HPV with a form of human cancer was reported in skin cancers from
patients with EV (Jablonska et al, 1972). More recently, the causative role ofHPV in
the induction of anogenital cancers has been documented and it is at this site that most
information relating to the oncogenic potential ofHPV has been generated (Arends et
al, 1990; Chang, 1990; Quan & May, 1991; Howley, 1991; Zur Hausen, 1989 and
1991).
2.3.1 Anogenital Cancer
Many epidemiological surveys have demonstrated that early age at first coitus, multiple
sexual partners and poor sexual hygiene are risk factors for the development of
cervical cancer, implying that a sexually transmitted agent is a causal factor in the
aetiology of this malignancy (Schneider, 1993; Brinton, 1992). It has also been
demonstrated that wives of men with penile cancer have elevated rates of cervical
cancer providing further epidemiological evidence that an infectious agent may be
involved (Smith et al, 1980). The observation that cervical cancer often occurs in
association with condylomata acuminata (genital warts), which are known to be caused
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by HPV, provides further circumstantial evidence that HPV may play an aetiological
role (Brinton et al, 1990; Palefsky et al, 1990). The first definitive evidence associating
HPV with cervical cancer was the observation that the morphological abnormalities
constituting cervical dysplasia are frequently associated with koilocytosis, which is the
cytopathic manifestation of an HPV infection (Meisels & Fortin, 1976). Since these
initial studies, numerous HPV prevalence studies have demonstrated HPV DNA in
high proportions of cervical intraepithelial neoplasia (CIN) and squamous cervical
cancers (Pater et al, 1986; Arends et al, 1991 and 1993; Zur Hausen, 1991; Lorincz et
al, 1992).
It may be argued that HPV have a predilection for infecting CIN and are passengers
rather than effectors in the carcinogenic process. Evidence to the contrary is provided
by the fact that different HPV types are associated with specific anogenital lesions.
Over 25 anogenital HPV types have so far been identified (Table 1.1) and these can be
classified as either "low risk" or "high risk" based on the malignant potential of their
associated genital tract lesions. The low risk types 6 and 11 are commonly associated
with benign genital warts and low grade dysplasia (CIN 1) whilst the high risk HPV
types 16 and 18 have been detected in association with up to 80% of high grade
dysplasias (CIN 2 and 3) and up to 90% of invasive carcinomas (Pater et al, 1986;
Arends et al, 1991 and 1993, Zur Hausen, 1991; Lorincz et al, 1992). Furthermore,
there is an increase in the prevalence of the high risk HPV types and a corresponding
decrease in the prevalence of the low risk HPV types with progression through the
spectrum of condyloma, CIN (with increasing degrees of dysplasia), in situ and
invasive carcinoma. Therefore, there is strong evidence in support of a causal role for
certain types ofHPV in the development of anogenital cancer.
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2.3.2 HPV. Cutaneous Cancer And Epidermodysplasia Verruciformis
Over 20 of the 70 recognised HPV types have been found in cutaneous neoplasms
from patients with EV (Table 1.1). These patients suffer from extensive, debilitating
VWs, pityriasis versicolor-like lesions, flat-topped wart-like plaques and in situ and
invasive SCCs (Ostrow et al, 1982; Orth, 1986; Yabe et al, 1989; Fuchs & Pfister,
1990). A large range of HPV types have been isolated from the VWs of these patients
but two specific types, HPV 5 and 8, have been found in up to 90% of SCCs (Orth et
al, 1979; Pfister et al, 1981 and 1983a). Malignant transformation of VWs has also
been observed in 25-30% of cases and HPV 5 DNA has been detected in metastatic
SCC from EV patients (Ostrow et al, 1982; Yabe et al, 1989). These data provide
strong evidence that high risk, skin-associated HPV types play a major role in
cutaneous carcinogenesis in EV patients.
2.3.3 HPV And Cutaneous Carcinogenesis In Renal Allograft Recipients
Clinical and histological evidence suggest that HPV may be a contributory factor in
cutaneous carcinogenesis of RARs (see Section 1.1 of the Introduction). Furthermore,
similarities exist between RARs and EV patients in that both have an increased
incidence of VWs and skin cancers on sun exposed sites, and both have a depressed
cell mediated immune system. However, investigations into the prevalence of HPV in
skin malignancies of RARs have been inconclusive, with EV associated types and a
variety of common cutaneous and genital HPV types being identified in some but not
all studies (Lutzner et al, 1980 and 1983; Rudlinger et al, 1986; Van der Leest et al,
1987; Barr et al, 1989; Rudlinger & Grob, 1989; Dyall-Smith et al, 1991; Soler et al,
1992; Euvrard et al, 1993). Furthermore, the potential role of the virus in the
cutaneous neoplastic process of RARs is presently incompletely understood.
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2.4 biology of Papillomaviruses
A causal role for HPV in the aetiology of anogenital cancer and cutaneous cancer from
EV patients, as implied by epidemiological and prevalence studies, is supported by
investigations into the molecular biology of the virus. These studies also provide
information on the mechanisms by which HPV may contribute to the carcinogenic
process.
2.4.1 Genome Structure And Function
Sequence analysis of a number ofPV genomes has revealed that all PV types exhibit a
similar overall organisation (Baker, 1987; Ward et al, 1989; Sousa et al, 1990). The
genome is divided into a number of ORFs which are all contained on a single coding
strand of DNA (Figure 1.3). The other DNA strand contains only small, unconsented
ORFs that are likely to be non-coding (Heilman et al, 1980). The early (E) region
contains eight ORFs which code for proteins associated with genome replication and
control. The late (L) region contains two large ORFs coding for the structural proteins
of the viral capsid. The upstream regulatory region (URR) lies between the stop codon
of LI and the start codon of E6 and contains the promotor and enhancer elements
required for regulation of viral transcription and replication. Functions were initially
assigned to the ORFs using BPVI as a model system. However, information on the
transcriptional and functional organisation ofHPV has more recently become available.
LI and L2
LI and L2 ORFs code for the viral structural proteins and are only expressed in
terminally differentiated keratinocytes (Baker et al, 1987; Matlashewski, 1989, Sousa
et al, 1990). The LI ORF is the most highly conserved viral gene and codes for the
major capsid protein which has an average molecular mass of 56KDa (Hjorth &
Moreno-Lopez, 1982). This protein carries the major antigenic determinants for group
specific cross reactivity within different groups of PVs (Nakai, 1987). L2 codes for a
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protein of similar size but is one of the most poorly conserved viral proteins (Danos et
al, 1983). Sequence analysis indicates that the L2 proteins fall into 3 homologous






The open reading frames (ORFs) of the coding strand of HPV8. Early (E) region
ORFs code for proteins associated with viral replication and control of viral gene
expression. Bovine papillomavirus and some anogenital HPV types have an additional
E5 ORE, however, no ORF equivilent to E5 has been identified in EV-associated HPV
types. The late (L) region contains two large open reading frames coding for the
structural proteins of the viral capsid. The upstream regulatory region (URR) contains
the promotor and enhancer elements required for regulation of viral transcription and
replication.
group: fibropapilloma producing (BPV-1), cutaneous (cottontail rabbit PV (CRPV),
HPV la) and mucosal (HPV 6b, 11, 16 and 18) (Baker, 1987). Antigenic determinants
carried by L2 do not cross react with antisera from any other PV, even within the same
group ofhomology (Komly et al, 1986).
El and E2
The full length El ORF is highly conserved among PV and encodes a 68KDa
phosphoprotein with ATP dependent, helicase activity (Giri & Danos, 1986; Sousa et
al, 1990; Lambert, 1991; Thorner et al, 1993). The El protein is essential for BPV1
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extrachromosomal DNA replication and deletion or mutation results in viral integration
into the host cell genome (Spalholz et al, 1993a and b). In addition to its positive
replication function, the El protein of BPV1 is also capable of inducing transcriptional
repression through the formation of a tight complex with the E2 transactivator protein
(Sandler et al, 1993). El mRNA has been identified in cervical biopsies containing
non-integrated HPV 16 DNA which suggests that the El protein may also be involved
in replication of episomal DNA in HPV (Shirasawa et al, 1988). However, a 70KDa
El protein has been identified in Hela cells which contain integrated HPV 18 DNA
(Seedorf et al, 1987), implying that the El protein may have additional functions in
HPV.
The transcriptional activation and repression of viral genes by different versions of the
E2 gene product comprises one of the most important regulatory circuits of PV gene
expression and appears to be a property shared by all PV types (Cripe et al, 1987; Chin
et al, 1988; Ward et al, 1989; McBride et al, 1991; Lambert, 1991; Spalholz et al,
1993b). The BPV1 model has been used most extensively to characterise the products
of the E2 ORE (Sousa et al, 1990; Lambert, 1991). E2 from BPV1 encodes 3 site
specific, DNA binding proteins involved in transcriptional regulation of the viral
genome (Monini et al, 1993; Lambert et al, 1989b)). The full length BPV1 E2 encodes
a 48KDa protein which functions as a transcriptional activator (E2_Ta) (Spalholz et al,
1985; Androphy et al, 1987; Haugen et al, 1987; Lambert et al, 1989b). Two other
polypeptides also encoded by the BPV1 E2 ORF are truncated forms of the E2 protein
lacking the N-terminal transactivation domain. One of these is a 31KDa protein termed
E2-Tr which specifically represses trans-activation by the full length E2 and is the most
abundant of the 3 proteins (Lambert et al, 1987 and 1989b; McBride et al, 1988;
Hubbert et al, 1988).
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Less is known about the HPV E2 polypeptides. All the HPVs so far sequenced encode
a full length E2 polypeptide analagous to the BPV1 transactivating protein (McBride
et al, 1991). However, in contrast to BPV1, the major promotors of HPV 16 and 18
are repressed by the full length E2 protein (Thierry & Yaniv, 1987; Bernard et al,
1989; Romanczuk et al, 1990a and b). It is thought that the binding of E2 to two E2
binding sites adjacent to the TATA box of the promotors interferes with the assembly
of the transcription complex (Romanczuk et al, 1990a). Disruption of the E2 ORF
during viral integration has been implicated as a mechanism for HPV 16 or 18 induced
carcinogenesis (see Section 2.5.4 of the Introduction) (Lazo et al, 1992; Krajinovic et
al, 1993). The E2-Tr repressor protein or other truncated versions of E2 have not yet
been identified for HPV. However, the C-terminal region of both the HPV 16 and
HPV 11 E2 ORFs have the coding capacity for a repressor function similar to BPV-1
E2-Tr (Cripe et al, 1987; Chin et al, 1988).
E4
The role of the E4 protein in the PV life cycle is still unclear. The RNA message
formed from a single splice between the beginning of the El and E4 ORFs codes for
the 17 KDa E1AE4 fusion protein which is the most abundant protein in HPV induced
lesions (Breitburd et al, 1987; Zur Hausen, 1991; Steele et al, 1993). Up to 8 E4
protein species have been isolated from HPV 1 induced warts which appear to be
specific for different layers of the epidermis and are thought to represent proteolysis
products of the major E1AE4 protein (Breiturd et al, 1987). A similar complexity of E4
protein species has also been identified in HPV 2, HPV 4 and BPV 1 induced lesions
and HPV 11 induced experimental tumours. The localisation and abundance of E4 in
the more differentiated layers of the epithelia suggests that this is a late protein and
may have a role in virion maturation. An association between HPV 16 E4 and the
collapse of the cytokeratin network has recently been demonstrated suggesting that E4
may aid virion release through disruption of the cellular cytokeratin matrix (Doorbar et
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may aid virion release through disruption of the cellular cytokeratin matrix (Doorbar et
al, 1991). It has also been suggested that regulation of E4 expression throughout viral
infection could modulate epithelial differentiation to favour different stages of the PV
life cycle (Roberts et al, 1993).
E5
The E5 ORF of BPV1 is responsible for 95-99% of the BPV-1 in vitro transforming
activity (Yang et al, 1985; Campo et al, 1989; Horwitz et al, 1989; Sousa et al, 1990).
This gene encodes a membrane bound, hydrophobic 7KDa protein which is found
within cells primarily as a 15KDa homodimer (Schlegel et al, 1987). All transformation
competent E5 mutants retain the ability to associate with the cellular membrane and to
form dimers, revealing the importance of these functions in transformation (Spalholz,
1993). BPV1 E5 protein is also known to complex with both the 16KDa component of
the vacuolar ATPase and the activated platelet derived growth factor receptor as a
trimeric complex (Goldstein et al, 1991 and 1992).
The role of E5 in HPV induced lesions has yet to be elucidated. The E5 proteins from
HPV types 6 and 11 share several structural similarities with BPV1 E5 and HPV types
6 and 16 E5 proteins exhibit transforming activity when assayed on NIH 3T3 and
CI27 cells (Chen & Mounts, 1990; Leechanachai et al, 1992). A recent study
demonstrated that HPV 6 and 16 E5 proteins, like BPV 1 E5, are localised to cellular
membranes and bind the 16KDa pore-forming protein component of vacuolar ATPase
(Conrad et al, 1993). No ORF with homology to E5 has been identified in the EV-
associated HPV types 5 and 8 (Fuchs & Pfister, 1990; Kiyono et al, 1992).
Upstream Regulatory Region (URR1
The length of the URR varies between PV species but it has several conserved regions
and maintains a similar overall organisation (Ward et al, 1989). The upstream region is
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of the virus in infected cells, whereas the downstream end contains several promotor
elements (TATA and CAAT boxes) for polymerase II binding and many repeats and
inverted repeats commonly found in viral control regions (Waldeck et al, 1984;
Howley, 1991). Also within the 5' region is the E2 enhancer/repressor which consists
of at least 2 tandem repeats of the E2 binding motif (Lambert & Spalholz, 1987).
EV-associated E1PV types seem to have a subgenus-specific organisation of the URR
(Krubke et al, 1987; Ensser & Pfister, 1990). Sequence analysis of the URR of HPV
types 5, 8, 19 and 25 has revealed that it is surprisingly short with a number of
conserved features unique to EV-associated HPV types. There are four palindromic E2
binding sites, one binding site for the transcription factor jun/APl, a series of more
than 25 AT dimers and a number of additional motifs that are highly conserved among
HPV 8 related HPV types (Ensser & Pfister, 1990). A number of features in the URR
have been identified which separate different EV-associated HPV types into three
groups. These groups do not correlate with the oncogenic activity of the HPV types,
as measured by their detection in SCCs ofEV patients.
2.5 CF.I.I/tJI.AR TRANSFORMATION BY HPV
Analysis of the biological functions of viral genes expressed in human tumours and
manipulation of these genes in animal and human cell lines, has been used to support a
role for HPV in cancer. These investigations have established E6 and E7 as oncogenes,
found that high risk and low risk HPV types differ in their in vitro transforming activity
and determined mechanisms by which E6 and E7 from the high risk genital HPV types
may function.
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2.5.1 Transformation By E6 And E7 From Genital Tract Associated HPV Types
E6 and E7 constitute the major transforming proteins of HPV. The E6 and E7 ORFs
encode small nuclear proteins that bind zinc through conserved cystein motifs at their
COOH-terminal end (Baker, 1987; Vousden, 1993). E6 contains two zinc binding
motifs whereas E7 contains only one (Figure 1.4). Neither protein has structural
similarities to any cellular genes although structural and functional similarities exist
between E6 and E7 and oncoproteins encoded by other DNA viruses such as
adenovirus and SV40 (Phelps et al, 1988). Although both proteins are poorly
conserved in genital tract associated HPV types, E6 from high risk, EV associated
HPV types show over 70% homology (Kiyono et al, 1992).
Figure 1.4:- HPV E6 And E7 Proteins
HPV 16 E6
HPV 16 E7
Schematic representation of HPV 16 E6 and E7 proteins showing the cys x x cys zinc
binding motifs (Vousden, 1993). The E6 protein is comprised of 151 amino acids (aa)
whereas E7 contains 93aa.
DNA isolated from cervical carcinomas has been shown to transform the immortalised
rodent fibroblast cell line NIH 3T3, as has DNA isolated from the high risk genital
HPV types (Zur Hausen, 1989; Matlashewski, 1989; Linder & Marshall, 1990;
39
Munger & Phelps, 1993). Early transfection experiments demonstrated that the E6 and
E7 ORFs are responsible for this in vitro transforming activity (Matlashewski et al,
1987; Yutsudo et al, 1988). More recent investigations into the transforming
properties of single HPV genes have shown that E7 from HPV 16 is sufficient to
transform NIH 3T3 cells, can immortalise primary baby rat kidney (BRK) cells and can
cooperate with activated c-Ha-ras to fully transform these cells (Phelps et al, 1988;
Munger & Phelps, 1993). The E6 proteins from HPV 16 show similar but weaker
transforming activities while E6 and E7 from low risk HPV types have no, or very
weak transforming potential in the same transformation assays (Storey et al, 1988;
Sedman et al, 1991).
Although transfection experiments using rodent cell systems have been useful in
establishing the oncogenicity ofHPV, they may not be a good model for the biological
events occurring in human cells. Further experiments using primary human
keratinocytes have demonstrated that the introduction of HPV 16 or 18 DNA into
primary human genital epithelial cells results in immortalisation, aneuploidy and
reduced growth factor requirement (Hashida & Yasumoto, 1991). Expression of both
E6 and E7 were required for this immortalisation, although the individual oncoproteins
demonstrated reduced immortalising activity when expressed from a strong
heterologous promoter (Munger et al, 1989; Hawley-Nelson et al, 1989; Sedman et al,
1991). These experiments were the first clear demonstration that E6 from high risk
genital HPV types can function as an oncoprotein. HPV immortalised keratinocytes
may be fully transformed by the introduction of an activated ras oncogene, herpes
simplex virus-2 sequences or continuous passage over time (Matlashewski et al, 1987
and 1989; Munger & Phelps, 1993). Furthermore, when grown in organotypic raft
culture, HPV 16 and 18 immortalised keratinocytes show defects in differentiation and
morphologically resemble high grade, pre-cancerous, intraepithelial lesions (Dipaolo et
al, 1989; Hurlin et al, 1991). E6 and E7 from low risk HPV types show no
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transforming activities in any of these assays (Barbosa et al, 1991). These studies
support the epidemiological evidence that infection with high risk HPV types gives rise
to CIN and suggest that the cellular changes are a result of the activities of the E6 and
E7 genes.
Research is now focused on the mechanisms by which E6 and E7 from high risk genital
HPV types function. Recent studies have demonstrated that at least some of their
transforming activity is related to their ability to complex with cellular proteins, in
particular, the products of tumour suppressor genes.
2.5.2 Interaction Of E6 and E7 from Genital Tract Associated HPV Types With
Cellular Proteins
E7
The retinoblatoma (RB) gene is deleted or mutated in many human tumours or tumour
cell lines and loss of this gene product (pRB) correlates with increased cell
proliferation and oncogenesis (Levine & Momand, 1990). E7 from high risk genital
HPV types has been shown to complex with pRB and the related protein pi05 (Figure
1.5) which is thought to contribute to the development of HPV associated cancers
(Munger & Phelps, 1993; Dyson et al, 1989 and 1992; Vousden, 1993). This
hypothesis is supported by a small study which demonstrated an inverse relationship
between the presence ofRB mutations and HPV DNA in anogenital cancer cell lines,
suggesting that E7 expression results in loss of RB function in HPV positive cancers
(Scheffner et al, 1991). More recent studies have provided a mechanism by which
E7/pRB complexes may stimulate cell proliferation and contribute to anogenital
carcinogenesis. E7 has been shown to displace host cellular proteins that are usually
bound to pRB such as c-myc and the transcription factor E2F (Rustigi, 1991;
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Chellappan et al, 1992). In vitro expression of E7 results in an increase in free,
transcriptionally active E2F which may ultimately result in increased activity of E2F
promotors and unscheduled progression through the cell cycle.
Figure 1.5:- AssociationOf HPV E7 ProteinWithCellularProteins
HPV 16 E7 and known associated cellular proteins (not to scale) (Vousden, 1993).
These associations probably occur at different stages of the cell cycle. Some of the
residues of E7 that have been shown to be important for transforming activity are
illustrated, including the two phosphorylated serines (S) and three amino acids in the
Rb binding region (D, C and E). The aspartic acid (D) in the Rb binding domain is only
found in the high risk HPV E7s and substitution of this amino acid into the
corresponding position in HPV 6 E7 enhances both its RB binding and transforming
ability. Substitution of the second amino acid (H) at the NH2 terminal of E7 destroys
the transforming ability of the protein without affecting Rb binding.
Additional support for the importance of the E7/pRB interaction in oncogenesis has
come from studies using directional mutagenesis. The presence of the high affinity
HPV 16 E7 pRB binding site has been found to be the major determinant for the
oncogenic potential of the E7 protein in transformation assays (Figure 1.5) (Heck et al,
1992). E7 mutants that do not bind pRB cannot disrupt the E2F complexes or
cooperate with insulin to induce DNA synthesis (Pater et al, 1992; Takami et al, 1992).
Furthermore, they have a very weak transforming activity measured by ras co¬
operation in BRK cells. The E7 proteins from the high risk genital HPV types have
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been shown to bind pRB with a 10-fold higher affinity than the E7 proteins from the
low risk HPV types (Munger et al, 1989; Barbosa et al, 1990; Heck et al, 1992;
Munger & Phelps, 1993). This difference is due to a single amino acid sequence in the
pRB binding site (Figure 1.5). A single point mutation substituting the amino acid
sequence from low risk HPV E7 to an amino acid sequence common to high risk HPV
E7 is able to increase the binding affinity of HPV 6 E7 to pRB and also increase its
transforming activity in rodent cell assays (Heck et al, 1992; Sang & Barbosa, 1992).
As well as initiating cell proliferation by interfering with pRB-associated block on the
cell cycle, E7 has also been shown to function later in the cell cycle, allowing the cell
to proceed through G2 into mitosis and cell division. Although the activity of E7
necessary for this function has not yet been identified, the E7 protein has been shown
to associate with a cyclin dependent kinase 2 (cdk2) specifically during this stage of
the cell cycle (Figure 1.5) (Davies et al, 1993; Tommasino et al, 1993). The cyclin
dependent kinases are important regulators of cell cycle progression, therefore
perturbation of cyclin A and cdk2 may interrupt the normal regulation of entry into
mitosis.
E6
In vitro studies have demonstrated that E6 binding results in the rapid proteolytic
degradation of the p53 oncoprotein through a ubiquitin dependent pathway (Werness
et al, 1990; Scheffner et al, 1990 and 1992). As loss or mutation of wild type p53
contributes to the development ofmany human tumours, the interaction ofE6 and p53
is probably an important step in the progression of most cervical malignancies. The
protein interaction between E6 and p53 will be discussed further in Section 3.4 of the
Introduction.
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2.5.3 Cellular Transformation By E6 and E7 Of EV-Associated HPV Types
In contrast to the high risk genital HPV types, a number of studies have demonstrated
that E6 is the major transforming gene ofEV associated HPV types and that E7 from
these HPV types has little or no transforming activity.
HPV types 5 and 8 and less frequently EtPV types 14, 17, 20 and 47 have been
detected in SCCs from EV patients (Fuchs & Pfister, 1990). The E6 genes from HPV
types 5, 8 and 47 have been shown to induce anchorage independence and reduced
serum requirements in established rodent cells such as C127, 3Y1 and Rat-1 (Watts et
al, 1984; Iftner et al, 1988; Deau et al, 1991; Kiyono et al, 1992). However, the
resultant cells are not tumourigenic in nude mice. E6 genes from HPV types 14, 20, 21
and 25 have also been shown to partially transform the immortalised 3Y1 cell line
although none were able to induce foci formation in soft agar or produce tumours in
nude mice (Kiyono et al, 1992). These data suggest that E6 genes from EV associated
HPV types are more weakly oncogenic than those from high risk, genital tract
associated HPV types. In keeping with this hypothesis, it has been demonstrated that
E6 from HPV 8 does not complex with p53 in vitro (Steger & Pfister, 1992). The
above HPV types can be divided into two clusters depending on their malignant
potential in vivo, their transforming activity in vitro and the amino acid sequence of
their E6 protein (Kiyono et al, 1992). HPV types 5, 8 and 47 are in the first cluster and
are classified as highly oncogenic on the basis that they are frequently found in skin
cancers from EV patients (Orth, 1986). By contrast, HPV types 14, 20, 21 and 25
have infrequently (HPV 14 and 20) or never (HPV 21 and 25) been found in skin
cancers and are classified as poorly oncogenic (Fuchs & Pfister, 1990). It has been
demonstrated that the HPV types in the second cluster have weaker transforming
activity in vitro and exhibit differences in the amino acid sequence of their E6 protein,
largely in the second zinc finger motif (Figure 1.4). These data imply that the primary
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structure of the second zinc finger of E6 may influence the transforming activity of
EV-associated HPV types.
Initial investigations found that the E7 gene ofHPV 8 does not transform established
rodent cells in vitro and furthermore, does not complex with pRB (Iftner et al, 1988
and 1990). However, a more recent study demonstrated that E7 from HPV types 5 and
8 can cooperate with activated ras to transform primary BRK cells and complex with
pRB in vitro (Yamashita et al, 1993). HPV 8 E7 operates at a lower efficiency than
HPV 5 E7 in these transformation assays and binds pRB with a lower affinity. Because
the amino acid sequence ofE7 from the two HPV types is very similar, the reasons for
this difference remain unclear. The discrepancy between this and other studies may be
due to the level of E7 expression in the transfection assays. Further studies are
therefore required to clarify the importance of the E7 gene in transformation by EV-
associated HPV types.
2.5.4 Genomic Integration Of HPV DNA
The integration ofHPV DNA into the cellular genome is a common event in malignant
progression of genital tract lesions (Howley, 1991; Chang, 1990; Fukushima et al,
1990; Cullen et al, 1991; Lazo et al, 1992). Viral DNA is usually integrated in high
grade dysplasias and carcinomas but is present in episomal form in benign and low
grade pre-malignant lesions (Fukushima et al, 1990; Cullen et al, 1991). Although no
specific integration sites have yet been shown in the host cell DNA, the integration site
in the viral DNA appears to be highly specific, usually occurring in the E1/E2 ORFs
(Lazo et al, 1992). This leads to the disruption of the E2 ORE repressor functions
which may allow over-expression of the E6 and E7 oncoproteins, thus promoting the
development of cervical neoplasia (Krajinovic et al, 1993). Chromosome 8q24 is a
documented integration site and contains at least 4 loci implicated in tumourigenesis
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including c-myc (Lazo et al, 1992). Disruption of cellular oncogenes provides another
mechanism by which integration may contribute to cervical carcinogenesis.
Contrasting with HPV associated genital cancers, integration of viral sequences has
only been reported in one EV skin cancer (Yabe et al, 1989). This was an HPV 5
infected skin cancer metastasis in which the major viral DNA species was a 40%
subgenomic fragment. This fragment contained the URR and the E6 and E7 ORFs,
implying that these regions are important in HPV associated skin carcinogenesis. The
presence of episomal DNA with deletions has been more frequently reported in EV
cancers, usually disrupting the late region (Yabe et al, 1989; McDeau et al, 1991).
These modifications may result in the deregulation of viral gene expression, playing a
similar role to integration in the progression ofEV tumours.
2.5.5 Additional Events Required For Malignant Progression
Several lines of evidence suggest that additional events are required for the
development of HPV-associated anogenital and skin cancers. First, there is a long
latency period between infection and the development of malignancy (Howley, 1991).
Second, a co-carcinogen is easily identified in many PV related cancers such as UV
radiation in EV skin cancers and bracken fern in bovine alimentary tract carcinomas
(Fuchs & Pfister, 1990, Pennie & Campo, 1992; Schneider, 1993). Finally, HPV types
16 and 18 require activated ras or other events for complete cellular transformation in
vitro (Phelps et al, 1988; Munger & Phelps, 1993). Further investigations into the
genetic events associated with these additional factors may provide insight into how
they cooperate with HPV to bring about carcinogenesis.
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3: THE P53 TUMOUR SUPPRESSOR GENE
3,1 P53 AND CARCINOGENESIS
3.1.1 p53 Mutations And 17p Deletions In Sporadic Human Tumours
p53 gene mutations are the most commonly observed genetic lesion in human cancers,
occurring in over 50% of colon (Nigro et al, 1989; Baker et al, 1989 and 1990;
Cunningham et al, 1992), lung (Nigro et al, 1989; Iggo et al, 1990; Henzel et al, 1992),
breast (Nigro et al, 1989; Varley et al, 1991), bladder (Sidransky et al, 1991),
hepatocellular (Brassac et al, 1991) and stomach (Tamura et al, 1991) carcinomas,
which account for most neoplasms observed in humans. Deletions of the short arm of
chromosome 17 (17p), harbouring the p53 locus, are also a frequent event in human
tumours and have been demonstrated in over 60% of colon, breast, lung, ovarian,
cervical, adrenocortical, bone and bladder cancers (Mackay et al, 1988; Delattre et al,
1989; Weston et al, 1989; Baker et al, 1990; Tsai et al, 1990; Carder et al, 1991;
Eccles et al, 1992; Busby-Earle et al, 1993). In 75-80% of cases, 17p deletions and
p53 point mutations occur simultaneously, resulting in inactivation of both alleles of
the p53 gene (Nigro et al, 1989; Baker et al, 1990; Levine et al, 1991; Stratton et al,
1992). Allelic losses, accompanied by inactivation of the remaining allele through
localised point mutation, usually indicates the presence of a tumour suppressor gene
(Knudson, 1971). Therefore, these data indicate that p53 acts as a tumour suppressor
gene and that inactivation of this gene is a critical event in human carcinogenesis.
3.1.2 Germline d53 Mutations
Three systems in which there are germline abnormalities of the p53 gene, support the
hypothesis that mutations in this gene are a causal event in carcinogenesis. Li-Fraumeni
syndrome is a rare, familial predisposition to cancer that is transmitted in an autosomal
dominant manner (Li & Fraumeni, 1969). The syndrome is characterised clinically by
sarcomas in children with female relatives who have a high incidence of breast cancer.
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Leukaemia, brain, lung and adrenal cortical tumours constitute less common features
of the syndrome. Li-Fraumeni patients carry one wild type and one mutant p53 in their
genome which does not appear to interfere with the developmental processes or
normal cellular functions (Malkin et al, 1990; Strivastava et al, 1990; Borressen et al,
1992). In cancers, the mutant allele is retained and expressed, but the wild type allele is
most commonly lost via deletion or, in a minority of cases, gene conversion. Thus, it
has been proposed that the germline mutations in p53 predispose Li-Fraumeni patients
to cancer since somatic mutation/deletion need only occur in one allele for a cell to
escape growth controls imposed by the tumour suppressor gene. The distribution of
mutations throughout the p53 gene in Li-Fraumeni patients is similar to that seen in
sporadic tumours, although, there is an increase in mutations in conserved region IV of
the gene (see Section 3.2 of the Introduction) (Soussi et al, 1990; Borressen et al,
1992).
Transgenic mice and p53 gene knockout mice have been used as model systems to
investigate the role of p53 in developmental processes and in carcinogenesis
(Donehower et al, 1992; Harvey et al, 1993; Purdie et al, 1994).. These studies
demonstrate that overexpression of the p53 val135 mutation in mice does not disrupt
the development of the animal but leads to (in 20% of cases) an excess of lung
adenocarcinomas, osteosarcomas and lymphomas, which is similar to the spectrum of
cancers seen in Li-Fraumeni patients (Laviguer et al, 1989). There is a long latent
period prior to cancer development in these transgenic mice, suggesting that
overexpression of mutant p53 alone is not sufficient to induce malignancies. Complete
knockout of the p53 gene has been achieved in mouse lines by gene targeting
techniques (Donehower et al, 1992; Harvey et al, 1993; Purdie et al, 1994). p53 null
mice also develop normally, indicating that the p53 gene is dispensable for mouse
development, however, the animals are susceptible to spontaneous tumours with nearly
75% of homozygous mice developing multiple cancers by 6 months of age
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(Donehower et al, 1993). p53 knockout mice appear to be particularly susceptible to
the development of T cell lymphomas, but a wide variety of cancers have been
demonstrated. Heterozygous mice, with one wild type p53 allele, also develop
spontaneous tumours but with a delayed onset compared to homozygouts and
osteosarcomas and soft tissue sarcomas predominate in these mice, reminiscent of Li-
Fraumeni families (Harvey et al, 1993). Interestingly, a number of homozygous mice
die of unresolved infections, suggesting that they may have a defect in their immune
systems (Purdie et al, 1994).
3.1.3 Accumulation And Mutation Of p53 In Cutaneous Carcino2enesis
p53 accumulation has previously been demonstrated in both pre-malignant and
malignant epidermal lesions from ICPs. However, the prevalence has been somewhat
inconsistent, ranging from 0-55% of solar keratoses, 17-80% of Bowens disease and
15-56% of cutaneous SCCs (Gusterson et al, 1991; McGregor et al, 1992; Ro et al,
1993; Helander et al, 1993; Nagano et al, 1993). More direct methods have also been
used to investigate the prevalence of mutated p53 in pre-malignant and malignant
cutaneous lesions from ICPs but once again, the detection level varies between studies:
Brash et al (1991) detected p53 gene mutations in 14/24(58%) cutaneous SCCs
whereas Pierceall et al (1991a) and Moles et al (1993) detected mutated p53 in 2/10
(20%) and 2/13(15%) cutaneous SCCs respectively. p53 gene mutations have also
been demonstrated in 48% of 20 Bowen's disease (Campbell et al, 1993a). The
distribution of p53 mutations observed in these investigations was similar to the
mutational spectra observed for other cancer types (see Section 3.5.1 of the
Introduction).
3.2 THE GENE FOR P53 AND ITS TRANSCRIPT
The p53 gene encompasses 16-20 KB ofDNA on the short arm of chromosome 17 at
17pl3.1 (Baker et al, 1989). Mouse, human and Xenopus laevis p53 genes have all
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been fully sequenced and comprise eleven exons interrupted by 10 introns (Soussi et al,
1987 and 1990). p53 cDNAs have also been cloned from rat, chicken, monkey,
hamster and trout genes, although no p53 related sequences have yet been identified in
invertebrate species. Northern blot analysis reveals that the mRNA for human p53 is 2-
3KB long and is most abundant in undifferentiated stem cells, spleen cells, cells
undergoing rapid embryonic development and other rapidly proliferating cell types
(Bendori et al, 1987; Khochbin & Lawrence, 1989; Schmid et al, 1991). The levels of
p53 mRNA have been shown to be elevated in some tumours but are down-regulated
in tumour cells induced to differentiate (Bendori et al, 1987). These data suggest that
the proliferative state of the cell correlates with the levels of p53 mRNA.
The human p53 protein comprises 393 amino acids (approximately 53 KDa) and
structurally resembles a transcription factor (Figure 1.6) (Donehower & Bradley,
1993). The protein can be divided into three domains based upon analysis of the
primary amino acid sequence (Soussi et al, 1990). The first 75-80 amino acids
comprise the acidic NH2 terminus which is highly charged and contains the
transcription activation sequence (Levine & Momand, 1990). The central portion of
the molecule is a proline rich domain which contains 5 highly conserved regions
(domains I-V in Figure 1.6) that share over 90% homology between species (Soussi et
al, 1987). The majority of missense p53 mutations are in these conserved regions,
implying that they may be of particular functional importance (Soussi et al, 1990;
Bennet et al,1992). This hypothesis is supported by the recent discovery that the
central conserved core of p53 represents the DNA binding domain of the protein (Cho
et al, 1994; Vogelstein & Kinzler, 1994). The COOH terminus is rich in basic amino
acids and contains oligomerisation signals which have been shown to be important in
the growth suppressor activities of p53 (Prives & Manfredi, 1993). Three nuclear
localisation signals (NLS) are also present in the COOH-terminus of p53 (Rotter et al,
1993).
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Figure 1.6: Structural Domains on The Human p53 Protein
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Structural domains on human p53 (Prives & Manfredi, 1993). The shaded boxes
containing Roman numerals represent the 5 conserved domains of p53. The three
nuclear localisation signals (NLS) are also shown. Indicated above are the known
phosphorylation sites on p53 (P): the two carboxy-terminal sites have been shown to
be phosphorylated by cdc2 and cdk2 kinases (CDK site) or casein kinase II (CKII site),
putative kinases for the amino four sites include double-stranded DNA protein kinase
(dsDNA-PK) and casein kinase I (CKI). The red dots in the centre show sites that are
commonly mutated in human tumours, the hot spots are identified by amino acid
number. TBP is the TATA box binding protein; hsc 70 is heat shock protein 70.
IKl indicates oligomerisation sequence
3.3 biological functions ofwild type P53
3.3.1 p53 Acts As Tumour Suppressor
The expression of wild type p53 in rat embryo fibroblasts transformed by mutant p53
(or other oncogenes such as c-myc, ElA and E7) plus activated ras actively suppresses
transformation, as measured by numbers of transformed foci (Eliyahu et al, 1989;
Finlay et al, 1989; Chen et al, 1990; Yin et al, 1992; Takahashi et al, 1992). The rare
foci that form under these conditions do not express the exogenous wild type p53
gene. In addition to suppressing transformation of rodent cells, the wild type p53 gene
is capable of reverting the transformed phenotype of human colon (Baker et al, 1990),
bladder (Chen et al, 1990), brain (Mercer et al, 1990) and bone (Diller et al, 1990)
cancer cell lines. These in vitro studies provide strong evidence that p53 functions as a
tumour suppressor gene and suggest that this gene is selected against during
transformation. The finding that both p53 alleles are inactive in the majority of human
tumours (see Section 3.1.1 of the Introduction) and in mouse erythroleukaemias
induced by Freind virus, supports the hypothesis that p53 acts as a tumour suppressor
gene (Mowat et al, 1985; Nigro et al, 1989; Baker et al, 1990; Levine et al, 1991 and
1993; Stratton, 1992).
3.3.2 p53. DNA Damage. Apoptosis And The Cell Cvcle
Exposure to DNA damaging agents contributes to the development of many human
cancers, especially those of organs frequently exposed to carcinogens such as the skin.
An important cellular response to DNA damage is inhibition of replicative DNA
synthesis and transient arrest in Gl-S phase of the cell cycle, presumably to allow time
for effective DNA repair (Hartwell, 1992). A number of human tumour cell lines have
been shown to arrest in the G1 phase of the cell cycle following overexpression of p53
(Baker et al, 1990; Chen et al, 1990; Diller et al, 1990). It has also been demonstrated,
both in vitro and in vivo, that cellular levels of p53 are elevated following exposure to
DNA damaging agents (such as ionising radiation, mitomycin C, etoposide and DNA
restriction enzymes) and that these elevated levels of p53 temporarily correlate with a
transient G1 arrest (Kastan et al, 1991; Keurbitz et al, 1992; Hall et al, 1993). Cells
that are devoid of p53 or express mutant p53 fail to block growth in the G1 phase of
the cell cycle following gamma irradiation, however, the restoration of a wild type p53
allele to these cells restores the G1 arrest response (Yin et al, 1992).
Another important cellular response sometimes induced by DNA damaging agents is
cell death by apoptosis. Apoptosis is a distinct, genetically programmed pathway of
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cell death that plays an important role in normal development and underlies processes
such as organogenesis, tissue homeostasis and the deletion of autoreactive clones from
the immune system (Williams & Smith, 1993). Apoptosis may also play a role in the
kinetics of tumour growth (Arends et al, 1994; Arends & Harrison, 1994).
Overexpression of wild type p53 in a murine myeloid cell line results in increased
apoptosis as indicated by characteristic cell morphological changes and DNA
fragmentation (Yonish-Rouach et al, 1991). Furthermore, a colon carcinoma cell line
expressing wild type p53 under an inducible promoter forms tumours in the absence of
the inducer but when the inducer is present, the tumours regress until they are totally
eliminated (Shaw et al, 1992). The cells induced to die have characteristics of
apoptotic cells. These data indicate that wild type p53 induces apoptosis in some
circumstances (Lane, 1993). Studies using p53 gene knockout mice have recently
demonstrated that thymocytes with no endogenous p53 are highly resistant to gamma
irradiation-induced apoptosis, both in vivo and in vitro (Clarke et al, 1993; Lowe et al,
1993a). However, these cells undergo a normal apoptotic response to treatment with
glucocorticoids, indicating that there are p53 dependent and independent pathways for
apoptosis (Clarke et al, 1993). Anticancer agents are thought to act by inducing DNA
damage and apoptosis in actively proliferating cells. The data acquired from the p53
null mice imply that tumour cells with only one or no copies of the wild type p53 gene
may be more resistant to the apoptotic response induced by these agents (Clarke et al,
1993; Lowe et al, 1993b). This suggests a mechanism whereby tumour cells can
acquire cross resistance to anticancer agents which has important implications for
cancer therapy.
On the basis of these data and the finding that p53 is not required for normal cell cycle
control, a model has been put forward for the function of wild type p53 (Figure 1.7)
(Lane, 1992 and 1993). It has been proposed that wild type p53 acts as a "molecular
policeman" monitoring the integrity of the genome in periods of cell stress. DNA
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damage results in the accumulation of p53 and the inhibition of DNA synthesis to
allow time for its repair. In circumstances of extensive, irrepairable DNA damage, p53
induces cell death by apoptosis. Inactivation of wild type p53 leads to the loss of
control of this cell cycle checkpoint and permits the development of genomic instability
which is a characteristic of transformed cells.
Figure 1.7:- A Model For The Function Of p53
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A model for the function of p53 (Lane, 1992 and 1993). A: normal cell division for
which p53 is not required. B: the genome guarding function of p53 in a normal cell is
induced in response to DNA damage. C: cells in which the p53 pathway is inactivated
by mutation or cellular or viral proteins replicate damaged DNA, resulting in mutation,
aneuploidy and cell death. Malignant clones may arise from cells that survive with
damaged DNA.
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Support for this hypothesis has come from the finding that primary fibroblasts from Li-
Fraumeni patients, passaged until they are homozygous for mutated p53, have
increased genetic instability (measured as a function of gene amplification) compared
to fibroblasts that contain one or two copies of wild type p53 (Bischoff et al, 1990a).
Similarly, fibroblasts from mice with no functional p53 amplify genes at a high
frequency whereas heterozygous and wild type cells do not (Tsukada et al, 1993).
These data are a direct indication that lack of p53 results in genetic instability. Patients
with the rare disorder ataxia-telangiectasia are hypersensitive to ionising radiation,
have a pre-disposition to cancer development and fail to block growth in the G1 phase
of the cell cycle following DNA damage (Khanna & Lavin, 1993). Kastan and
colleagues (1992) demonstrated that cells from these patients lack the ionising
radiation-induced increase in p53 that is commonly observed in normal cells, thus
providing further evidence for a link between DNA damage, p53, genetic instability
and cancer.
3.3.3 p53 And Differentiation
A number of studies have suggested that p53 may be involved in differentiation in
some cell types (Rotter et al, 1993). When wild type p53 is expressed in a B cell line
that has no endogenous p53, the cells proceed to a more advanced stage of B cell
differentiation, as indicated by increased expression of cytoplasmic IgM as well as
other B cell differentiation markers (Shaulsky et al, 1991a and b). When transplanted
into mice, B cells expressing wild type p53 give rise to tumours at a lower frequency
and of a smaller size compared to those arising from the parental cells with no
endogenous p53. Furthermore, tumours expressing wild type p53 show terminal cell
differentiation and express high levels of heavy and light immunoglobulins, whereas
tumours arising from p53 non-producers are highly proliferative and are more rapidly
lethal to the host (Shaulsky et al, 1991b). Transgenic mice bearing a p53 responsive
promotor adjacent to a chloramphenicol acetyletransferase (CAT) reporter have
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elevated CAT expression in the testes, implicating a role for p53 in sperm cell
differentiation and maturation (Rotter et al, 1993). Transfection of wild type p53 into
human osteosarcoma Soas-2 cells, followed by injection of these cells into nude mice,
results in metastases consisting almost entirely of differentiated bone tissue (Prives &
Manfredi, 1993). The demonstration of an upregulation of p53 mRNA in myoblasts
induced to undergo terminal differentiation suggests that p53 may also be involved in
muscle cell differentiation (O'Halevy, 1993). Finally, it has been observed that p53
mRNA is detected in mid-gestation embryos, particularly in regions of accelerated cell
differentiation activity, and that Xenopus laevis oocytes and early embryos, contain
substantial quantities of p53 protein and RNA (Rogel et al, 1985; Prives & Manfredi,
1993). These experiments suggest that p53 may be involved in differentiation and
developmental processes. However, B cell differentiation and spermatogenesis both
involve DNA rearrangements followed by DNA repair. Therefore, p53 may have a role
in these differentiation processes through the induction of G1 arrest to allow time for
this repair. The notion that p53 is essential for cell differentiation and development in
vivo is also challenged by the existence of the p53 null mouse (Donehower et al, 1992;
Purdie et al, 1994).
3.4 REGULATORY PATHWAYS OF WILD TYPE P53
3.4.1 p53 Is A Transcriptional Transactivator And Repressor
Recent studies have demonstrated that p53 is a sequence specific DNA binding protein
with transcriptional activator and repressor properties (Kern et al, 1991; Funk et al,
1992; Farmer et al, 1992; Unger et al, 1992; El-Diery et al, 1992; Tarunina et al, 1993;
Chumakov et al, 1993). The first demonstration of mammalian gene regulation by p53
was the muscle specific creatine phosphokinase (mck) gene (Weintraub et al, 1991).
p53 has subsequently been shown to bind to and transactivate a number of other
mammalian genes including the murine double minute-2 (mdm-2) gene (see Section
3.4.2 of the Introduction) (Liu et al, 1993; Shilo et al, 1993; Juven et al, 1993). Wild
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type p53 can also negatively regulate a wide variety of viral and cellular promotors
such as those from c-fos, beta actin, c-jun, IL-6, heat shock protein (hsp) 70, Rb,
multidrug resistance gene, Rous sarcoma virus, HIV, herpes simplex virus-1, SV40
and cytomegalovirus (Donehower & Bradley, 1993). p53 appears to repress
transcription by an indirect mechanism, possibly through the inactivation of general
transcription factors (see Section 3.4.2 of the Introduction). It has recently been
demonstrated that p53 can transactivate its own promotor and sequences similar to the
p53 consensus binding site appear to be critical for this autoregulation (Deffie et al,
1993).
It is likely that all the observed biological functions of p53 are mediated by the
regulation of genes at the transcriptional level. Support for this hypothesis comes from
the finding that viral oncoproteins that bind p53 and induce cellular transformation,
also inhibit p53 mediated transcriptional transactivation (see Section 3.5.3 of the
Introduction) (Yew & Berk, 1992; Lechner et al, 1992; Moran, 1993; Kessis et al,
1993). Mutant viral proteins that are defective in transformation are also defective in
blocking p53 induced transcription. These data suggest that transactivation is
necessary for p53 to function as a tumour suppressor. Increased expression of the
GADD45 damage response gene usually occurs following exposure to DNA damaging
agents (Kaufman & Kaufman, 1993). Therefore, the demonstration that p53 binds
strongly to a conserved element within the GADD45 gene and upregulates expression
of this gene provides further evidence that p53 may induce G1 arrest following DNA
damage through transactivation of other genes (Kastan et al, 1992; Donehower &
Bradley, 1993). p53 is also able to directly induce expression of WAF1, which is a
potent inhibitor of cyclin dependent kinases and inhibits growth of human tumour cell
lines and normal diploid fibroblasts, further supporting this hypothesis and suggesting
that p53 functions as part of a complex pathway of cell cycle control (El-Deiry et al,
1993 and 1994; Harper et al, 1993). However, the suggestion that p53 functions only
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through activation of cell cycle control genes is challanged by the finding that wild type
p53 can induce apoptosis in immortalised pituitary cells in the presence of large doses
of transcription and translation inhibitors, implying that p53 has other functional
properties (Caelles et al, 1994).
.3.4.2 p53 Protein Interacts With Cellular Proteins
The mdm-2 oncogene product was the first cellular protein found to complex with p53
in vitro (Momand et al, 1992; Oliner et al, 1992). This protein binds to the p53 protein
adjacent to its transactivation domain and inhibits the ability of p53 to activate
transcription, perhaps by concealing its transactivation domain from the cell's
transcriptional machinery (Momand et al, 1992, Oliner et al, 1993). The level of mdm-
2 protein/p53 protein complex increases in the G1 phase of the cell cycle, implying that
the product of the mdm-2 gene may regulate p53 at the protein level, which in turn
regulates mdm-2 gene expression (see above) (Olson et al, 1993). On the basis of this
data, an autoregulatory model involving the mdm-2 gene has been proposed for p53.
CAAT binding protein (CBP), E6-Ap, replication protein A (RPA), Spl, TATA
binding protein (TBP), TFIID and the Wilms tumour gene product have more recently
been shown to form protein complexes with p53 (Pietenpol & Vogelstein, 1993). The
interactions between p53 and the general transcription factors CBP, TBP and TFIID
are of particular interest because these may provide an indirect mechanism for p53
mediated regulation of transcription (Liu et al, 1993). Further experiments are required
to determine the biological relevance of interactions between p53 and cellular proteins.
3.5 MODIFICATION OF WILD TYPE P53
Modification of wild type p53 commonly occurs through 17p deletions and/or p53
point mutations in human tumours (see Section 3.1.1). However, it is now known that
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interactions with cellular or viral proteins may also result in inhibition of the normal
functions of wild type p53.
3.5.1 Distribution And Nature Of d53 Gene Mutations In Human Tumours
The majority of p53 mutations are missense single base substitutions resulting in
replacement of one amino acid by another in the p53 protein (Prives & Manfredi,
1993). These mutations are not distributed randomly across the p53 gene but are found
clustered between codons 120-290 out of 393 amino acid residues (Figure 1.6).
Mutations are particularly prevalent in four regions of the protein product (residues
117-142, 171-181, 234-258 and 270-286) which correspond with four of the most
highly conserved regions of the gene amongst several different species (see Section 3.2
of the introduction) (Soussi et al, 1990). In fact, about 40% of the missense mutations
in carcinomas occur in one of five "hotspot" codons (residues 175, 249, 273, 281 or
284) which appear to be specific for different cancer types. It has recendy been
demonstrated that these frequently mutated residues are all at or near the p53 protein-
DNA interface suggesting that they function through altering the DNA binding
properties of wild type p53 (Cho et al, 1994). The nature of p53 mutations also
appears to be tumour specific and related to the mutagen involved. For example, G to
T transversion mutations, which are known to be induced by benzopyrene in cigarette
smoke, are present in lung cancers but are never observed in colorectal cancers where
different mutagens act upon the DNA (Chiba et al, 1990; Harris, 1991). Similarly, CC-
TT double base mutations, which are almost unique to UV induced DNA damage,
have only been demonstrated in skin cancers (Brash et al, 1991). However, if the
narrow distribution and nature of the p53 mutations were simply a function of the type
of mutagen involved, a broader spectrum of mutations would be expected in human
cancers. Alternatively, mutations in these "hotspot" regions may be selected for in
human cancers, suggesting that such cancers do not just result from loss of function
mutations, but that altered p53 proteins contribute some functional advantage to the
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tumour. This hypothesis has now been tested, and indeed, mutated p53 proteins can
confer new phenotypic properties on cells lacking endogenous p53 (Dittmer et al,
1993).
3.5.2 Mutant p53 And Transformation
Early studies demonstrated that transfection of mutant forms of p53 into rodent
fibroblasts rapidly induced an immortal phenotype in the transfected cells (Hinds et al,
1989; Zambetti et al, 1992; Zambetti & Levine, 1993). Mutant p53 can also co-operate
with activated ras to fully transform primary rat embryo fibroblasts in culture. The
mechanisms underlying transformation by mutant p53 are presently unknown,
however, a number of suggestions have been made. Mutant p53 proteins have an
altered conformation when compared to wild type protein and mutant forms of p53
have been shown to form heterologous complexes with wild type p53, driving the wild
type protein into a mutant conformation (see Section 3.5.3 of the Introduction) (Kraiss
et al, 1988; Milner et al, 1991; Milner & Medcalf, 1991; Stenger et al, 1992).
Therefore, one suggestion is that mutant p53 transforms cells through binding and
inactivating the wild type protein. The selective pressure in human cancer for mutant
p53 rather than no p53 at all suggests that mutant p53 may contribute to the gain of
some growth altering function rather than inactivating wild type p53 activity. Evidence
for gain of function mutations in p53 comes from the finding that mutant forms of p53
transform immortal murine fibroblasts, lacking endogenous p53, to a fully
tumourigenie cell line (Dittmer et al, 1993). These cells do not express wild type p53,
therefore, mutant p53 cannot be functioning in a dominant negative manner in these
assays.
3.5.3 Conformation And Stability OfWild Type And Mutant p53
In non-transformed cells, wild type p53 is rapidly degraded via a ubiquitin dependent
pathway. However, missense mutations of the p53 gene uniformly result in stabilisation
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of the p53 protein which increases in its half life from 5-40min (wild type) to several
hours (mutant forms) (Oren et al, 1981; Milner & Cook, 1986; Finlay et al, 1988).
Consequently, mutant p53 accumulates within transformed cells allowing its detection
by immunocytochemical techniques (Dippold et al, 1981; Rotter et al, 1981;
Benchimol et al, 1982; Jenkins et al, 1984; Bartek et al, 1991; Montenarh, 1992;
Wynford-Thomas, 1992). Wild type p53 is usually present in cells at such low levels
that it cannot be detected by this technique. Thus, immunocytochemical demonstration
of p53 in tissues may indicate the presence of mutated p53, even if conformation-
independent antibodies (those that bind to wild type and mutated p53) are used.
However, non-transformed cells that have recently been exposed to DNA damaging
agents, such as cutaneous keratinocytes exposed to UV radiation, also exhibit
immunocytochemically detectable levels of wild type p53 (Hall et al, 1993).
Immunocytochemical methods have been used extensively to investigate human
malignancies for p53 gene mutations and it has been found that accumulation of p53 is
a common event in a wide variety of human cancers (Cattoretti et al, 1988; Iggo et al,
1990; Bartek et al, 1990 and 1991; Rodriguez et al, 1990; Purdie et al, 1991; Scot et
al, 1991; Varley et al, 1991; Bodner et al, 1992; Thomson et al, 1992). In the majority
of these studies, immunoreactive p53 was confined to malignant cells which supports
the hypothesis that immunocytochemically detectable p53 indicates an abnormality in
the p53 pathway.
The missense mutant forms of p53 have an altered conformation when compared to the
wild type protein. The monoclonal antibody PAb246 binds to wild type p53 at an
epitope between amino acid residues 88 and 109 but fails to bind to mutant forms of
the protein (Yewdell et al, 1986). Conversely, monoclonal antibody PAb240 binds to
many diverse mutant forms of the p53 protein at an epitope between residues 206 and
211 but this antibody fails to bind to the wild type protein (Gannon et al, 1990). A
number of groups have demonstrated concordance in the cells within a tumour that
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stain with the mutant specific antibody PAb240 and the conformation-independent
antibody PAbl801 which also supports the contention that immunocytochemically
detectable p53, using a conformation-independent antibody, is indicative of an
abnormality in the p53 pathway (Bartek et al, 1990; Rodriguez et al, 1990; Purdie et
al, 1991; Varley et al, 1991; Vojtesek et al, 1992; Bums et al, 1993).
3.5.4 Cellular Proteins Inactivate Wild Type p53
The product of the mdm-2 gene binds and inactivates wild type p53 (Momand et al,
1992; Oliner et al, 1992 and 1993). Amplification of this gene has been demonstrated
in over one-third of human sarcomas and in the majority of these sarcomas, the p53
gene is not mutated (Oliner et al, 1992). Furthermore, transfection of mdm-2 plus
activated ras plus wild type p53 into primary rat embryo fibroblasts results in the
formation of transformed foci expressing wild type p53 (Finlay et al, 1993). Therefore,
amplification of mdm-2 in sarcomas may overcome the growth suppressive properties
of wild type p53 and thus contribute to carcinogenesis. It is likely that other cellular
proteins inactivate wild type p53 during carcinogenesis, although these proteins have
yet to be identified.
3.5.5 Viral Proteins Inactivate Wild Type p53
In addition to complex formation with cellular proteins and gene deletions and
mutations, wild type p53 may be inactivated by complex formation with the
transforming proteins of some DNA tumour viruses (Yew & Berk, 1992; Lechner et
al, 1992; Moran, 1993; Kessis et al, 1993). It has been demonstrated that the SV40
large T antigen, the adenovirus E1B protein and the E6 protein from the high risk HPV
types all complex with p53. However, these proteins bind to the p53 protein at
different regions (Figure 1.6) and appear to inactivate p53 by different mechanisms.
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SV40 large T antigen
p53 was first discovered as a cellular protein because it formed a tight complex with
the SV40 large T antigen and was therefore co-immunoprecipitated, with anti T
antibodies, from extracts of SV40 transformed cells (Lane & Crawford, 1979; Linzer
& Levine, 1979). It has recently been demonstrated that large T antigen has the ability
to block the binding of p53 to DNA, which suggests that the oncogenic potential of T
antigen is mediated by its ability to inhibit transcriptional regulation by p53. SV40
transformed cells have increased cellular levels of wild type p53, therefore, it was
originally presumed that binding of T antigen to p53 stabilised the p53 protein and
increased its half life in the cell (Montenarh et al, 1986; Kraiss et al, 1988). However,
more recent experiments have demonstrated that the half lives of free p53 and T
antigen-complexed p53 are identical in SV40 transformed cells (Ludlow, 1993). This
suggests that the stabilisation of p53 may result from factors other than T antigen
binding, possibly as part of a cellular mechanism whereby the cell attempts to resist
viral transformation. The reduced p53 turnover may also be attributed to metabolic
changes associated with viral transformation.
Adenovirus E1B
Adenovirus E1B encodes two protein products of 55KD and 19KD which are
important for adenovirus transforming activity. The 55KD protein binds the acidic
amino terminus of p53, thus blocking p53 mediated transcriptional transactivation
(Yew & Berk, 1992; Moran, 1993). E1B transformation defective mutants are also
defective in blocking p53 induced transcription, which suggests that this function of
p53 is integral to the mechanism by which the 55KD protein contributes to
transformation (Yew & Berk, 1992). Stable complexes between 55KD and p53 have
also been shown to inactivate p53 by sequestering the protein outside the nucleus.
More recent studies suggest that one of the main functions of the E1B protein in
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transformation is to block apoptosis that may otherwise be induced by E1A, the other
major transforming protein of adenovirus (Debbas & White, 1993).
HPV E6
In contrast to adenovirus and SV40 induced stabilisation of p53, in vitro studies have
demonstrated that binding of HPV 16 or 18 E6 results in the rapid, proteolytic
degradation of the p53 protein via a ubiquitin dependent pathway (Figure 1.8)
(Werness et al, 1990; Scheffner et al, 1990 & 1992; Ciechanover et al, 1991; Vousden,
1993). In vivo studies have subsequently found that human epithelial cells expressing
E6 also show a marked reduction in the stability of newly synthesised, endogenous p53
(Band et al, 1991). E6 degradation of p53 requires two independent domains of the E6
protein: a C-terminal region of E6 is important for p53 binding and N-terminal
sequences are necessary to direct p53 degradation (Crook et al, 1991c; Lechner et al,
1992; Scheffner et al, 1992). The precise mechanism by which E6 targets p53 for
degradation has not yet been established, although binding to p53 seems to be essential
in this process. Proteolysis of p53 usually occurs via a ubiquitin dependent pathway,
therefore, it may be that E6 binding enhances this normal pathway. Alternatively, E6
may direct degradation by a novel ubiquitin dependent pathway (Vousden, 1993).
Another cell encoded protein, E6-AP, has been identified which associates with E6 and
is necessary for p53 degradation to occur (Huibregtse et al, 1991). The involvement of
cellular factors suggests that there may be cell-type dependent differences in the effect
of E6 on p53.
Similar to large T antigen and E1B, E6 has the ability to inhibit p53 mediated
transcriptional transactivation and repression (Crook et al, 1991; Lechner et al, 1992;
Kessis et al, 1993). It has been demonstrated that these functions of p53 are required
for p53 induced inhibition of cell proliferation. Therefore, the interaction between E6
and p53 probably represents an important step in cervical carcinogenesis. Support for
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Figure 1.8:- HPV E6 Inactivates The Normal Functions OfWild type p53
Uninfected Cell
Consequences ofE6 expression on p53-mediated transcriptional control. In uninfected
cells, p53 regulates gene expression through transcriptional activation and repression.
In HPV infected cells, wild type p53 is inactivated through degradation, thus
preventing p53 mediated transcriptional control. TBP = TATA box binding protein.
this hypothesis originally came from studies demonstrating that anogenital carcinomas,
and derived cell lines, that are not infected by HPV have mutations in the p53 gene,
whereas most of those cancers that are infected with HPV types 16 and 18 show wild
type p53 (Scheffner et al, 1991; Crook et al, 1991a and 1992). However, subsequent
studies have found that this inverse relationship is not absolute (Cooper et al, 1993;
Busby-Earle et al, 1993). p53 mutations have been demonstrated in metastases from
cervical cancers showing low levels of mutated p53 (Prives & Manfredi, 1993;
Mitranirosenbaum & Tsvieli, 1994). This suggests that mutation of p53 contributes to
the further progression of cervical cancers that initially contained wild type p53,
inactivated at the protein level by E6
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E6 proteins from the low risk HPV types 6 and 11 have also been shown to bind to
and degrade p53 in vivo (Band et al, 1991). However, in vitro assays have produced
conflicting reports with some suggesting that these E6 proteins bind to p53 but do not
direct its degradation, while other reports suggest that the E6 proteins from the low
risk HPV types do not bind p53 but do enhance its degradation (Werness et al, 1990;
Crook et al, 1991c; Lechner et al, 1992). It seems likely that E6 proteins of both high
and low risk HPV types bind and mediate degradation of p53, but with significantly
different efficiencies.
3.6 Summary
The development of skin cancer following renal transplantation is a serious clinical
problem, even in countries such as Britain where patients are exposed to only mild to
moderate levels ofUV radiation. The number of patients receiving such transplants is
increasing and improvements in immunosuppression have produced significantly longer
graft survival times. Therefore, the incidence of immunosuppression related cutaneous
disease is set to rise. Thus, investigations into the factors involved in the development
of skin neoplasms in RARs, and their associated genetic events, are of considerable
importance.
The possible association between HPV infection and the development of skin cancer in
RARs was initially suggested by observations in the rare, inherited skin disease EV.
Similar to transplant patients, EV patients have a decrease in cell mediated immunity
and an increase in VWs and SCCs on sun exposed body sites. Over 90% of cutaneous
SCCs from EV patients are infected with HPV types 5 or 8. The clinical and
histological overlap between VWs and SCCs in RARs also provides supportive
evidence to suggest that HPV contribute to the carcinogenic process of RARs.
However, reports on the prevalence and types of HPV DNA present in cutaneous
neoplasms from RAR have been inconsistent and the role of the virus in the
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carcinogenic process has yet to be fully characterised. In particular, it is not known
whether HPV contribute directly to skin carcinogenesis by supplying viral oncogenes
that induce neoplastic change or indirectly by promoting cell proliferation.
Although a number of putative aetiological factors have been implicated in cutaneous
carcinogenesis of RARs, little is known of the associated genetic events and whether
these differ in RARs and ICPs. Mutations in the p53 tumour suppressor gene are the
most commonly observed genetic lesion in human cancers. It has recently become
established that p53 acts as part of a DNA damage response pathway, therefore, it is
possible that this tumour suppressor gene plays an important role in the skin where
epidermal keratinocytes are frequently exposed to the damaging effects of UV
radiation. Furthermore, it has been reported that viral oncoproteins may contribute to
carcinogenesis through inactivation of p53 in anogenital HPV associated malignancies.
However, to date there has been no systematic study of the role of p53 in the
development of cutaneous lesions in RARs.
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3.7 ATMS OF STUDY
The aims of this study therefore, were to determine:
• the prevalence of HPV DNA in benign, premalignant and malignant lesions from
RARs and ICPs.
• the prevalence of putative oncogenic HPV types 5, 8, 16 and 18 and the more
common cutaneous HPV types 1 and 2, and the common "low risk" genital HPV
types 6 and 11, in cutaneous lesions from RARs and ICPs.
• whether the pattern of HPV prevalence in the spectrum of cutaneous neoplasia
associated with RARs suggests the stage at which HPV act in the oncogenic
process.
• the prevalence of accumulated p53 in pre-malignant and malignant lesions from
RARs and ICPs.
• the relationship between positive immunocytochemistry and p53 gene mutations
in cutaneous cancers.
• the stage at which p53 acts in the carcinogenic process of RARs and ICPs.






CHAPTER 2 ; MATERIAL^ AND METHQDS
1: CLINICAL AND HISTOPATHOLOGICAL DATA
lil PATIENT DETAILS
Two groups of patients were investigated. The first comprised 64 immunosuppressed
patients, 61 RARs plus 3 cardiac allograft recipients (mean age 49 years, range 20-70
years), all of whom received transplants between 1965 and 1992 (mean duration of
transplant 10.5 years, range 1-26 years). Prior to 1984 patients received
immunosuppressive therapy with prednisolone and azathioprine, but since then all new
allograft recipients have been treated with prednisolone and cyclosporin A, a few
subsequently being switched to azathioprine. All RARs were assessed for their level of
sun exposure on the scale of low = indoor occupation, no outdoor leisure activities;
moderate = indoor occupation, outdoor leisure activities; high = outdoor occupation
and/or more than 3 months living in a tropical climate. The second patient group
comprised 83 immunocompetent individuals (mean age 68 years, range 12-94 years)
who were referred for treatment of suspected warts or skin malignancies. All
IECs/SCCs came from 18 RARs and 48 ICPs. All patients were treated in the
Department ofDermatology at the Royal Infirmary of Edinburgh.
1.2 TISSUE COLLECTION
173 and 89 therapeutic skin biopsies were collected from RARs and ICPs respectively.
These included 57 SCCs and 67 IECs. They also included BCCs collected from RARs
(7) and ICPs (14) which were not investigated in this study. 6mm biopsies of
uninvolved, sun exposed, forearm skin were also obtained from 24 RARs (11 with and
13 without skin tumours elsewhere) and 12 healthy ICPs who volunteered to undergo
this procedure. Immediately following excision, each lesion was bisected longitudinally
with a sterile blade to minimise the risk of contamination; half was immediately placed
in 10% buffered formalin or PLPD (periodate-lysine-paraformaldehyde-dichromate)
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(Holgate et al, 1986) and fixed for 24 hours at 4°C before paraffin embedding.
Histological assessment (haematoxylin and eosin stained sections) and
immunocytochemistry were carried out on paraffin embedded material. The other half
was immediately snap frozen in liquid nitrogen and stored at -70°C to await virological






Made up to 50mls in 0.05M phosphate buffer, pH 7.4
0.05M phosphate buffer
12.5g Disodium hydrogen orthophosphate
2g Sodium dihydrogen orthophosphate
2 litres Double distilled water (DDW)
Part A was combined with 5% potassium dichromate in 50mls of distilled water
immediately before use.
1.3 HISTOPATHOT.OGTCAI. CHARACTERISATION OF IF.STONS
Cutaneous lesions were assessed for standard morphological features suggestive of
actinic damage and for degrees of dysplasia progressing to intraepidermal and invasive
carcinoma (Blessing et al, 1989). They were designated as viral warts (VWs), actinic
and verrucous keratoses (AKs and VKs), intraepidermal carcinomas (IECs) and
squamous cell carcinomas (SCCs). VWs showed architectural symmetry,
hypergranulosis and koilocytosis. Lesions showing double layered basal budding, basal
hypermelanosis, dysplasia and loss of granular layer with superficial parakeratosis were
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classified as actinic keratoses. Lesions that showed some features suggestive of HPV
infection, but various degrees of basal budding and basal dysplasia, were termed
verrucous keratoses. IECs exhibited either full-thickness dysplasia or severe dysplasia
in the basal layer. The designation of SCC was confined to lesions where there was
evidence of dermal invasion. In some instances, the complex architecture of VK and
the variable dysplasia made confirmation of invasion difficult, so the term SCC was
used only when dermal invasion was unequivocal (Blessing et al, 1989).
2: PREPARATION OF PURIFIED HPV DNA
2.1 TRANSFORMATION OF COMPETENT BACTERIAL CELLS WITHHPV DNA
Plasmids containing HPV DNA of common cutaneous and EV associated HPV types
were received from the original cloning laboratories (Table 2.1). Most of the HPV
DNAs were cloned into pBR322 at the tetracyclin resistance site, resulting in an
ampicillin resistant plasmid. HPV 19 and 20 were cloned into the pUC9 vector which
was also resistant to ampicillin.
Competent HB101 bacteria were prepared by a method based on that of Hanahan
(1983). Briefly, a 5ml overnight culture of HB101 E coli cells was used to inoculate
200mls of L-broth which was then incubated for 3 hours at 37°C in an orbital shaker.
The bacteria were pelleted by centrifugation at 8000rpm, 4°C for 20min then
resuspended in lOmls of TSB and incubated on ice for 30min. The cells, which were
now competent, were aliquoted into 200yu.l aliquots and immediately snap frozen in a
dry ice, ethanol bath. In order to transform these bacteria, lOOfd of thawed cells were
immediately aliquoted into pre-chilled eppendorf tubes. 50-100ng of purified HPV
plasmid DNA were then added, mixed gently and incubated on ice for 30min. After
heat shock at 42°C for 45sec followed by 2min on ice, 900ft 1 of TSB containing
200mM glucose were added and the sample incubated for lhour at 37°C, shaking in an
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orbital shaker. lOOpl and 200|il aliquots of the transformed cells were then plated onto
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The L-broth plus Bacto-agar were autoclaved then cooled to 55°C and ampicillin
added. This solution was poured into approximately 15 petri dishes and left to set.
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2.2 SMALL SCALE FLASMID PREPARATION
Five colonies of transformed bacteria were picked from the LB-ampicillin plate and
each used to inoculate lOmls of L-broth. Following overnight incubation at 37°C in an
orbital shaker (225rpm), 1.5mls of each culture were transferred to an eppendorf tube
and microcentrifuged at low speed for 5min (the remainder of the culture was stored at
4°C to await large scale plasmid preparation). The resulting bacterial pellets were
resuspended in lOOpl of lysis solution, 200|ll of alkaline/SDS and 100p.l of 3M
potassium acetate and incubated for 5min, 5min and 15min respectively at 4°C. The
samples were then microfuged at high speed for 5min at 4°C and the supernatant was
removed to a clean eppendorf tube. Plasmid DNA was extracted from this solution by
the addition of an equal volume of phenol chloroform (x 2) followed by an equal
volume of chloroform (the supernatant was removed each time). An isopropanol
precipitation was carried out and the plasmid DNA resuspended in 30|il of TE . In
order to verify that the plasmid contained HPV DNA, prior to large scale plasmid
preparation, each plasmid sample was digested with the enzyme used to clone the
particular HPV type (see Table 2.1 for the enzymes used).
Lysis Solution












lOmM Tris pH 8.0
ImMEDTA pH 8.0
2.3 LARGE SCALE PLASMID PREPARATION
For each HPV type, 500mls of sterile L-broth, containing 50^g/ml of ampicillin, were
inoculated with 5mls of transformed bacteria and incubated at 37°C overnight in an
orbital shaker. The entire 500ml culture was then transferred to 2 X 250ml
polycarbonate centrifuge bottles which were centrifuged at 8000rpm, 4°C for 20min.
Following careful removal of the supernatant, the plasmid DNA was recovered using a
basic alkaline lysis technique, in one of two ways.
Method 1
The bacterial pellets were resuspended in lOmls of ice cold lysis solution and left at
4°C for 5min. Bacteria were then lysed by the addition of 20mls of alkaline SDS. The
solutions were mixed gently by swirling then incubated on ice for a further 5min.
Following the addition of 15mls of potassium acetate, the solutions were mixed
thoroughly, incubated for lOmin on ice, then cleared by centrifugation at 4°C,
8000rpm for 15min. The supernatants were transferred to clean oak ridge tubes and
nucleic acid precipitated by the addition of 0.6 volumes of isopropanol at room
temperature for 15min. After centrifugation at 8000rpm for lOmin at room
temperature, the pellet was washed twice with 70% ethanol and air dried. In order to
purify further the plasmid DNA, the bacterial pellet was resuspended in 4mls of TE
then 4.8g CsCl and 200^tl ethidium bromide (lOmg/ml) added. This solution was
transferred to an ultracentrifuge tube and the plasmid DNA was banded by
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centrifugation for 4 hours at 63,000rpm, 20°C on a Beckman ultracentrifuge. The
plasmid DNA band was visualised under UV light and removed by inserting a needle
into the centrifuge tube and sucking the DNA out into a 3ml syringe. The CsCl was
removed by 3 washes with isoamyl alcohol, the plasmid DNA resuspended in 4ml TE
(pH 7.5) and precipitated by the addition of 12mls of ethanol at -20°C for lhour.
Subsequent to centrifugation at 10,000rpm for lOmin at 4°C, the plasmid DNA pellet
was air dried and resuspended in TE to a concentration of lmg/ml. All solutions were
as for small scale plasmid preparation.
Method 2
The second method utilised the Quiagen kit for maxi-plasmid preparation (Hybaid
LTD). The bacterial pellet was resuspended in lOmls of buffer PI, then lOmls of buffer
P2 were added and the solution gently mixed. Following incubation for 5min at room
temperature, lOmls of buffer P3 were added, mixed immediately, incubated on ice for
20min then centrifuged at 15000 rpm, 4°C, for 30min. In order to ensure a particle free
lysate, the resultant supernatant was centrifuged again for a further lOmin at 4°C. The
supernatant was applied to a Quiagen column 500, which had previously been
equilibrated with lOmls of buffer QBT, and allowed to enter the resin by gravity flow.
The column was washed twice with 30mls of buffer QC before the purified plasmid
DNA was eluted with 15mls of buffer QF. The plasmid DNA was then precipitated in
0.7 volumes of isopropanol at room temperature for 30min followed by centrifugation
at 10,000 rpm for lOmin at room temperature. The pellet was washed twice in 70%
ethanol and dissolved in TE to lmg/ml. All solutions were supplied in kit form.
2.4 VALIDATION OF HPV PLASMID DNA
Five micrograms of purified HPV plasmid DNA were restriction digested as per
standard procedure (Sambrook et al, 1989) then electrophoresed through a 0.8%
agarose gel (Sigma) containing 0.5|ig/ml ethidium bromide. Electrophoresis was
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Table 2.1 - Source And Cloning Data Of HPV DNA
HPV TYPE SOURCE ENZYME * FRAGMENT SIZE
HPV1A P.M Howely (1) BamHI 1 Fragment - 8Kb
HPV2A P.M Howely (1) Ban 1 Fragment - 8Kb
HPV3 R.S Ostrow (2) BamHI 1 Fragment - 8Kb
HPV4 P.M Howely (1) BamHI 1 Fragment - 8Kb
HPV5/48 H. Pfister (3) EcoRI 1 Fragment - 1.7Kb
HPV5/49 H. Pfister (3) EcoRI 1 Fragment - 5.8Kb
HPV8 G.Orth (4) BamHI 1 Fragment - 8Kb
HPV10 G.Orth (4) Sail 2 Fragments -6.7, 0.5 Kb
HPV12 G.Orth (4) HindiII 1 Fragment - 8Kb
HPV13 H. Pfister (5) BamHI 3 Fragments 5.5, 1.7, 0.6Kb
HPV14 EM. De Villiers (6) BamHI 1 Fragment - 8Kb
HPV17 G. Orth (6) BamHI 1 Fragment - 8Kb
HPV19 H. Pfister (6) BamHI 1 Fragment 8Kb
HPV20 H. Pfister (7) BamHI 1 Fragment - 8Kb
HPV6b EM. De Villiers (8) BamHI 1 Fragment - 8Kb
HPV11 EM. De Villiers (9) Hindlll? 1 Fragment - 8Kb
HPV16 EM. De Villiers (10) BamHI 1 Fragment - 8Kb
HPV18 EM. De Villiers (11) EcoRI 1 Fragment - 8Kb
* Enzyme used to clone the HPV DNA. Apart from HPV 19 and 20 which were
cloned into pUC9, all the HPV types were cloned into pBR322. (1) Heilman et al,
1980; (2) Ostrow et al, 1983 (3) Pfister et al, 1983a; (4) Kremsdorf et al, 1983; (5)
Pfister et al, 1983b; (6) Kremsdorf et al, 1984; (7) Gross et al, 1988; (8) De Villiers et
al, 1981; (9) Gissmann et al, 1982; (10) Durst et al, 1983; (11) Boshart et al, 1984.
carried out in TBE, at 50V for approximately 2 hours. A DNA size marker (Kilobase
ladder, Gibco) was included on all gels. Restriction fragments were visualised using a
UV transilluminator and the image recorded by a camera linked to a Mitsubishi video
copy processor. Each purified HPV plasmid DNA was cut with at least three different














2.5 PREPARATION OF PURIFIED HPV DNA FOR USE AS PROBES
Fifteen micrograms of HPV plasmid DNA were digested with the restriction enzyme
used to clone that HPV type (Table 2.1) then loaded, along with 10|al of loading
buffer, into a large well of a 0.8% low melting temperature agarose gel containing
0.5|ig/ml ethidium bromide, then electrophoresed at 50V, 4°C for 2-4 hours. The
resulting DNA fragments were visualised and HPV DNA bands extracted from the gel.
Every precaution was taken to prevent cross contamination between DNA of different
HPV types. HPV DNA was purified using The Geneclean II kit (Stratech LTD) as per
manufacturer's instructions. The solutions used in this procedure were provided in the
kit.
The concentrations of purified HPV DNA were measured by aliquoting 5(il of HPV
DNA onto ethidium bromide plates alongside 5|il of standard solutions of known
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concentration. The concentration of HPV was then estimated by comparing the
intensity ofUV illumination ofHPV DNA to that of the standards.
Ethidium Bromide Plates
lg Agarose (Life Technologies)
10/d Ethiduim bromide (lOmg/ml)
lOOmls TBE
5-10mls of agarose solution were poured into plastic petri dishes and left to set.
Standards
Serial dilutions of Kb Ladder (Gibco) were carried out to give final concentrations of
30gg/ml, 15gg/ml. 7.5/ig/ml, ~4gg/ml, ~2 gg/ml and ~lgg/ml.
3: SOUTHERN HYBRIDISATION ANALYSIS
3.1 PREPARATION OF GENOMIC DNA
A small cube of frozen tissue was added to 700/xl of lysis solution in an eppendorf tube
and minced using sharp, surgical scissors. 50/d of fresh proteinase K (25mg/ml) were
then added and the sample incubated at 37°C in an orbital shaker overnight. Following
centrifugation to remove the undigested tissue, the DNA was extracted by a standard
phenol chloroform extraction technique (1 x phenol, 1 x phenol/chloroform, 1 x
chloroform) (Sambrook et al, 1989). The DNA was then precipitated by the addition
of 1 volume of isopropanol followed by incubation at -20°C for 1 hour. Subsequent to
centrifugation, the DNA pellet was washed twice with 70% ethanol the pellet was then
redissolved overnight in 400/d of TE. 50/d aliquots of genomic DNA were removed
from the stock solutions for use in PCR assays. All procedures were carried out using








3.2 RADIOACTIVE LABEI.ITNG OF HPV DNA
50-75ng (25ng of each HPV type in mixed probes) of HPV DNA were labelled using a
random priming, DNA labelling kit (Megaprime kit, Amersham International) as per
manufacturer's instructions. Breifly, l-10pl of DNA plus 5pi of primer solution and
DDW (final volume 50pl) were denatured for 5min at 95-100°C. 10pl of nucleotide
mix, 50|iCi (5ul) alpha-32P (dCTP) and 2pl of Klenow enzyme were then added and
the DNA labelled for 15-20min at 37 °C. The buffers and reagents were supplied in kit
form.
Labelled DNA was separated from unincorporated, radioactive dNTPs by passage
through a Nick Column (Pharmacia) as specified by the manufacturer. Labelled DNA
was eluted in 400|il of TE and denatured at 95-100°C prior to use.
3.3 DOT BI.OT HYBRIDISATION OF HPV PTASMID DNA
3.3.1 Preparation Of Filters
Dot blot filters containing HPV types 1, 2, 3, 4, 5, 8, 10, 12, 13, 14, 17, 19 and 20
were made for use in initial optimisation experiments. 50pg of purified HPV DNA
were denatured (95-100°C for 5min) and spotted onto a charged nylon membrane
(Hybond N+, Amersham) which had been pre-soaked in lOxSSC. The filter was then
baked for 1 hour at 80°C in a vacuum oven to ensure binding of DNA to the filter.
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3.3.2 Prehvhridisation And Hybridisation
The filter containing HPV DNA of multiple types was sealed in a plastic hybridisation
bag (Hybaid) and 30mls of prehybridisation solution added to one port with a syringe,
ensuring that all air bubbles had been removed. Following 6 hours prehybridisation at
either 45°C, 55°C or 65°C, denatured labelled probe (95-100°C for 5min), containing
one or more HPV types, was added to the hybridisation bag and hybridisation carried
out overnight in a shaking water bath at the same temperature as prehybridisation.
3.3.3 Washing Conditions
Hybridisation solution containing the radioactively labelled probe was discarded and
unbound radioactivity washed off by running 500mls of 2xSSC over the filter using a
Hybaid vacuum pump. 250mls of 2xSSC, 1% SDS were added to the bag which was
then incubated at the appropriate temperature (as for hybridisation) for 30min. Some
filters were removed from the hybridisation bag at this point, sealed in a plastic bag and
exposed to X-ray film (Fugi) (in an x-ray cassette with intensifying screens), either
overnight or for 3 days, at -70°C. Some of the filters were washed with a further wash
of 0.5xSSC, 1% SDS for 30min and in some cases this was followed by an even more
stringent wash of O.lxSSC, 1% SDS for 30min (all at the same temperature as
hybridisation), prior to exposure to X-ray film for 24 hours or 3 days at -70°C. The
autoradiographs were developed using standard photographic solutions.
3.3.4 Re-Prohing
Bound probe was removed from filters by boiling the filter in O.lxSSC, 1% SDS for










lOOpg/ml denatured and snap cooled salmon sperm DNA
Made up in distilled water and heated to 65°C prior to use.
3.4 Southern hybridisation analysis of genomic DNA
3.4.1 Restriction Digestion Of Genomic DNA
8-10|ig of genomic DNA were digested with the restriction enzyme BamHI (NBL)
overnight at 37°C. Some samples were also digested with PstI (NBL) and Hindlll
(NBL). In all cases, the enzyme was present in a twofold excess and the total volume
of the reaction was no less than 30pl 3jil of loading buffer were added and the
samples run on a 20 x 20, 0.8% agarose gel (containing 0.5|ig/ml ethidium bromide) at
50mA, room temperature, overnight. Positive (purified DNA of various HPV types
diluted in 5jig of restriction digested, placental DNA) and negative (restriction
digested placental DNA) controls were included on each gel. To confirm adequate
digestion of genomic DNA, the DNA was visualised on a UV transilluminator and the
image recorded. The gel bound DNA was then denatured for 30min in 0.5M NaOH,
1.5M Tris prior to transfer to nylon filters.
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3.4.2 Southern Transfer Of Genomic DNA
Whatman 3mm filter paper, pre-soaked in 0.5M NaOH, 1.5M Tris, was placed on a
plate suspended over a glass dish containing the same alkaline solution, with the ends
of this paper serving as a wick to draw up the solution. The gel was then placed on top
of this filter paper and a 20 x 20 sheet of charged nylon membrane (Hybond N+,
Amersham) placed on top of the gel, followed by 2 sheets of 20 x 20, 3mm filter paper.
Bubbles between the gel and membrane were removed prior to the addition of a 3inch
stack of absorbent paper towels with a very heavy weight on top to aid capillary
movement of the buffer through the gel and membrane. Transfer took place over 16-20
hours before the membrane was removed and neutralised in 3M NaCl, 0.5M Tris (pH
7.4) for 30min.
3.4.3 Prehvbridisation And Hybridisation
For filters containing genomic DNA, prehybridisation and hybridisation were carried
out as specified for dotblot filters but at a temperature of 55°C. A probe cocktail
containing HPV types 3, 8 and 13 was used on all filters, as was a probe cocktail
containing HPV types 2 and 12. Each filter was also probed with single HPV types and
other combinations of HPV types to a maximum of 4 re-probings. The filters were
initially washed with 2XSSC, 1%SDS for 30min at 55°C then exposed to X-ray film
for 24 hours. Following development of the autoradiograph, the filter was exposed to
X-ray film for a further 3 days. If a high background of radioactivity was present, the
filter was washed at 0.5XSSC, 1%SDS for 30 min at 55°C then exposed to X-ray film
for a further 1-3 days.
4; POLYMERASE CHAIN REACTION
4.1 PRIMF.R DESIGN
Oligonucleotide primers, situated in E6 of the HPV genome, were designed from
published sequence data (Danos et al, 1982; Fuchs et al, 1986; Zachow et al, 1987;
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Hirsch-Behnam, 1990) to detect HPV types 1, 2, 5 and 8 in type specific assays (Table
3.3). The secondary structure, G-C content, specificity (with regards other HPV types)
and annealing temperature of all primers were analysed with the aid of the University
of Wisconsin (UW) Genetics Computer Group software. Oligonucleotides suitable for
primers were synthesised on an Oswel Gene Synthesiser (Dept. of Chemistry,
University of Edinburgh, UK) and were HPLC purified. Primers for HPV types 6b, 11,
16 and 18 were received from M.J Arends and had been validated in previous studies
(Arends et al, 1991). Consensus primers MY09 and MY11, situated in LI of the HPV
genome and known to amplify genital HPV types, were received from M. Manos
(Manos et al, 1989).
4.2 PGR ANALYSTS
PCR was carried out in a lOOpl reaction containing 10|il of pre-prepared xlO reaction
buffer (NBL), 200(iM of each dNTP (Boehringer), l.OpM of each primer and 0.5 units
of taq DNA polymerase (NBL). Purified HPV DNA, diluted in genomic DNA, was
used to optimise the PCR assay for each primer pair. The optimal cycle conditions on a
Hybaid automated heating block were as follows: one cycle of 94°C for 5min; 30
cycles of 58°C (55°C for HPV1) for 2min, 72°C for 3min and 94°C for lmin; and one
cycle of 58°C (55°C for HPV1) for 2min and 72°C for lOmin. 30|il of amplified PCR
product were run alongside a DNA size marker on a 2% NusieverSeakem (3:1)
agarose gel (Flowgen Instruments) containing 0.5|lg/ml ethidium bromide in TBE
buffer. DNA was visualised on a UV transilluminator and the image recorded. Samples
were scored as positive when a band of the correct size was visible.
4.3 PCR ANALYSIS OF GENOMIC DNA
Prior to amplification with HPV primers, each sample was amplified with control Ki¬
ms primers to confirm adequate preservation of DNA. These primers were as follows:
pi- GACTGAATATAAACTTGGTGG, p2 - CTCTATTGTTGGATCATATT, and
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resulted in a product size of 109bp. A lfig aliquot of genomic DNA was used as
template in a 100|il reaction and positive (lpg and 0.0lpg of HPV DNA) and negative
(template free and colonic DNA) controls were included in each reaction.
4.4 CONSENSUS PRIMER PCR
The consensus primer PCR assay was based on that of Lungu et al, (1992). lOpg of
HPV types 1, 2, 3, 4, 8, 10, 12, 14, 17, 19, 20, 6 and 18, mixed with lqg of human
placental genomic DNA or lqg of sample DNA were amplified using the HPV
consensus PCR primers described by Manos et al, (1989). In initial studies, PCR
reaction conditions were according to the protocol of Manos et al, (1989). 10(0.1 of
sample DNA were added to a 100|il reaction mixture containing 50mM KC1, 4mM
MgCl2, lOmM Tris (pH 8.5), 200uM dNTPs, 1 (iM of each PCR primer and 2.5U Taq
DNA polymerase (NBL). This reaction mixture was subjected to 35 cycles of 95°C for
lmin, 37°C for 1.5min and 72°C for 1.5min. Subsequently, the above buffer was
replaced by NBL pre-prepared xlO reaction buffer and the cycle conditions altered to
1 cycle at 95°C for 5min, 30 cycles at 45°C for lmin, 72°C for 2min , 95°C for lmin
and 1 cycle at 45°C for lmin, 72°C for lOmin.
Following amplification, 30ql of PCR product were electrophoresed as for the
standard PCR protocol. To type the product by restriction fragment length
polymorphism, the paraffin oil was removed from each HPV positive sample and the
remaining product precipitated by the addition of 1 volume of ethanol followed by
incubation at -20°C. DNA was pelleted by microcentrifugation, washed in 70% ethanol
and resuspended in lx restriction enzyme buffer containing lOmM Tris HC1 (pH 7.9),
lOmM MgCl2 , 50mM NaCl and ImM DTT. 2jil of a cocktail of enzymes containing
10U each of Haelll, Pstl and Rsal (Boehringer) was then added and the mixture
incubated at 37°C for 4-12 hours. The entire reaction was then analysed by gel
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electrophoresis as described above. A DNA size marker (Boehringer, marker V) was
included on all gels.
4.5 PROCEDURES TO MINIMISE THE RISK OF CONTAMINATION
Stringent precautions were taken to minimise the risk of contamination of the PCR
solution with HPV DNA from unwanted sources. In the preparation of genomic DNA,
the scissors used to mince the tissue were stringently cleaned with 1M HC1 between
cases and pipettes specifically for genomic DNA, with filtered pipette tips, were used
during the extraction procedures. Filtered pipette tips were also used when adding
genomic DNA to the PCR reaction. Separate laboratories were used for preparation of
the PCR reaction, analysis of the PCR products and preparation of genomic DNA.
Positive displacement pipettes were used in setting up the PCR reaction which was
carried out in a class II biological safety cabinet.
5: IMMIJNOCYTOCHEMISTRY
5.1 IMlVnJNOCYTOCHEMICAL ASSAY FOR THE DETECTION OF ACCUMULATED P53
3pm sections of PLPD or formalin fixed, paraffin embedded tissue were cut, floated
onto glass slides and allowed to dry at 30°C. Sections were dewaxed in xylene,
rehydrated in graded alcohols then washed for 5min in TBS. Normal rabbit serum
(NRS), diluted 1:1000 with TBS (NRS/TBS), was then applied for 30min followed by
incubation with an anti-p53 monoclonal antibody (PAbl801 (DAKO) or MAb Do-7
(Novocastra)), diluted 1:100 with NRS/TBS, for 1 hour (PLPD fixed material) or
overnight (formalin fixed material). Bound antibody was detected by treatment with
biotinylated rabbit antibody to mouse immunoglobulin (1:400 NRS/TBS) for lOmin
followed by incubation with avidin-biotin comlpex linked to horseradish peroxidase
(Dako) for 30min. After TBS washing, bound antibody was visualised with
diaminobenzidene (lmg/ml in 0.2M Tris pH 7.6, 0.03% hydrogen peroxide) for 2 min
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followed by a tap water wash, a light haematoxylin counterstain and dehydration in
graded alcohols and xylene, prior to mounting under coverslips.
Tris Buffered Saline
145mM NaCl
20mM Tris pH 7.6
5.2 ASSESSMENT OF EXTENT OF IMMIINOPOSTTTVTTY
Each section was scored by two independent observers and the extent of staining
recorded on the following graded scale: 1=<10%, 2=10-50%, 3=>50% of cells in a
lesion showing positive nuclear staining. Sections were scored as positive when
immune precipitate was visible in > 10% of cells in the lesion i.e., grades 2 and 3 only.
The significance of sparse nuclear p53 staining is presently unknown, therefore, lesions
with grade 1 score were considered to be negative. The histological localisation of
stabilised p53 within each lesion was also noted.
6: SINGLE STRAND CONFORMATIONAL POLYMORPHISM AND
SEQUENCING TO DETECT P53 MUTATIONS
6.1 PRC OF EXONS 5 TO 8 OF P5.3 FOR SSCP ANALYSIS
The polymerase chain reaction was performed on 0.1-l|ig of tumour genomic DNA
(and in most instances, paired normal DNA), in a lOOjil reaction with reagents as
specified in Section 4.2 of the materials and methods and primers specific for exons 5,
6, 7 and 8 of the p53 gene (Table 2.2). PCR was performed in an automated
thermocycler (Hybaid) with the following temperature profile: 1 cycle of 94°C for
5min, 30 cycles of 94°C for lmin, 58°C for lmin, 72°C for lmin and 1 cycle of 72°C
for lOmin.
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6.2 SSCP analysis of PCR products
The amplified products were extracted once with 24:1 chloroform/isoamylalcohol to
remove any mineral oil. 5-10(0.1 of purified products were then denatured in 80uM
NaOH, lOuM EDTA, at 48°C for 5min, 10pl of sequencing stop solution was then
added and the whole sample loaded onto a 5% glycerol, 0.5x MDE Hydrolink gel
(Hoefer Scientific). The gel was ran in IX TBE on the SE600 PAGE apparatus
(Hoefer Scientific) at 25°C, 20W for 2-3 hours. Bands were visualised by a silver stain
(Biorad) as per manufactures instructions. The gel was dried onto 3mm paper and
laminated.
Table 2.2 Primers Used Tn SSCP Analysis Of Exons 5 To 8 Of p53 And
Sequencing Of Exon 7












6.3 Cloning of PCR products for sequencing exon 7 mutations
6.3.1 PCR Of Genomic DNA
Genomic DNA from samples found to have an exon 7 mutation by SSCP analysis were
amplified using primers 890 and 891 (Table 2.2) that amplify exons 7-9 of the p53
gene. Standard reaction conditions, as previously specified for HPV DNA, were
applied (see Section 4.2 of Materials and Methods). The PCR reaction consisted of 30
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cycles of 96°C for 1.3min, 53°C for 1.6min and 71°C for 2.5min. On completion of the
reaction, the entire sample was electrophoresed through a 1% low melting temperature
gel. Following extraction of the amplified band, the DNA was purified from agarose
using the Geneclean II kit (as specified by the manufacturer, Stratech LTD) and the
concentration measured using ethidium bromide plates (see Section 2.5 of Materials
and Methods). The purified product was then restriction digested by adding 2|il of
BamHI enzyme, 2(0.1 of Hindlll enzyme, 2|il BamHI enzyme buffer and 4(il of water
then incubating at 37°C for lhour. 5|il of digested product were run on an 1% agarose
gel to test for adequate digestion and the remaining digested product was purified once
more using Magic Cleanup Columns (Promega) as specified by the manufacturer. 50ng
of pUC18 were also restriction digested using BamHI and Hindlll and purified with
Magic Cleanup Columns. The concentrations of restriction digested insert and vector
were estimated using ethidium bromide plates.
6.3.2 Ligation
Approximately lOng of vector and 5ng of insert were ligated in a reaction containing
lmg/ml bovine serum albumin, ImM ATP, 1 x ligase buffer and l(il T4 DNA ligase
(New England Biolabs). The reaction was incubated overnight at 16°C and used to
transform competent DH5a E.coli as specified for HPV DNA (see Section 2.1). 5-10
transformed colonies were pooled and cultured overnight in lOmls of L broth.
Miniprep DNA was prepared from these cultures using a Magi Mini-prep kit
(Promega) as per manufacture's instructions.
10 X Ligase Buffer





5ng of plasmid DNA were initially mixed with lOng of primer DNA (the upstream
exon 7 primer used for SSCP analysis) and denatured by the addition of l(il of NaOH
at 37°C for lOmin. The mixture was then neutralised with l|il 1M HC1 and 2pi 5x
sequencing buffer added and incubated for a further 5min at 37 °C. Sequencing was
then carried out using the dideoxy chain termination method with the Sequenase 2.0 kit
(United States Biochemical) as per manufacturer's instructions. All the solutions were
supplied in kit form.
6.3.4 Polvacrvlamide Gel Electrophoresis
A 0.25mm thick denaturing, polyacrylamide gel was poured between the glass plates of
a Gibco BRL sequencing apparatus and allowed to polymerise. The gel was then pre-
run at 40W until it had reached 50°C. 2pl of denatured (75°C for 2min) sequencing
reaction (4 reactions per sample) were loaded onto the gel and the gel run at 40-50W
until the bromophenol blue dye had run through the gel once. Following separation of
the plates, the gel was fixed in 12% methanol, 10% acetic acid for 2 X lOmin. Once
the final fix was removed, the gel was adhered to a piece of Watmann 3mm filter
paper, vacuum dried at 80°C for lhour then exposed to X ray film (Kodak) overnight
at -70°C. Following development using standard photographic solutions, the sequence
was read by eye.
6% Urea Acrylamide Gel
6% Acrylamide:bisacylamide (39:1)
1 XTBE
lpl 25% Ammonium persulphate per ml of gel
lpl TEMED per ml of gel
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6.4 use of DYNABEADS for sequencing exon 5 mutations
Sequencing was performed by this method on samples found to contain exon 5
mutations by SSCP analysis.
6.4.1 PCR Of Genomic DNA
PCR of exons 5 to 6 was carried out using a biotinylated upstream primer (pi in Table
2.2) and the exon 6 reverse primer (p2) as for SSCP analysis. The reaction components
were as previously specified (see Section 4.2 of Materials and Methods) and the
cycling conditions were as for SSCP analysis (see above).
6.4.2 PreparatiQn Qf Single Stranded DNA
The two strands of PCR amplified products were separated using DYNABEADS
(Dynal). 20|il of DYNABEADS per sample were prewashed in 60jil of lx B+W
buffer. The beads were then placed next to a magnet and the wash buffer removed.
Following resuspension in lOOp.1 of B+W buffer, the beads were added to IOOjllI of
amplified product and mixed periodically for 15-20min. The samples were then placed
next to a magnet, the supernatant removed and the sample washed once in B+W
buffer. The supernatant was removed once again followed by 2 5min incubations with
20|a.l of 1M NaOH. The samples were washed once in 200pl of B+W buffer and once
in 200|il TE then resuspended in 5pl DDW. 5(il of single stranded DNA attached to
DYNABEADS were used in each sequencing reaction.
B+W Buffer




6.4.3 Sequencing And Electrophoresis







1: CLINICAL AND PATHOLOGICAL FEATURES
1.1 CLINICAL FEATURES
Renal allograft recipients residing in the Edinburgh area are routinely monitored for the
presence of cutaneous lesions including VWs, keratoses and skin malignancies. During
the period 1989-1993, 173 cutaneous biopsies were collected from 19 female and 33
male RARs (Table 3.1). 6mm punch biopsies of non-involved, sun-exposed forearm
skin were also obtained from a further 11 male and 2 female patients. All IEC/SCC
came from 18 RARs whose details are given in tables 3.2A and B. Seven patients
(patients 16, 20, 23, 34, 54, 26 and 64), all with graft lives of 10 years or more,
exhibited multiple dysplastic and malignant skin neoplasms over the 4 year collection
period (Tables 3.2A and B and appendix 1). However, 9 of the 15 patients with graft
lives of 15 years or more, exhibited no, or very few, cutaneous lesions (Table 3.2A).
Conversely, 1 IEC and 1 SCC were collected from a patient with a graft life of only 2
years (Table 3.2B). Face, hands, scalp (in bald men) and forearms were the most
common sites for VW and skin cancer development although, a small number of IECs
and SCCs were removed from non sun-exposed body sites. Although the majority of
patients with IECs/SCCs had moderate to high sun exposure, some patients with
multiple cutaneous SCCs had low sun exposure whilst other patients with graft lives of
>15 years and high sun exposure, exhibited no skin cancers (Table 3.2A).
103 lesions from 83 ICPs were also obtained during the period of this study (Table
3.1). BCCs are far more common than SCCs in ICPs and therefore, SCCs from ICPs
were difficult to obtain for this study. Overall, cutaneous lesions from ICPs were
derived from an elderly, chronically sun-exposed population with lesions on sun-
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exposed body sites. The 48 ICPs exhibiting IECs/SCCs were on average, over 20 years
older (mean age 75 years) than RARs with comparable lesions (mean age 54 years).
T.2 histopathological features
Histological examination of VWs, keratoses, IECs and invasive SCCs from RARs
revealed a spectrum of change from a typical viral wart to an invasive SCC (Figure
3.1). The majority of VWs from RARs exhibited mild to moderate dysplasia as well as
viral features, such as symmetry of lesion, papuliferous architecture, irregular patterns
of vascularity and focal koilocytic change (Figure 3.1A). Likewise, some degree of
dysplasia was observed in all verrucous keratoses from RARs (Figure 3. IB). In fact,
in 8 of these lesions, this dysplasia was full thickness and almost amounted to IEC
(Figure 3.1C). The combination of viral features and severe dysplasia was also
observed in several SCCs which showed viral architecture and cytological features at
one margin and typical features of an SCC at the other (Figure 3. ID). However, in
general, the viral features diminished as dysplastic and invasive aspects emerged.
Table 3.1:- Cutaneous Lesions From RAR and TCP
HISTOLOGICAL TYPE OF LESION
PATIENTS VW AK VK IEC SCC BCC MISC. US
RAR 28 28 20 35 41 7 14 24
ICP 8 15 3 32 17 14 2 12
RAR = renal allograft recipient; ICP = immunocompetent patient; VW = viral wart;
AK = actinic keratoses; VK = verrucous keratoses; IEC = intraepidermal carcinoma;
SCC = squamous cell carcinoma; BCC = basal cell carcinoma; MISC. = miscellaneous
lesions (including 5 seborrheic warts and 4 keratoacanthomas); US = uninvolved,
sun-exposed forearm skin.
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Table 3.2:- Distribution Of lesions Per Patient
A: PatientsWith a Graft Life Of >15 Years
PATIENT DETAILS CUTANEOUS LESIONS
Code Age/Sex Graft Life Sun Aza/ High VW K IEC SCC US MISC
(m/f) (yrs) CyA Risk
1 44 m 15 Mod Aza - - - - 1 -
3 39 m 18 Low Aza 1 - - - 1 -
12 55 f 15 Low Aza 1 6 - 1 - -
16 49 m 17 Mod Aza + - 4 3 6 1 1
20 36 f 21 Low Aza + 1 2 4 9 - -
21 60 m 23 High Aza - - - - 1 -
23 56 f 23 Low Aza + 4 4 7 1 - 1
34 44 m 26 High Aza + 1 1 3 8 - -
41 45 m 21 Low Aza - - - - 1 -
46 42 m 16 High Aza - - - - 1 -
49 46 f 25 Low Aza - 1 - - - -
54 52 m 15 High Aza + - 5 2 3 1 1
57 48 m 15 Mod Aza - 1 - - - -
60 43 f 20 Low Aza 1 - - - - -
61 58 f 15 Low CyA - 1 - - - -
B: Patients Exhibiting IEC/SCC With A Graft Life Of <15 Years
PATIENT DETAILS CUTANEOUS LESIONS
Code Age/Sex Graft Life Sun Aza/ High VW K IEC SCC US MISC
(m/f) (yrs) CyA Risk
6 55 m 2 Mod Aza - - 1 1 1
8 56 m 6 Mod CyA - 2 1 - -
13 58 m 5 High CyA - - 1 - -
14 56 m 4 Low CyA - - 1 - 1
26 52 m 10 High Aza + 3 5 4 7 -
27 66 m 8 High CyA - 1 2 - 1
39 59 m 9 C uk CyA - - - 1 -
40 59 m 13 High Aza - 2 1 - 1
53 33m 6 High CyA 1 - 1 - -
58 76 m 10 High Aza - - - 1 -
59 69 m 1 Low CyA - - 1 - 1
64 57m 12 High Aza + - 1 3 3 1
Lesions collected at the Royal Infirmary of Edinburgh, Department of Dermatology,
during the period 1989-1993.
Sun exposure: low = very little, mod = outdoor leisure activities, high = outdoor
occupation or more than 3 months in a tropical climate. Aza = azathioprine;
CyA = cyclosporin A; m/f = male/female; VW = viral wart; K = keratoses;
IEC = intraepidermal carcinoma; SCC = squamous cell carcinoma; US = uninvolved,
sun-exposed forearm skin; MISC = miscellaneous lesions (including BCCs);
C = cardiac allograft recipient; uk = unknown.
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Figure 3.1:- (A) Viral wart exhibiting papuliferous architecture. Inset shows cell
vacuolation (koilocytic change) and cytoplasmic inclusions at high power.
(B) Verrucous keratosis with the topography of a viral wart but lacking the cytological
features. There is some irregularity of the basal tongues. (C) Verrucous keratosis with
widespread dysplasia amounting to intraepidermal carcinoma. (D) Invasive squamous














2: HPV IN CUTANEOUS NEOPLASIA OF RENAL
ALLOGRAFT RECIPIENTS
2.1 DESIGN AND OPTIMISATION OF HPV DETECTION ASSAYS
2.1.1 Validation Of HPV Probes
Prior to use in Southern hybridisation and PCR assays, all HPV containing plasmid
DNAs were digested with multiple restriction enzymes in order to confirm that they
were of the specified HPV type. The restriction digest patterns of all HPV types used
in this study were as published. Figure 3.2 demonstrates the validation of HPV 5 and 8
plasmid DNA. HPV 10 was received as two plasmids, one containing the 6.7Kb and
the other the 0.5Kb BamHI fragments. Only the 6.7Kb fragment was used in
optimisation assays and as a DNA probe. The two EcoRI fragments of HPV 5C had
also been cloned separately (HPV5/48 and 5/9 in Figure 3.2A). Control HPV 5 DNA
and HPV 5 DNA probes contained a mixture of both these fragments. The three
BamHI fragments of HPV 13 were previously cloned by partial digestion into a single
pBR322 vector. In this case, DNA probes contained a mixture of the two larger
fragments (5.5Kb and 1.7Kb), purified separately. For all other HPV types, the full
HPV genome was used in optimisation assays, as controls for Southern hybridisation
analysis and as DNA probes.
2.1.2 Optimisation Of The Southern Hybridisation Assay
Dot blot filters containing purified HPV DNA of types 1, 2, 3, 4, 5, 8, 10, 12, 13, 14,
17, 19 and 20, were prepared and used to optimise a Southern hybridisation assay in
which multiple HPV types could be detected using a single cocktail of HPV probes.
Initial experiments indicated that at low hybridisation (Tm -35°C) and washing
(Tm -40°C) stringency, a single HPV probe, containing either HPV type 8 or 12, is
able to detect HPV types 5, 8, 12, 14, 17, 19 and 20. Similarly, a DNA probe of HPV
type 2 or 3 was found to cross hybridise with HPV types 2, 3 and 10, and an HPV 13
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probe with HPV types 1, 2, 3, 10, 13, 19 and 20, under the same hybridisation and
washing stringencies. Subsequently, it was found that by using a probe cocktail of
HPV types 3, 8 and 13 at a low hybridisation (Tm- 35°C) and washing (Tm -40°C)
stringency, it was possible to detect HPV types 1, 2, 3, 5, 8, 10, 12, 13, 14, 17, 19 and
20 (Figure 3.3 A). A probe cocktail containing HPV types 2, 4 and 12 was also found
to cross hybridise with multiple HPV types, including HPV type 4 which was not
consistently detected in the other assay. Neither probe cocktail hybridised to control
human genomic DNA or pBR322 under these conditions of stringency (Figure 3.3A).
The results obtained from dot blot filters were confirmed, with identical HPV type
specificity, by performing Southern hybridisation analysis on control genomic DNA
(placental DNA) spiked with purified HPV DNA (Figure 3.3B). HPV 6,11,16 and 18
were not tested in these assays, although they are known to hybridise to HPV 13 (de
Villiers, 1989).
The sensitivity of the Southern hybridisation assay was assessed using serially diluted,
purified HPV 16 DNA mixed with a known concentration of control genomic
(placental) DNA. These preliminary investigations demonstrated that Southern
hybridisation analysis, using similar hybridisation and washing conditions and an FIPV
16 probe radioactively labelled to a specific activity of 4 x 10^ c.p.m/ ml, could detect
5pg of viral DNA in a background of 1 Oug of genomic DNA following an overnight
exposure to X-ray film (Figure 3.4A). This detection level is equivalent to 0.2 copies
of HPV DNA per cell. Southern analysis, using mixed HPV probes to detect multiple
HPV types, was sensitive to 50pg of viral DNA in a background of lOug of genomic
DNA, which is equivalent to 2 copies ofHPV DNA per cell.
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Figure 3.2:- ValidationOf HPV Type 5 And 8 Plasmid dna




A HPV5/48 EcoRl 4,1.7 4, 1.7
B HPV5/9 EcoRl 4, 5.8 4, 5-6
C HPV5/48 PstI 4.7, 1.2 4-5, 1.3
D HPV5/9 Psil 8.7, 1.2, 0.75 9-11, 1.4,0 8
E HPV5/48 EcoRl+PstI 3.4, 1.3,0.7, 0.5 3.5, 1.3,0.8, 0.6
F HPV5/9 EcoRl+PstI 5.1,3.4, 0.7,0.75, 0.5 5-6, 3-4,0.75, 0.7, 0.5
G HPV8 BamHI 8.0, 4.0 4.0, 8.0
H HPV8 BamHE Pvtill 5.2J2.8, 1.8, 1.2, 10 5.0,2.5, 1.7, 1.3, 1.0
I HPV8 PvuII 5.2,3.5, 1.9, 1.22 5.0, 3-4, 1.8, 1.2
M = 1Kb Ladder (Gibco) size marker; HPV5/48 = 1 7Kb EcoRl fragment ofHPV5C
cloned into pBR322; HPV5/9 = 5 8Kb EcoRl fragment ofHPV5C cloned into
pBR322; HPV8 = full length HPV 8 cloned into pBR322 * = Length of restriction
fragments in Kb.
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Figure 3.3:- (A) Autoradiograph of dot blot filter containing HPV types 1, 2, 3, 4, 5,
7, 8, 10, 12, 13, 14, 17, 19 and 20 probed with a probe cocktail of HPV types 3+8+13
at low hybridisation (Tm-35°C) and washing (Tm-40°C) stringency. 1 = 50pg of
purified HPV DNA; 2 = 5pg of purified HPV DNA; C = control human genomic
(placental) DNA; pBR322 = 50pg of purified pBR322 plasmid DNA.
(B) Autoradiograph of Southern hybridisation analysis performed on lOOpg of purified
HPV DNA (of types 1 to 20) mixed with 10|ig of BamHI restricted, human genomic
(placental) DNA, hybridised with a probe cocktail of HPV types 3+8+13 at low







































































2.1.3 Design of PCR Primers For HPY Types 1. 2. 5 And 8
Several factors were taken into account when designing primers for the HPV detection
assay. In anogenital cancers, viral integration has been shown to disrupt all but the
URR and the E6 and E7 ORFs. In addition, E6 from HPV types 5 and 8 is known to
be oncogenic in transformation assays (Watts et al, 1984; Iftner et al, 1988; Fuchs &
Pfister, 1990). Therefore, the E6 ORF was chosen as the target sequence for primer
design. In order to design absolutely type specific PCR primers for HPV types 5 and 8,
the nucleotide sequences of which are over 75% homologous, the University of
Wisconsin (UW) computer program GAP was used to identify sequences unique to
each HPV type. This program allows the determination of the exact extent of base
mismatching of the most similar HPV types. Using this program, the published
nucleotide sequences within the Genbank/EMBL databases of HPV types 5 and 8 were
compared to each other and to those of HPV 1 and 2. Regions with a high degree of
mismatching at either end of the E6 ORF were selected for the design of unique PCR
primers for each HPV type. Within these regions, sequences suitable for efficient
primers were identified on the basis of several other criteria, including GC content,
predicted secondary structure and 3' complementarity, following guidelines set out by
Saiki (1989). Primers of 25-30bp with an even distribution of GC to AT nucleotides
were chosen to allow the use of stringent annealing temperatures, further ensuring type
specificity. The sequences chosen for use as oligonucleotide primers are shown in
Table 3.3.
2.1.4 Optimisation Of PCR Assays For HPV Types 1. 2. 5 And 8
The PCR reaction conditions for all primer pairs were optimised by performing PCR
on serially diluted, purified HPV DNA mixed with a known concentration of genomic
(placental) DNA, over a range of annealing temperatures. Primers for HPV types 2, 5
and 8 were found to specifically amplify HPV DNA at an optimal annealing
temperature of 58°C whereas the optimal annealing temperature for HPV 1 primers
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was 55°C. Denaturing, annealing and extension times of lmin, 2min and 3min
respectively were more efficient than equivalent times of 30sec, lmin and lmin. For all
HPV types, these optimal reaction conditions allowed detection of O.Olpg of HPV
DNA in a background of lug of genomic DNA which is equivalent to 4x10" ^ copies of
HPV genome per cell (Figure 3.4B). Each set of primers was also tested against a
panel of cloned HPV types 1, 2, 3, 4, 5, 8, 10, 12, 13, 14, 17, 19 and 20, and found to
be absolutely type specific.
Table 3.3:- HPV Primer Sequences Used to Detect HPV Types 1. 2. 5 and 8
































* = Nucleotide position in HPV genome defined by EMBL/Genebank database
2.2 HPV prevalence in cutaneous neoplasia from RAR AND ICP
A total of 125 skin biopsies from RARs, including 60 IEC and SCC specimens from 16
patients, together with 71 specimens from ICPs were analysed by Southern
hybridisation using the mixed probe cocktails 3, 8 and 13 and 2, 4 and 12 (as described
above), to screen for the presence of HPV DNA. As expected, detection of HPV DNA
was greatest in VWs (50%), but 23% of keratoses, 29% of IECs and 41% of SCCs
from RARs contained HPV DNA (Table 3.4 and Figure 3.5). In both
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figure 3.4:- SensitivityOf HPV Detection Assays
(A)
pg HPV DNA





(A) Autoradiograph of Southern analysis performed on serially diluted, purified HPV
16 DNA mixed with 10/ig of RamHI digested genomic (placental) DNA. The filter
was probed with a full length HPV 16 probe at high hybridisation (Tm-25°C) and
washing (Tm-30°C) stringency and exposed to X ray film overnight. Under these
conditions of stringency, 5pg of viral DNA could be detected in a background of 10/xg
of genomic DNA which is equivalent to 0.2 copies of HPV per cell. (B) Ethidium
bromide stained gel of serially diluted, purified HPV 8 DNA, mixed with 1/xg of
genomic DNA, amplified using HPV 8 primers. Using the conditions specified in the
text (see 2.3.1), 0.01 pg of HPV 8 DNA could be detected in a background of 1/xg of
genomic DNA which is equivalent to 4 X 10"^ copies of HPV genome per cell
Identical results were obtained for the primers designed to amplify HPV types 1, 2 and
5 (not shown). M = 1Kb molecular weight marker (Gibco).
pg HPV DNA
M 10 1 0.1 0.01 0.001
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populations, only one specimen (out of 21 for RARs and 12 for ICPs) from normal
skin was positive for HPV DNA. Within the RAR group, this rate of positivity was
significantly less than that of SCCs (41%; p < 0.01), IECs (29%; p < 0.05), and VWs
(50%; p < 0.001) using a x^ test. Except for 6 viral warts, lesions from ICPs showed
lower HPV DNA prevalence than those from RARs (Table 3.4). Statistical comparison
of the results for each histological category between RARs and ICPs revealed that
IEC/RAR differed significantly (p<0.05 by x^ test) from IEC/ICP. Statistical
significance was not reached for the comparison of SCCs due to the small number of
SCCs from ICPs analysed.
Table 3.4 - HPV DNA Prevalence Detected by Southern
Hybridisation Analysis
Patient Group Number (%) lesions positive
RAR
ICP
VW K IEC SCC US
7/14 (50) 7/30 (23) 9/31 (29) 12/29 (41) 1/21 (5)
6/6(100) 1/13 (8) 1/25 (4) 3/15 (20) 1/12(8)
RAR = renal allograft recipient; ICP = immunocompetent patient, VW = viral wart;
K = keratosis; IEC = intraepidermal carcinoma; SCC = squamous cell carcinoma;
US = uninvolved, sun-exposed skin.
X2 tests revealed significant differences of p < 0.001 for comparisons of VW/RAR
with US/RAR, p < 0.05 for comparison of IEC/RAR with US/RAR, p < 0.01 for
SCC/RAR versus US/RAR, and p < 0.05 for IEC/RAR versus IEC/ICP.
2.3 HPV TYPES AND PHYSICAL STATUS OF HPV DNA IN CUTANEOUS NEOPLASIA
FROM RAR
Some of the cases found to be HPV positive by the initial screen for HPV DNA were
further analysed by high stringency Southern hybridisation (Tm -50°C for hybridisation
and Tm -55°C for washing) with single HPV probes and by Southern hybridisation
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Figure 3.5:- Autoradiographs showing HPV positive and negative cutaneous lesions.
All specimens were from immunosuppressed patients and the size markers are
indicated. A probe cocktail of HPV types 3+8+13 was used with BamHI digested
genomic (sample) DNA. Track (A) is an HPV positive SCC (sample 77) from patient
34; tracks (G) (sample 68) and (N) (sample 18) are HPV positive dysplastic keratoses;
tracks (D) (sample 82), (F) (sample 88), (H) (sample 70) and (O) (sample 17) are
HPV positive viral warts. See Appendix 1 for patient codes of samples. Track A shows
evidence of HPV genome integration within a DNA fragment greater than 12Kb in
size. Track N shows multiple restriction fragments, the sum of which are greater than
8Kb. This banding pattern was reproducible suggesting that viral integration may also
have occurred in this sample. Tracks D, F, G and H show episomal HPV genomes
cleaved into two fragments of approximately 2Kb and 6Kb (see Table 3.5 for details of
the typing of these samples). Tracks (I), (J) and (M) are HPV negative SCC; (C) and
(K) are HPV negative IEC; (B) (this sample was HPV 16 positive by PCR) and (E)
are HPV negative keratoses. (L) is an SCC which was negative when probed with the
HPV 3+8+13 probe cocktail but was HPV positive when probed with a probe
containing HPV types 2 and 12. This sample was also HPV 2 positive by type specific
PCR
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using the restriction enzymes PstI and HincUII, in an attempt to determine more
precisely the type of HPV present (Table 3.5, Figure 3.6). Although some of the
restriction patterns obtained were similar to those of published HPV types, none were
identical to those published for HPV types 1 to 57. Overall, multiple different common
cutaneous and EV-associated HPV types appeared to be present in both dysplastic
VWs and pre-malignant and malignant skin tumours from RARs. In one IEC, only a
single 3-3.5Kb band was present when the lesion was digested with both BamHI and
PstI, while in other cases, the Hindlll and PstI digests resulted in multiple bands, the
sum of which were greater than 8Kb. Due to the apparently small copy numbers of
HPV genomes within lesions from ICPs, no attempt was made to further type the HPV
detected by the initial screen of these lesions.
Restriction pattern analysis identified complex patterns of HPV DNA bands, that could
not be explained by single episomal forms of HPV types 1 to 57 (for which restriction
enzyme patterns have been well characterised), in 2 VWs, an actinic keratosis and an
SCC from 4 separate RARs. When digested with the single cut enzyme BamHI, these
cases gave either multiple restriction fragments (sample 18, Figure 3.5), the sum of
which was greater than 8Kb but dissimilar to the size of multiple episomes or, a high
molecular weight band of >12Kb (samples 46, 77 and 78, Table 3.5, Figure 3.5).
Similarly, PstI digestion resulted in multiple high and low molecular weight bands, the
sum of which was greater than 8Kb, in these samples (Figure 3.6A and D). These
banding patterns were reproducible, excluding incomplete digestion. Possible
explanations for these complex banding patterns include integration of HPV genomes,
infection with two different HPV types (both episomal or episomal and integrated),
intra-episomal DNA rearrangements such as URR duplications, or a combination of
these. These possibilities cannot be reliably distiguished by the availabe data, although,
band sizes of >12Kb favour the possibility of viral genome integration.
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Tart.f. 3.5 - Type and physical status of HPV DNA in cutaneous neoplasia
FROM RAR















































































































# = All Southern analysis was carried out at low hybridisation (Tm -35°C) and washing
(Tm -40°C) stringency; * = the most closely related HPV type to that of the sample, as
determined by restriction fragment length analysis. None of the samples had restriction
fragment banding patterns identical to HPV types 1 to 57; int/mul = HPV integrated or
sample infected by multiple HPV types; @= this sample was HPV 2 positive by PCR;
** = this sample hybridised to an HPV 14 probe at high hybridisation (Tm -45°C) and
washing (Tm -48°C) stringency. VW=Viral wart; AK=actinic keratoses;
VK=verrucous keratoses; IEC=intraepidermal carcinoma; SCC=squamous cell
carcinoma. (1), (2) and (3) = patients exhibiting multiple typed samples (see Apendix 1
for patient codes of samples)
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Figure 3.6:- Southern hybridisation autoradiographs showing DNA from cutaneous
lesions, digested with a variety of restriction enzymes and probed with HPV probes at
varying stringencies. The molecular weights of fragments are shown. M = 1Kb Ladder
(Gibco) size marker. (A); Two HPV positive viral warts. In both samples, the DNA
was digested with the restriction enzyme PstI and the resulting filter probed with HPV
13 at medium stringency. Sample 78 gave a high molecular weight band (>12Kb) when
digested with BamHI providing evidence for viral integration into the host cell
genome. Sample 70 was HPV 2 positive by type specific PCR. (B); DNA from a
dysplastic keratosis (sample 68) digested with PstI (track 1) and HindiII (track 2) and
probed with an HPV 3 probe at high stringency. The sizes of the resulting restriction
fragments were similar to those published for HPV 10. (C); DNA from a viral wart
(sample 88) digested with PstI and probed with HPV 2+12 at low stringency. This
sample also has a restriction pattern similar to HPV 10. (D); DNA from a dysplastic
keratosis (sample 18) digested with PstI (track 1) and Hindlll (track 2) and probed
with HPV 3+8+13 at low stringency. This sample appears to contain integrated HPV
DNA. See Table 3.5 for details of the typing ofHPV in these samples.
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2.4 PREVALENCE OF SPECIFIC HPV TYPES IN CUTANEOUS LESIONS FROM RAR AND
ICP, AS DETERMINED BY TYPE SPECIFIC PCR ASSAYS
A total of 139 specimens from RARs and 81 from ICPs were analysed by type specific
PCR for HPV types 1, 2, 5 and 8 (Tables 3.6A and B, Figure 3.7). In each sample,
c-Ki-ras sequences could be detected with appropriate ras primers. Relatively few
lesions were positive for HPV DNA compared with the results from Southern
hybridisation analysis. In particular, HPV 5 DNA was only present in a small number
of benign and premalignant lesions from RARs and ICPs and was not detected in any
SCCs. HPV 8 DNA was found in only one SCC from an ICP. Interestingly, HPV 5
DNA was present in two uninvolved skins from RARs whilst HPV 1 and 2 were
detected in both premalignant and malignant lesions from RARs and ICPs (Tables
3.6A and B). Overall, there was no dominant HPV type in any of the histological
categories and the distribution of types was broadly similar for immunosuppressed and
immunocompetent patients.
One hundred and sixteen and 73 specimens from RARs and ICPs respectively, were
also tested for the common genital HPV types 6, 11, 16 and 18 (Tables 3.6A and B).
Genital HPV types were detected in 9 cutaneous specimens from RARs compared to
none from ICPs. There was no dominant HPV type in any of the histological
categories. Two IECs, from 2 separate RARs, were repeatedly found to have 2 highly
specific bands of 600 and 700bp, when amplified with HPV 16 primers (Figure 3.7C).
This is compared to the expected product size of 346bp. Four VWs from RARs
contained more than one HPV type; 5 and 2, 5 and 6, 5 and 11 and 2 and 11. Rigorous
anti-contamination procedures were followed throughout (Arends et al, 1991) and
there was no evidence to suggest that any of these positive results were due to
contamination from other sources.
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Table 3.6: HPV Type Prevalence by Type-Specific PGR




HPV Ty pe and \umber Positive Lesions
Number
Examined
1 2 5 8 Number
Examined
6 11 16 18
VW 20 0 4 3 0 15 j 1 2 0 0
K 33 2 2 1 0 25 0 0 1 0
IEC 33 0 2 1 0 30 0 0 2 0
SCC 31 1 2 0 0 26 1 0 1 0





HPV Type and Number of Positive Lesions
Number
Examined
1 2 5 8 Number
Examined
6 11 16 18
VW 7 1 1 0 0 6 0 0 0 0
K 15 0 0 2 0 14 0 0 0 0
IEC 31 2 1 2 0 27 0 0 0 0
SCC 16 0 1 0 1 14 0 0 0 0
US 12 0 1 0 0 12 0 0 0 0
VW = viral wart; K = keratoses; IEC = intraepidermal carcinoma; SCC = squamous
cell carcinoma; US = uninvolved, sun-exposed skin
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Figure 3.7:- Ethidium bromide stained agarose gels showing HPV positive and
negative cutaneous neoplasms by type specific PCR. (A); Two HPV 1 positive
dysplastic keratoses (samples 13 and 14) from RAR patient 54; +C = lOpg of purified
HPV 1 plasmid DNA. (B); An HPV 2 positive viral wart (sample 63) and squamous
cell carcinoma (sample 1) from two separate allograft recipients; +C = lOpg of purified
HPV 2 plasmid DNA. (C); An HPV 5 positive intraepidermal carcinoma (sample 28)
from renal allograft recipient 20; +C = lOOpg of purified HPV 5 plasmid DNA.
(D); Two intraepidermal carcinomas from two separate renal allograft recipients
showing specific bands of 600bp and 700bp. This is compared to the expected PCR
product size of 346bp (+C track); +C = lOpg of purified HPV 16 plasmid DNA. See
Table 3.8 for patient details of these samples. M = molecular weight marker (1Kb
ladder, Gibco).
116

















2.5 CONSENSUS PRIMER PCR
A consensus primer PCR assay was used in an attempt to develop a rapid and
sensitive method for screening for multiple HPV types and also as a means of
determining the HPV type present in lesions found to be positive by the low
stringency Southern hybridisation screen. The assay involved amplification of sample
DNA with consensus PCR primers as described by Manos et al (1989), followed by
restriction enzyme digestion of the products with a cocktail of enzymes described by
Lungu et al (1992). The Manos consensus primers were designed primarily for the
detection of genital-associated HPV types, therefore, reaction conditions were
initially optimised to allow the detection and identification of common cutaneous and
EV-associated HPV types. A primer annealing temperature of 45°C was found to
amplify HPV types 1, 2, 3, 4, 5, 8, 10, 12, 17, 20, 6 and 18 in the presence of
genomic DNA. However, while the PCR reaction was highly sensitive for the control
HPV types 6 and 18, the quantity of amplified product was often very poor for the
skin-associated HPV types (Figure 3.8A). HPV 14 and 19 were not amplifiable using
these consensus primers. When digested with the combination of enzymes described
by Lungu et al (1992), the RFLPs of the EV-associated HPV types were found to be
very similar (Table 3.7). The enzyme Mnll, which cuts HPV 5 and 8 at different sites,
was therefore added to the cocktail but the restriction digest patterns of HPV 8, 12 17
and 20 were still almost indistinguishable. The RFLPs observed when the amplified
products of the control HPV types 6 and 18 were digested using the above enzyme
cocktail were very nearly as expected (Table 3.7).
Of 17 cutaneous lesions (mostly VWs and keratoses) known to contain HPV DNA by
low stringency Southern hybridisation and type specific PCR assays, only 8 exhibited
HPV DNA by consensus primer PCR; 4 VWs, 3 keratoses and 1 IEC (Table 3.7 and
Figure 3.8B). However, consensus primer PCR did reveal HPV DNA in 2 of the 25
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Table 3.7 Consensus Primer PCR/RFLP Analysis Assay Applied To
Cutaneous HPV Types And Cutaneous Samples From RAR
Sample Fragment sizes (bp) # Total (bp)**
HPV1 350, 100 450
HPV4 210, 230 440
HPV 10 220, 230 450
HPV12 320, 134 450
HPV17 320, 140 460
HPV20 360, 120 480
HPV6 124, 3x80, 57, 30* 450
HPV18 134, 100, 2x80,30 * 420
17 (VW) 320, 140 460
43 (VW) 100x2, 201,50 450
110(VW) 270, 100, 50 420
140 (VW) 450 + 330 +100 450 + 430
18 (K) 250, 110, 70 430
68 (K) 210, 230 440
13 (K) >12Kb -
Gtl (VIN I) 450,370,70 450 + 440
Gt2 (Anal cancer) 210,130,70x2 480
Gt3 (CIN II) 300, 220,70x2 660
Gt4 (Vulval wart) 370,70 440
# = Samples digested with the enzyme cocktail Haelll + PstI + Rsal; * = the published
RFLPs are 122,78,73,71,67,37 bp for HPV 6 and 134, 107, 85, 73, 38, 18 bp for HPV
18 (Lungu et al, 1992); ** = the product size of the Manos LI consensus primers is
450bp. VW = viral wart; K= keratoses; VIN = vulval intraepithelial neoplasia;
CIN = cervical intraepithelial neoplasia. GT = genital tract lesion. See Appendix 1 for
the association between sample numbers with patient codes.
skin specimens investigated (an SCC and a VW) in which no HPV DNA had
previously been detected. Two distinct amplification products of 450 and 600bp were
repeatedly observed when sample T18 (a keratosis) was amplified using the Manos
consensus primers (Figure 3.8B). This sample was believed to contain integrated
HPV DNA by Southern hybridisation analysis (Table 3.5). Amplification product was
obtained for all 4 genital tract lesions assayed (Figure 3.SB). With one exception, the
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Figure 3.8:- Consensus Primer PCR Applied To Cutaneous HPV Plasmids
And Cutaneous Neoplasms From RARs
(A)
HPV Type





M 13 17 18 C
650bp>
450bp^
(A) Ethidium bromide stained agarose gel showing HPV plasmid DNA amplified using
the Manos consensus PCR primers that were designed to detect multiple genital
associated HPV types, a = template of 1 ng of purified HPV DNA; b = template of 1 ng
of purified HPV DNA mixed with lug of genomic (placental) DNA. (B) Ethidium
bromide stained agarose gel showing cutaneous lesions from RARs amplified using the
Manos consensus PCR primers. 13 = a dysplastic keratosis that was previously HPV 1
positive by type specific PCR; 17 = a viral wart that was positive by low stringency
Southern hybridisation and showed restriction digest patterns similar to HPV 13 or 20
(Table 3.5 and Figure 3.5); 18 = an actinic keratosis that was positive by low
stringency Southern hybridisation and was believed to contain integrated viral DNA
(Table 3.5 and Figure 3.6); C = control sample of a genital lesion known to contain
HPV 16 DNA; M = molecular weight marker (1Kb Ladder, Gibco).
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RFLPs of the HPV types in the above samples, including the 4 genital tract lesions
obtained from 2 female RARs, were dissimilar to those published by Lungu et al,
(1992) and to those of the HPV types investigated in this study by type specific PCR
and Southern hybridisation analysis (Table 3.7). However, the RFLP of sample 68,
which had previously been shown to contain HPV 10 DNA by Southern hybridisation
analysis, was very similar to the RFLP of HPV 10 in this assay (Tables 3.5 and 3.7).
Overall, the consensus primer PCR/RFLP analysis assay worked well on plasmid
DNA of genital HPV types but the results obtained when it was applied to cloned
HPV of common cutaneous and EV-associated HPV types, and to skin samples
known to contain HPV DNA, were difficult to interpret.
2.6 CORRELATION OF HPV DNA DETECTION BY SOUTHERN HYBRIDISATION AND
TYPE SPECIFIC PCR
Twenty eight specimens of keratoses, IECs and SCCs from RARs exhibited HPV
DNA by low stringency Southern hybridisation analysis, however, only 3 of these were
HPV positive by type specific PCR (Table 3.8). Likewise, of the 17 specimens of
keratoses, IECs and SCCs from RARs that were HPV DNA positive by type specific
PCR, only 3 (out of 16 analysed) were positive by the Southern hybridisation screen
(Table 3.8). A combination of both detection assays resulted in 10/14(71%) VWs,
13/30(43%) keratoses, 13/31(42%) IECs, 15/29(52%) SCCs and 3/21(14%)
uninvolved skin from RARs containing HPV DNA (Table 3.9). The combined results
for ICPs gave HPV prevalences of 6/6 (100%) for VWs, 2/13 (15%) for keratoses,
5/25 (20%) for IECs, 4/15 (27%) for SCCs, and 1/12 (8%) for US (Table 3.9). No
statistically significant differences by the y} test were found comparing HPV
prevalence in each histological group between ICPs and RARs. However, SCCs
(p<0.002) and IECs (p=0.05) from RARs showed a significantly higher HPV
prevalence than uninvolved skin from RARs. Overall, HPV DNA was detected at a
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Table 3.8:- Clinico-Pathological Details of HPV Positive Lesions From
RenalAllograft Recipients
PATIENT HISTOLOGY SITE HPV TYPE
Number Age/Sex Graft Life (yrs) Southern * PCR
8 56m 6 AK (D+++) Face pos uk neg
EC Up/back pos uk neg
16+ 49m 17 SCC Scalp pos 2
see Ear pos uk neg
EC Hand neg 16#
64+ 57m 12 AK (D+) Finger pos ** neg
SCC Hand pos uk neg
EC Ear pos 12 neg
18 55m 6(c) AK (D++) D. hand pos uk neg
VK D. hand pos 10 neg
20+ 36f 21 EC Presternal pos 5
VK Thigh ND 5
SCC Neck neg 16
SCC Chest neg 2
SCC Chest pos uk neg
EC L. thumb pos uk neg
EC D. hand pos 3C neg
SCC Forearm neg 6
23+ 56f 23 EC Finger pos uk neg
SCC Temple pos uk neg
EC Thumb neg 16 #
26+ 52m 10 VK (D+) Neck pos uk neg
EC Up. back pos uk neg
SCC Neck pos uk neg
SCC Hand pos 3A neg
SCC Shoulder pos uk neg
SCC Shoulder pos 1
34+ 44m 26 EC Scalp neg 2
SCC Forearm pos uk neg
SCC Neck pos uk ** neg
EC Scalp pos uk neg
SCC Scalp pos uk neg
40 59m 13 EC Scalp neg 2
50 62m 8 AK (D++) Forearm neg 16
VK (D+) Forearm pos uk neg
54 + 52m 15 VK (D+) Forearm neg 1
AK Forearm neg 1
VK Forearm pos uk neg
VK (D+++) Thigh neg 2
VK (D+) Neck neg 5
59 69m 1 EC D. hand pos uk neg
61 58f 15 VK (D+) Thumb neg 2
* = Details of the typing of these samples are given in Table 3.5; + = high risk subset
of patients; ** = these samples appeared to be integrated (Tables 3.5 and 3.7, Figure
3.8). AK = Actinic keratosis; D+ = mild dysplasia; D++ = moderate dysplasia; D+++
= severe dysplasia; SCC = squamous cell carcinoma; IEC = intraepidermal carcinoma;
VK = verrucous keratosis. D. hand = dorsum of the hand; Up back = upper back.
ND = not done; uk = unknown; neg = negative. # = These two lesions gave unusual
bands when amplified with HPV 16 (see Section 2.4). See Appendix 1. for sample
numbers.
greater prevalence by Southern hybridisation analysis than by type-specific PCR
(Tables 3.4, 3.6A and B).
Table 3.9:- Combined HPV Prevalence by Southern Hybridisation
Analysis and Type-Specific PCR Assays
Patient Group Number (%) Lesions Positive
VW K IEC SCC US
RAR 10/14(71) 13/30 (43) 13/31 (42) 15/29 (51) 3/21 (14)
ICP 6/6 (100) 2/13 (15) 5/25 (20) 4/15 (27) 1/12 (8)
RAR = renal allograft recipient; ICP = immunocompetent patient; VW = viral wart;
K = keratosis; IEC = intraepidermal carcinoma; SCC = squamous cell carcinoma;
US = uninvolved, sun-exposed skin.
%2 tests revealed the prevalence of HPV DNA in both SCC (p<0.02) and IEC
(p = 0.05) was significantly greater than that in US from RARs. For both VW/RAR
versus US/RAR and VW/ICP versus US/ICP, P<0.00003 by %2 tests.
2.7 prevalence of HPV DNA in individual patients
Fourteen patients included in this study had graft lives of 15 years or more. A
comparison of these patients with patients with a graft life of <15 years revealed no
difference in the combined prevalence of HPV DNA detected by Southern
hybridisation analysis and PCR (Figure 3.9). Seven RARs (patients 16, 20, 23, 34, 54,
26 and 64) were identified who appeared to have an increased susceptibility to the
development of pre-malignant and malignant skin tumours (Tables 3.2A and B). The
majority of these patients were found to have multiple HPV infected lesions exhibiting
different HPV types (Table 3.8). Although there was no specific pattern or
combination of HPV types in these patients, the prevalences of HPV DNA in keratoses
(8/16 (50%)), IECs (10/22(45%)) and SCCs (14/27(52%)) from these 7 patients were
increased in comparison to that observed in keratoses (4/14(29%)), IECs (2/9 (22%))
and SCCs (0/2(0%)) from 45 RARs with single, or few skin neoplasms (Figure 3.9). In
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fact, the level ofHPV positivity in RARs with a small number of skin neoplasms was
more similar to the overall HPV prevalence in ICPs (Figure 3.10 and Table 3.9). The
combined HPV positivity of keratoses+IECs+SCCs for 5 (out of 7) patients with
multiple skin cancers was found to be greater than the 24% (6/25) observed for the
RAR population with single or few skin tumours: 3/11(27%) for patient 16, 7/10(70%)
for patient 20, 3/11(27%) for patient 23, 6/13(46%) for patient 26, 5/9(56%) for
patient 34, 5/8(62%) for patient 54 and 5/10(50%) for patient 64. This difference
reached statistical significance in patient numbers 20 (p< 0.02 by x^ test) and 54
(p<0.05 by test).
Figure 3.9:- HPV DNA Prevalence In PatientsWith Skin Cancer For
> 15 Years And For <15 Years
RAROIByrs)
RAR (<15yrs)
RAR(>15yrs) = renal allograft recipients with renal transplants for >15yrs;
RAR(<15yrs) = renal allograft recipients with transplants for <15yrs; VW = viral wart;
K = keratoses; IEC = intraepidermal carcinoma; SCC = squamous cell carcinoma;
US = uninvolved, sun-exposed skin.
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RAR(M) = renal allograft recipients with multiple cutaneous neoplasms;
RAR(S) = renal allograft recipients with single or few skin neoplasms;
ICP = immunocompetent patients; VW = viral wart; K = keratoses;
IEC = intraepidermal carcinoma; SCC = squamous cell carcinoma; US = uninvolved,
sun-exposed skin.
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3: P53 ACCUMULATION AND MUTATION IN CUTANEOUS NEOPLASIA
FROM RENAL ALLOGRAFT RECIPIENTS
3.1 Optimisation of immiinocytochemical techniques
The PAbl801 epitope on p53 is destroyed by formaldehyde fixation (Banks et al,
1986), therefore, in the majority of cases the superior antibody MAb Do-7, which
recognises a formalin fixation resistant epitope of p53, was employed (Vojtesek et al,
1992). Experiments were initially carried out to optimise the immunocytochemical
detection of p53 in formalin and PLPD fixed material using this new monoclonal
antibody. These preliminary investigations indicated that MAb Do-7 stained p53 in
sections fixed in both formalin and PLPD at an optimal dilution of 1:100. Clear
immune-precipitate was present in PLPD fixed sections following a 1 hour incubation
with MAb Do-7. However, overnight incubation was required for a similar clarity of
staining in formalin fixed material. A comparison of the prevalence of p53
immunoreactivity in RAR lesions fixed in formalin and PLPD showed closely similar
data, thus permitting the results from both fixatives to be combined (Table 3.10). A
comparison of the specificity and sensitivity of MAb Do-7 and PAbl801 was also
carried out on 74 PLPD fixed lesions. In the majority of cases (57), the grade of
staining was identical when using the two antibodies and within each section both
antibodies reacted with similarly located cells. However, a discrepancy in positivity
between MAb Do-7 and PAbl801 was found in 3 cases. One US showed no p53
staining when MAb Do-7 was employed and grade 2 staining when PAbl801 was used
as the primary antibody, whereas 2 cases (an AK and an SCC) were negative when
treated with PAbl801 but showed grade 3 staining with MAb Do-7. There were also
discrepancies in the grade of staining between MAb Do-7 and PAbl801 in that 8 cases
showed a higher grade of staining when treated with MAb Do-7 as opposed to PAb
1801, while 6 cases showed more positive cells when treated with PAb 1801 compared
to MAb Do-7. Overall, MAb Do-7 gave a more intense precipitate than PAb1801
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although some minor variation in intensity occurred between assays. The results
presented are those obtained from MAb Do-7 staining.
Table 3.10 : A Comparison Of The Prevalence Of Accumulated P53 In
Cutaneous Lesions From RARs Fixed In Formalin And PLPD
No. Lesions (%) Demonstrating Accumulated p53#
FIXATIVE US VW K IEC SCC
Formalin 0/1(0) 2/14(14) 9/21(43) 10/17(59) 10/19(53)
PLPD 5/20(25) 1/7(14) 8/20(40) 12/17(70) 12/20(60)
# = Sections with staining in >10% of nuclei in the lesion (grades 2 and 3) were scored
as positive. PLPD = periodate-lysine-paraformaldehyde-dichromate; US = uninvolved,
sun exposed skin; VW = viral wart; K = verrucous and actinic keratoses;
IEC = intraepidermal carcinoma; SCC = squamous cell carcinoma.
3.2 p53 accumulation in cutaneous lesions from RARs and ICPs
A total of 156 biopsies from RARs and 80 from ICPs were screened for the presence
of Accumulated p53 using MAb Do-7 (Table 3.11, Figure 3.11). In both populations,
over 50% of IECs and SCCs exhibited p53 immunoreactivity in >10% of cells (grades
2 and 3). Accumulated p53 was also demonstrated in dysplastic keratoses from RARs
(17/41(41%)) but the prevalence was lower than in IECs (22/34(65%)) and SCCs
(22/39(56%)) and decreased with the decreasing level of dysplasia. A comparison of
the results from IECs and SCCs with those from keratoses, VWs (3/21(14%)) and
uninvolved skin (5/21(24%)) revealed that in RARs, significantly more IECs than
keratoses (p<0.05 by x? test) and significantly more IECs and SCCs than uninvolved
skin (p<0.05 by yp- test) and VWs (p<0.01 by test) exhibited accumulated p53. A
similar trend was revealed in ICPs although a lower proportion of cases stained
positive for p53. The differences between SCCs or IECs and keratoses or US were not
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statistically significant in the immunocompetent population. Overall, the grade of
staining within cutaneous neoplasia from RARs and ICPs correlated positively with the
degree of dysplasia present (Figure 3.11). However, sparse nuclear staining, involving
less than 10% of cells (grade 1), was observed in 10/39(25.6%) SCCs from RARs
compared to 1/17 (6%) SCCs from ICPs and 3/34 (9%) EECs from RARs.
Tabt.f. 3.11 - Prevalence Of Accumulated P53 In Cutaneous Lesions
From RARS Anp ICPs
No. Lesions (%) Demonstrating Accumulated p53#
PATIENTS US VW K IEC SCC
RAR 5/21(24) 3/21(14) 17/41(41) 22/34(65) 22/39(56)
ICP 3/12(25) 0/7(0) 4/16(25) 15/28(53) 9/17(53)
# Sections with staining in >10% of nuclei in the lesion (grades 2 and 3) were scored
as positive. RAR = renal allograft recipients; ICP = immunocompetent patients;
VW = viral wart; K = keratoses; IEC = intraepidermal carcinoma; SCC = squamous
cell carcinoma; US = uninvolved, sun exposed skin.
X2 tests revealed significant differences of p < 0.05 for comparisons of SCC/RAR with
US/RAR; p < 0.05 for IEC/RAR versus US/RAR and IEC/RAR versus K/RAR;
p < 0.01 for comparison of IEC/RAR with US/RAR; p < 0.01 for comparison of
SCC/RAR with US/RAR.
3.3 distribution of accumulated P53
In both RARs and ICPs, immunostaining of lesions was confined to nuclei of dysplastic
epithelial cells and was most abundant in areas of severe dysplasia (Figure 3.12).
However, some variability in staining among dysplastic cells within the same section
was frequently observed. Within keratoses and IEC lesions, staining was generally
strongest in basal epithelial layers, particularly at sites of basal budding where
































































































notable in keratoses exhibiting actinic features. In dysplastic keratoses and IECs,
acantholysis and suprabasal clefting were also observed to correlate with strong p53
staining. Even in cases with extensive proliferation of p53 positive keratinocytes, the
specialised lining cells of skin appendages, such as the hair follicle, always remained
negative, with staining confined to the surrounding dysplastic cells (Figure 3.12C).
Whilst the majority of SCCs showed stabilised p53 (Figure 3.12D), there was a
tendency for greater positivity to occur in less well differentiated lesions. In those
SCCs showing some degree of differentiation, the positive cells were located mainly in
the basal layer of the keratinising tumour mass. In 5 cases of SCCs, p53 was detected
in dysplastic basal cells and overlying IEC but not in contiguous tongues of invasive
carcinoma. Seventeen cases of IEC/SCC contained adjacent areas of normal epidermis
which always remained unstained (Figure 3.12A). The positive staining in non-lesional,
sun-exposed skin was light in intensity and predominantly basal in location in cells
exhibiting only mild dysplastic change.
3.4 p53 immiinoreactivity in cutaneous lesions from patients with
differing susceptibility to neoplasia
The 66 EECs/SCCs investigated for accumulated p53 were collected from 18 RARs. A
comparison of the results for RARs with multiple skin cancers (see Results Section
1.1) with those for RA^s with few, or no skin cancers, revealed no difference in the
prevalence of immunoreactive p53. Similarly, the percentage of immunocytochemically
positive IECs and SCCs for each individual patient with multiple skin cancers was
comparable to the percentage of p53 positive IECs and SCCs from RARs with few
skin malignancies. There was also no difference in the number of cutaneous lesions
from RARs with graft duration of >15 years and RARs with graft duration of <15years
exhibiting accumulated p53.
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Figure 3.12:- Histological distribution of accumulated p53. (A) Severely dysplastic
keratosis (right) is associated with strong p53 immunostaining as compared with
negative normal epidermis (left). (B) p53 immunostaining is localised to the dysplastic
basal cells in actinic keratosis. (C) Dysplastic basal cells are positive for p53 while the
specialised cells in appendages are negative. (D) Nuclear localisation of p53 in an
invasive squamous cell carcinoma from a RAR. p53 immunocytochemistry was





























































3.5 P53 immunoreactivity and sun exposure
While the majority of IECs/SCCs from both RARs and ICPs arose on sun exposed
body sites, in 4 out of 44 cases showing grade 2 or 3 staining for p53, the site of the
lesion suggested that UV light was not a significant aetiological factor in its
development. p53 immunoreactivity was observed in a similar proportion of SCCs
from patients with and without a history of high sun exposure.
3.6 P53 mutations in cutaneous malignancies
SSCP analysis was used to investigate 28 IECs/SCCs, from 8 RARs and 12 ICPs, for
the presence of p53 mutations in exons 5 to 8 of the p53 gene (Table 3.12 and Figure
3.13). Matched uninvolved skin specimens from 7 RARs and 5 ICPs were also
investigated. Overall, a similar number of SCCs (3/15(20%)) and IECs (3/13(23%))
displayed p53 SSCPs. Three of the SSCPs were in exon 7, two in exon 5 and one in
exon 8. In contrast, no SSCPs were detected in 12 uninvolved skin samples, including
4 from patients exhibiting SSCPs in skin malignancies. A comparison of the results for
RARs and ICPs revealed mutated p53 was present in more SCCs from RARs (3/9)
than from ICPs (0/6). However, the number of lesions investigated was too small to
determine the significance of this difference. Direct DNA sequencing of one SCC with
an SSCP mutation in exon 7 revealed a C-T transition at codon 248 (Figure 3.13). 5 of
the 6 IECs/SCCs exhibiting mutated p53, including the SCC with a mutation at codon
248, arose on sun-exposed body sites, implicating UV radiation as a possible causative
factor. However, an IEC with an SSCP in exon 7 of the p53 gene was removed from
the trunk of a patient with low sun exposure which is presumed to be a non sun-
exposed site.
its
Figure 3.13:- (A) Examples of SSCP mutations in exons 5 and 7 of p53 in cutaneous
malignancies from renal allograft recipients and immunocompetent patients. Using
SSCP analysis, a single base change, such as a point mutation, is visualised as a band
of altered migration (as indicated by arrows) in a polyacrylamide gel. Samples 1 and
16 = squamous cell carcinomas from renal allograft recipients, both with grade 3
staining by immunocytochemistry; sample 36 = an intraepidermal carcinoma from an
immunocompetent patient with grade 2 staining by immunocytochemistry. (B) Direct
DNA sequencing of exon 7 from sample 1 showing a C - T transition at codon 248 of
p53.
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3.7 SSCP analysis of P53 immtinopositive and immiinonegative lesions
15 of the 28 IECs/SCCs analysed by SSCP were immunopositive (grades 2 and 3)
while 6 were immunonegative and 7 showed grade 1 staining (Table 3.12 and Figure
3.14). A relationship was observed between the number of malignancies displaying p53
SSCPs and the grade of p53 staining by immunocytochemistry in that 5/9 (56%) of
grade 3, 1/6(17%) of grade 2 and none of grade 1 lesions showed SSCPs. No SSCPs
were detected in immunonegative malignancies. With one exception, all cases with
SSCP detectable p53 mutations showed grade 3 positivity by immunocytochemistry,
irrespective of the exon involved.
Tari.f. 3.12 - SSCP Analysis Of Immunopositive And Tmmtjnonegative
Tumours From RARs And ICPs
Extent Of p53 Immunoreactivitv And SSCP Positivity*
Patients Histology Neg grade 1 grade 2 grade 3
SCC 0/1 0/3 0/2 3/3
RAR IEC 0/3 0/1 0/1 1/2
US 0/5 0/2 _
SCC 0/2 0/2 0/2
ICP IEC 0/2 0/1 1/1 1/2
US 0/5 -
SSCP = single strand conformational polymorphism; * = extent of p53
immunoreactivity assessed as grade 1 = < 10%, 2 = 10 - 50%, and 3 = > 50 % of cells
in a lesion showing positive nuclear staining. RAR = renal allograft recipients;
ICP = immunocompetent patients; SCC = squamous cell carcinoma;
EEC = intraepidermal carcinoma; US = uninvolved, sun exposed forearm skin.
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4 : P53 ABNORMALITIES AND THE PRESENCE OF
HPV DNA
4.1 HPV STATUS ANn ACCUMULATED P53
One hundred and twenty eight biopsies from RARs and 75 from ICPs were screened
for both p53 immunoreactivity and the presence of HPV DNA (Table 3.13). Overall,
no clear relationship was observed between the presence or extent of accumulated p53
and HPV DNA in pre-malignant or malignant cutaneous lesions from RARs or ICPs.
However, a statistical relationship was found between the presence of HPV DNA and
accumulated p53 in VWs from RAR (p<0.05 by y}- test) but this reflects only one p53
immunopositive VW out of 10 that were HPV positive and no p53 immunopositive
VWs that were HPV negative. Therefore, this finding is probably not biologically
significant. The prevalence of the specific HPV types 1,2,5,8,6,11,16 and 18 was also
too low to determine whether any correlation existed between these HPV types and
p53 immunoreactivity (Table 3.14).
4.2 HPV STATUS AND MUTATED P53
SSCP analysis was carried out on 12 HPV positive and 16 HPV negative malignancies.
These included 3 cases exhibiting HPV 2 DNA, 1 HPV 5 DNA and 1 HPV 8 DNA.
p53 mutations were detected in 3 of the HPV positive and 3 of the HPV negative
malignancies. Neither the HPV 5 nor the HPV 8 positive cancers showed mutated
p53, however, an exon 7 mutation was found in an SCC containing HPV 2 DNA.
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Table 3.13 - Relationship Between The Presence Of HPV DNA And
Accumulated p53 In Cutaneous Lesions
RAR ICP
HPV+ HPV- HPV+ HPV-
Histology p53 + p53- p53+ p53- p53+ p53- p53+ ■a
US 0/3 3/3 5/16 11/16 1/1 0/1 2/11 9/11
VW 1/10# 9/10# 0/5 5/5 1/5 4/5 1/1 0/1
K 4/10 8/10 6/19 13/19 0/3 3/3 3/11 8/11
IEC 8/12 4/12 13/20 7/20 2/4 2/4 13/24 11/24
SCC 7/15 8/15 10/16 6/16 3/5 2/5 4/10 6/10
p53+ = Sections with staining in >10% of nuclei in the lesion (grade 2 and 3) were
scored as positive. RAR = renal allograft recipient; ICP = immunocompetent patient;
US = uninvolved, sun exposed skin; VW = viral wart; K = keratoses;
IEC = intraepidermal carcinoma; SCC = squamous cell carcinoma.
# = p<0.05 (%2 test)
Table 3.14 - Relationship Between The Presence Of Specific HPV Types
And Accumulated p53 In Cutaneous Lesions
No. HPV Positive Lesions* Exhibiting Stabilised p53
HPV Type VW K IEC SCC US
HPVl 0/0 1/2 1/1 1/1 0/0
HPV2 0/5 0/2 2/3 2/3 1/1
HPV5 1/3 0/3 1/1 0/0 0/2
HPV8 0/0 0/0 0/0 1/1 0/0
HPV6 0/1 0/0 0/0 1/1 0/0
HPVl 1 1/2 0/0 0/0 0/0 0/0
HPV16 0/0 1/1 1/2 1/1 0/1
HPV18 0/0 0/0 0/0 0/0 0/0
The results are a combination of data from renal allograft recipients and
immunocompetent patients. * = As detected by type specific PCR assays.
US = uninvolved, sun exposed skin; VW = viral wart; K = keratoses;






1: CUTANEOUS NEOPLASIA IN RENAL ALLOGRAFT RECIPIENTS
I.T SUSCEPTIBILITY TO CUTANEOUS NEOPLASIA IN RARS
The majority of premalignant and malignant skin lesions collected during this study
were derived from a small number of RARs, implying that some transplant patients
have an increased susceptibility to the development of skin cancer. Longer graft
survival times have previously been associated with a greater risk of cutaneous
malignancy following renal transplantation (Benton et al, 1992). However, this study
found that some patients who have had transplants for 15-21 years developed no
cutaneous neoplasms over the 4 year sample collection period whereas IECs and SCCs
occurred in patients with short graft lives, sometimes of only 2 years. This suggests
that allthough graft duration may be important in skin cancer development in RARs,
other factors are involved.
The role of immunosuppressive treatment in the development of cutaneous cancers in
RARs has been investigated by comparing the incidence of carcinomas in patients
receiving corticoids and/or azathioprine with the incidence in those receiving
cyclosporin A (Shuttleworth et al, 1989; Bunney et al, 1990; Sheil et al, 1991). While
some of these studies found that patients treated with cyclosporin have a reduced risk
of developing cutaneous malignancies, this could not be confirmed by others.
Immunosuppressive drugs per se are unlikely to play a role in increased cancer
susceptibility in this series of patients since most of the long term transplant recipients
received similar drug regimes. However, RARs with dysplastic lesions are reported to
have higher levels of the active azathioprine metabolite 6-thioguanine in their
erythrocytes than matched control subjects without lesions, raising the possibility that
cancer susceptibility may reflect differences in levels of immunosuppression associated
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with intrinsic differences in the way RARs metabolise immunosuppressive drugs
(Lennard et al, 1985).
A role for sun exposure in the aetiology of cutaneous tumours in RARs was confirmed
by the findings of this study that VWs and skin cancers arose predominantly on sun-
exposed body sites and that the majority of RARs developing cutaneous malignancies
had been exposed to moderate to high levels of LTV light. However, patients were
identified who developed multiple skin malignancies yet had a low sun exposure or
malignancies on non-exposed sites and others were found to have had high sun
exposure (who were matched for graft survival time) but no cutaneous cancers. UV
radiation from sun exposure is undoubtedly playing a role as a carcinogen, but factors
other than sun exposure also contribute to an increased susceptibility to the
development of skin cancers in some allograft recipients. It should be noted that the
assessment of sun exposure in this study was subjective and non-verifiable. Recent data
suggest that sun exposure in the first 30 years of life is a critical factor determining the
future risk of developing cutaneous SCCs (Bouwes Bavnick et al, 1993a). Therefore,
in order to assess accurately the contribution ofUV radiation to skin carcinogenesis of
RARs, a more detailed survey would be required including skin type, very detailed
history of sun exposure prior to transplantation and recent episodes of sun burn.
The distribution of cutaneous neoplasia and the early age of cancer development
observed in this RAR population confirms previous studies of the clinical profiles and
characteristics of transplant patients (Hoxtell et al, 1977; Blohme & Larko, 1984; Sheil
et al, 1985; Shuttleworth et al, 1987; McLelland et al, 1988; Hartevelt et al, 1990).
The histological overlap between viral and malignant features also confirms prevoius
work on cutaneous neoplasia from RARs (Blessing et al, 1989). This combination of
the importance of duration and type of immunosuppression, clinically identified
acceleration of cutaneous neoplasia and histological demonstration of viral features, all
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highlight the importance of investigating the viral contribution in the development of
these neoplasms.
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2: HPV AND CUTANEOUS CARCINOGENESIS OF RENAL ALLOGRAFT
RECIPIENTS
2.1 PREVALENCE OF HPV DNA IN SPECTRUM OF CUTANEOUS NEOPLASIA IN RARS
Compelling evidence exists for a contributory role for high risk genital HPV types 16
and 18 in the development of SCC of the genital tract (Arends et al, 1990, 1991 and
1993; zur Hausen, 1991; Lorincz et al, 1992). Similarly, in EV the role of HPV 5 and
8 in the aetio-pathogenesis of cutaneous SCC is suggested by their presence in over
90% of cancers (Orth et al, 1979; Orth, 1986; Fuchs & Pfister, 1990). The progression
of papillomas to alimentary tract carcinomas in bracken eating cattle is strong evidence
that papillomaviruses also play a role in naturally occurring animal malignancies
(Jarrett et al, 1984; Campo et al, 1985; Pennie et al, 1992 and 1993). However, the
stage at which papillomaviruses act in the neoplastic process appears to differ in these
models of viral carcinogenesis. For example, in cervical neoplasia, the prevalence of
HPV (of specific high risk types) increases throughout the cervical intraepithelial
neoplasia spectrum implying that HPV plays a role in the malignant progression of
cervical cancers (Stanley, 1990; Arends et al, 1991 and 1993; Lorincz et al, 1992).
This is in contrast to the bovine model where there is a decrease in the number of
lesions exhibiting BPV DNA as papillomas undergo malignant progression to
carcinomas, in which no viral particles are detected suggesting a "hit and run"
mechanism of PV involvement (Jarrett et al, 1984; Campo et al, 1985). Skin cancers
from EV patients exhibit increased prevalences of specific, high risk, HPV types
compared to benign and premalignant lesions from these patients, suggesting that the
role of HPV in the cutaneous neoplastic process of EV is similar to that of cervical
carcinogenesis (Orth et al, 1979; Pfister et al, 1981 and 1983a; Ostrow et al, 1982;
Fuchs & Pfister, 1990). In order to investigate the role of HPV in cutaneous
carcinogenesis of RARs, a large unselected series of cutaneous lesions from
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throughout the neoplastic spectrum of RARs and ICPs were investigated for the
presence ofHPV DNA.
The prevalence of HPV positivity was found to be closely similar in premalignant
(dysplastic) and malignant skin lesions from RARs; 43% of keratoses, 42% of IECs
and 51% of SCCs. This level of HPV positivity was significantly greater than the 14%
observed in non-involved, sun-exposed skin from RARs and substantially increased in
comparison to that of cutaneous neoplasia from ICPs; 15% of keratoses, 20% of IECs
and 27% of SCCs. These data provide strong evidence that HPVs play an early but
persistent role in cutaneous carcinogenesis of RARs. This pattern of HPV positivity
differs from the above (bovine alimentary and cervical/EV) models of PV induced
carcinogenesis implying that the putative role is neither as an initiating agent nor as an
inducer ofmalignant progression (see Section 4 for further discussion).
The prevalence of HPV DNA in carcinomas reported here is in broad agreement with
that of Soler et al, (1992) and Euvrard et al, (1993) who detected HPV DNA
sequences in 7 of 19 and 14 of 30 SCCs from RARs respectively. In contrast, Barr et
al, (1989) found HPV DNA in 60% of SCCs from RARs and Dyall-Smith et al, (1991)
detected no HPV DNA in 235 SCCs from RARs. However, it is inappropriate to
compare the results of this investigation with those of the two above mentioned studies
due to differences in the sensitivity and specificity of the detection methods employed
and differences in sample size studied.
2.2 SPECIFIC HPV TYPES IN CUTANEOUS NEOPLASMS FROM RARS
In the bovine, cervical and EV models of papillomavirus induced carcinogenesis, only
some of the infecting virus types appear to have the potential for oncogenicity. This is
exemplified by skin cancers developing in cutaneous neoplasms of EV patients. While
the skin of affected individuals harbours a multiplicity of HPV types, SCCs arise
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mostly in lesions containing HPV types 5 and 8 (Orth et al, 1979; Lutzner et al, 1980;
Ostrow et al, 1982; Pfister et al, 1983a; Orth, 1986). Similarly, there is a predominance
of HPV 16 and 18 and a near absence of HPV 6 and 11 in invasive cervical cancers
(Arends et al, 1990 and 1991; Lorincz et al, 1992) and of the BPV types that infect
cattle, only BPV 4 is associated with malignant progression (Lynch, 1982; Quan &
Moy, 1991).
In this study, restriction pattern analysis of samples found to contain HPV DNA by
low stringency Southern hybridisation indicated that multiple different HPV types are
present in both premalignant and malignant skin tumours from RARs. Some of these
appeared to be related to common cutaneous HPV types while others gave PstI
restriction patterns comparable to those of EV associated HPV types. Similarly, "high
risk" (HPV 5, and 16) and "low risk" (HPV 1, 2 and 6) cutaneous and mucocutaneous
HPV types were detected in a small number of IECs/SCCs from RARs by type specific
PCR. These data suggest that numerous "high risk" and "low risk" HPV types may
contribute to the development of skin cancers in RARs which is unlike the other
models of PV induced carcinogenesis. These results are in keeping with those of Soler
et al, (1992), Euvrard et al, (1993) and Tieben et al, (1994) who also detected different
EV-related HPV types in skin carcinomas from transplant patients.
Type specific PCR, using highly sensitive primers, indicated that only a small
proportion of skin lesions from both RARs and ICPs exhibit HPV 5 or 8 DNA. This is
in contrast to previous findings from South East Scotland (Barr et al, 1989) where 15
out of 25 SCCs were found to contain HPV 5/8 DNA. The study of Barr et al used
mostly dot blotting techniques to detect HPV 5/8 DNA which does not exclude the
possibility of cross hybridisation with other EV-associated HPV types. Other recent
studies have also been unable to detect HPV 5 or 8 DNA in significant numbers of skin
malignancies from transplant patients (Soler et al, 1992; Euvrard et al, 1993; Tieben et
145
al, 1994). Therefore, the balance of evidence now suggests that HPV 5 and 8 are
present relatively infrequently in tumours from RARs (Lutzner et al, 1983; Rudlinger
et al, 1986; Rudlinger & Grob, 1989; Van der Leest, 1987).
One of the important features of papillomaviruses is their propensity to infect
squamous epithelium at specific sites. Although the mucocutaneous HPV type 16
DNA has previously been detected in cutaneous neoplasia from RARs and ICPs, most
studies suggest that such findings are confined to SCCs of the periungual site (Stone
et al, 1987; Ostrow et al, 1987 and 1989; Rudlinger et al, 1989; Eliezri et al, 1990;
Ashinofif et al, 1991). In contrast, this study demonstrated anogenital HPV types in
cutaneous lesions from throughout the neoplastic spectrum of RARs and at sites
outwith the periungual area. Anogenital HPV types could not be detected in skin
lesions from ICPs. These findings suggest that the site specific distribution of HPV is
no longer observed in cutaneous lesions of RARs. Two positive SCCs, one containing
HPV 6 and the other HPV 16 DNA, came from a female RAR (patient 20) who, in
addition to multiple cutaneous SCCs developed SCCs of the cervix, vulva and anal
canal. HPV 16 DNA has also been detected in her genital tract tumours (Alloub et al,
1989; Rudlinger et al, 1986) indicating that this patient may have a high background
level ofHPV infection (see Section 4.6 of the Discussion).
2.3 PHYSICAL STATUS OF HPV DNA IN CUTANEOUS LESIONS FROM RARS
HPV 16 and 18 DNA are maintained mainly as extrachromasomal episomes in
condyloma and mildly dysplastic genital tract lesions but are integrated into the host
genome in the majority of cervical cancers. This suggests that viral integration is an
important step in the malignant progression of cervical neoplasia (Fukushima et al,
1990; Cullen et al, 1991). In contrast, high copy numbers of episomal HPV 5 and 8
DNA are usually present in skin cancers of EV patients. (Yabe et al, 1989; Fuchs &
Pfister, 1990). In this study, 2 VWs, a dysplastic keratosis and an SCC gave high
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(>12Kb) and low molecular weight restriction fragments when digested with the single
cut (or in some cases double cut) enzyme BamHI and the multicut enzyme Pstl.
Furthermore, amplification of the dysplastic keratosis with LI consensus primers
resulted in two specific products, one of the correct molecular weight (450bp) and
another of increased molecular weight (650bp). These data raise the possibility that
both episomal and integrated forms of HPV may be present in cutaneous neoplasms of
RARs. However, the numbers of affected lesions were too small to determine whether
integration plays a significant role. Although integration of cutaneous HPV types has
rarely been observed in vivo, the common cutaneous HPV type 1 has previously been
found integrated into the host genome at 2q33 in an experimentally generated
SV40/HPV1 transformed human keratinocyte cell line (Parton et al, 1990).
Evidence from this study also suggests that the physical state of episomal HPV DNA is
altered in some cutaneous lesions from RARs. First, aberrant restriction digest patterns
(giving restriction fragments with a combined molecular weight of greater than 8Kb)
were observed when some samples (mainly EECs/SCCs) were digested with one of
BamHI/PstI but not the other. This may indicate the presence of mutant viral species
that have lost or gained BamHI/PstI restriction sites or new, previously unidentified
HPV types. Second, digestion of one IEC with both BamHI and Pstl resulted in a
single fragment of 3-3.5Kb suggesting that in this case, the major viral species was a
deletant mutant of HPV. Finally, amplification of two more IECs with F1PV 16 primers
resulted in two specific products with molecular weights greater than the expected
size. One explanation for this result is that duplication has occurred within the E6 ORF
of HPV 16 in these malignancies. Consequently, it appears that RARs are not only
susceptible to multiple HPV infections with rarer HPV types but that there is also
greater variation within these types. The results presented here are in keeping with
those ofWilson et al (1989) who demonstrated novel variants of HPV 2 in VWs from
RARs. In EV, the bulk of unit length HPV molecules is typically accompanied by a
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variable proportion of genomes showing various deletions or duplications (Yabe et al,
1989).
2.4 OTHER HPV TYPES IN CUTANEOUS NEOPLASMS OF RARS
Some cases found to contain HPV sequences by PCR could not be confirmed by
Southern hybridisation analysis indicating that in many cases copy numbers of HPV
genomes were too low to be detected by Southern analysis. Not surprisingly, the
absolutely type specific assays for HPV types 1, 2, 5, 8, 6, 11, 16 and 18 did not detect
other HPV types found by Southern hybridisation. Therefore, through a combination
of a wide variety of HPV types involved and low copy number of HPV genomes, it is
possible that this and other studies have underestimated the true prevalence of HPV in
cutaneous neoplasms of RARs. In order to address this possibility, a consensus primer
PCR assay was investigated. Since very little sequence information was available for
skin associated HPV types, the consensus primers used in this assay were designed
from genital HPV DNA sequences and had previously been shown to amplify a large
range of genital associated HPV types (Manos et al, 1989). It was found that these
primers detect common cutaneous and EV associated HPV types poorly, even when
using cloned HPV DNA as template. Furthermore, the assay could only detect HPV
DNA in a small number of samples shown to contain HPV by low stringency Southern
hybridisation analysis. However, consensus primer PCR did identify HPV DNA in 2 (a
VW and an SCC) of the 25 HPV "negative" skin lesions investigated, confirming the
suggestion that the overall HPV prevalence given in this study is an underestimate of
the true figure. Overall, it was concluded that in order to obtain meaningful results
from a consensus primer PCR assay, primers must be used that are designed to detect
skin associated HPV types. Additional sequence information for cutaneous HPVs has
recently become available and consequently, consensus primers have been published
that are reported to efficiently detect cutaneous HPV types (Snijders et al, 1991;
Tieben et al, 1994).
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Restriction fragment length polymorphism (RFLP) analysis of consensus primer PCR
products was also investigated as a method of characterising the HPV types found by a
Southern hybridisation analysis screen (Lungu et al, 1992). The RFLPs obtained from
the small number of amplifiable samples were dissimilar to those of the genital HPV
types published by Lungu et al, (1992) and to those of the HPV types investigated in
this study. These results confirm the presence of multiple HPV types in cutaneous
neoplasia from RARs. The enzyme cocktails employed by Lungu et al (1992) were
designed primarily to identify genital HPV types amplified using the Manos consensus
primers. These enzyme cocktails were found to be inefficient at distinguishing between
cloned EV-associated HPV types and, the RFLPs obtained from other cloned
cutaneous HPV types were difficult to reproduce. Once again, additional sequence
information is required to design an enzyme cocktail that will efficiently distinguish
between cutaneous HPV types amplified using consensus PCR primers.
In conclusion, the similar (40-50%) prevalence of HPV DNA found in keratoses,
IECs and SCCs from RARs implies that HPV acts at an early stage in cutaneous
carcinogenesis of transplant patients. Multiple common cutaneous,
mucocutaneous and EV-associated HPV types were detected in tumours from
throughout the neoplastic spectrum of RARs, although HPV 5 and 8 were
present only at a low frequency in skin cancers from both RARs and ICPs. "Low
risk" and "high risk" HPV types were present in broadly equivalent numbers
with no single HPV type predominating in any group of neoplasms.
149
3: P53 IN CUTANEOUS CARCINOGENESIS OF RENAL ALLOGRAFT
RECIPIENTS
3.1 P53 accumulation and progression in cutaneous carcinogenesis
The exact stage at which p53 acts in the carcinogenic process appears to be
characteristic for different cancers types. For example, aflotoxin in liver cancer may
induce direct modifications to the p53 gene, implying that p53 mutations are an
initiating event in this cancer type (Vogelstein and Kinzler, 1992b). In contrast, p53
mutations are associated with malignant conversion (from benign adenoma to invasive
carcinoma) in colorectal carcinogenesis (Purdie et al, 1991; Carder et al, 1993). In
HPV infected cervical cancers, mutation of the p53 gene is reported to associate with
the late metastatic stage of the disease (Mitranirosenbaum & Tsvieli, 1994). Previous
investigations into the prevalence of stabilised and mutated p53 in dysplastic and pre-
malignant cutaneous lesions from ICPs have been inconsistent, therefore, the stage at
which p53 acts in human skin carcinogenesis is presently unknown.
This study was the first to examine the role of p53 in cutaneous carcinogenesis of
RARs and the first to investigate a large series of cutaneous tumours from throughout
the neoplastic spectrum in ICPs. The prevalence and extent of p53 immunoreactivity
increased as lesions progressed through the spectrum of neoplasia to the pre-invasive
state; 14% of VWs; 24% of sun exposed skin; 41% of keratoses and 65% of EECs
exhibited accumulation of p53. Topographically, there was a close correlation between
the extent of staining in these lesions and the severity of dysplasia. However, a similar
prevalence of immunoreactive p53 was observed in IECs and SCCs (56%) with a
similar extent of staining. These results suggest that accumulation of p53 in skin
carcinogenesis of both RARs and ICPs represents an important step in neoplastic
progression but is not the rate limiting step in the progression from in situ to invasive
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SCC. Other genetic events would appear to occur prior to the development of
malignancy. This hypothesis is supported by the finding of Dotto et al (1988) that
mutated p53, introduced into murine papilloma cell lines, accentuates the dysplastic
changes in the resultant tumours in vivo but does not convert these tumours to
malignancy. In contrast, Kemp et al (1993) demonstrated that inactivation of p53
specifically associates with the conversion of benign papillomas to SCCs in p53
deficient mice and that papillomas and carcinomas from these mice are less well
differentiated than their counterparts with wild type p53. In this study, a comparison of
immunopositive and immunonegative (including those with grade 1 staining) SCCs
revealed no differences in the differentiation state of the lesion. This supports the
hypothesis that genetic events other than accumulation of p53 are associated with loss
of differentiation and development of malignancy in human SCCs.
The finding of accumulated p53 in approximately 50% of IECs and SCCs is in broad
agreement with some previously reported studies where the prevalence has ranged
from 15-56% for SCCs and 17-80% for IECs (Gusterson et al, 1991; McGregor et al,
1992; Ro et al, 1992; Helander et al, 1993). The trend of p53 positivity in neoplasia
from throughout the histological spectrum observed in this study is similar to that
demonstrated by Gusterson et al (1991) who detected p53 immunoreactivity in
0/12(0%) solar keratoses, 2/12(17%) Bowens disease (IECs) and 3/20(15%) SCCs
from ICPs. By comparison, McGregor et al (1992) found a similar prevalence of
stabilised p53 in solar keratoses, IECs and SCCs from ICPs and, Ro et al (1992)
detected immunoreactive p53 in an increasing number of such lesions. These
discrepancies may be explained by the small number of lesions investigated in one or
more of the histological categories of keratoses/IEC/SCC in these previous
investigations and the criteria employed for determining a positive or negative result.
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3.2 p53 accumulation in cutaneous neoplasia from RARs and ICPs
The overall prevalence and extent of stabilised p53 was higher (but not statistically
significantly greater) in VWs and keratotic skin lesions of RARs compared to those of
ICPs. However, a similar proportion of uninvolved skin from RARs and ICPs exhibited
immunoreactive p53. One explanation for these results is that epidermal keratinocytes
with proliferative activity from RARs (such as those of VWs and keratoses) have
increased levels of genetic instability compared to those from ICPs and consequently
aquire accumulated p53 earlier in the neoplastic spectrum. The accumulation of p53
(and associated loss of function) may in turn lead to increased dysplasia and
accelerated rate of progression of these lesions (see section 4 for further discussion).
This hypothesis is supported by the clinico-pathological observations that, unlike VWs
from ICPs which are benign and show no evidence of dysplasia, VWs from RARs may
be dysplastic and if left untreated can even progress to malignancy (Blessing et al,
1989; Benton et al, 1992). Similarly, keratoses from ICPs usually show low levels of
dysplasia in the basal layer of the epithelium and rarely progress to malignancy (Marks
et al, 1986 and 1989), whereas comparable lesions from RARs are usually severely
dysplastic and may even show areas of in situ carcinoma (IEC) (Blessing et al, 1989).
An alternative hypothesis is that RARs lack immune-surveillance of cells expressing
abnormal p53 which results in increased incidence and clinical rate of progression of
skin neoplasia. Although anti-p53 antibodies have been detected in the serum of
patients with certain types of cancer (Caron De Fromental et al, 1987; Schlichtholz et
al, 1992), this hypothesis is unlikely since RARs do not have an increase in common
solid malignancies, such as those of the lung, breast and colon, which are also
associated with accumulation of p53 (Shuttleworth et al, 1987; Alloub et al, 1989;
Barr et al, 1989).
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Sparse nuclear staining (involving less than 10% of cells), although observed in all
histological categories, was surprisingly prevalent in SCCs from RARs. It has
previously been demonstrated that epidermal keratinocytes express increased levels of
wild type p53 in response to UV induced DNA damage (Hall et al, 1993). It may be
possible that SCCs from RARs have a high degree of genetic damage or instability so
increased numbers of cells express wild type p53 in order to undergo DNA repair (see
Section 4 for further discussion). Sparse nuclear staining was only observed in a small
proportion of SCCs from ICPs raising the possibility that SCCs from RARs have
increased levels of genetic instability compared to those from ICP. A small number of
SCCs from RARs, but none from ICPs, were found to have p53 staining in superficial
dysplastic epidermis and adjacent areas of IEC but not in contiguous tongues of
invasive SCC. One possible explanation for this may be that gross chromosomal
deletions, involving 17p, have occurred in more invasive malignant elements,
abolishing all p53 gene expression. This also raises the possibility that SCCs from
RARs are more genetically unstable than SCCs from ICPs and suggests that malignant
conversion of cutaneous IEC to SCC may be associated with complete deletion of p53
and the development of aneuploidy. Further studies such as static cytometric ploidy
analysis, microsatellite instability or PCR allelotyping would be required to investigate
possible differences in ploidy and genetic instability in these lesions. Chromosomal
deletions of p53 have previously been reported in some sarcomas although overall, this
is a rare phenomenon (Baas et al, 1994).
3.3 P53 mutation and cutaneous carcinogenesis
SSCP analysis demonstrated mutated p53 in approximately 20% of both IECs and
SCCs, and this is substantially lower than that reported for common solid malignancies
such as the colon and lung (Baker et al, 1990a; Hollstein et al, 1991). There are a
number of possible explanations for this. First, the overall proportion of cases with
mutated p53 may have been underestimated because of the selection of p53
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immunopositive and immunonegative lesions for analysis by SSCP. However, the
results presented here are in agreement with the majority of reports on p53 mutation in
skin malignancies which suggests that this is not the case (Pierceall et al, 1991a; Moles
et al, 1993; Burns et al, 1993; Campbell et al, 1993a). Mutations may have occurred
outwith exons 5 to 8, but studies of other common cancers, including skin, suggest
that this is likely to account for only a small proportion (less than 10% in cancers of
the colon and lung) of cancers (Baker et al, 1990a; Brash et al, 1991; Campbell et al,
1993a). Alternatively, p53 may be inactivated by mechanisms other than mutation in
cutaneous carcinogenesis, such as the binding of viral or cellular proteins (see Section
4 for further discussion). With one exception, gene mutations occurred in exons 5 and
7, consistent with the suggestion that these exons contain mutational hotspots for p53
in various forms of human malignancy (Brash et al, 1991; Hollstein et al, 1991;
Pierceall et al, 1991a; Campbell et al, 1993a; Levine, 1993).
In this study, SSCP analysis was used to detect mutations in the p53 gene. This
technique is based on the principle that single stranded DNA molecules take on specific
secondary structures under non-denaturing conditions (Orita et al, 1989; Mashiyama,
1990; Hayashi, 1992). Molecules differing by as little as a single base substitution may
form different secondary structures and therefore, migrate aberrantly in a non-
denaturing, polyacrylamide gel. The sensitivity of SSCP depends on how the mutation
affects the secondary structure of single stranded DNA and therefore, its
electrophoretic mobility (Smith et al, 1992; Sheffield et al, 1993). Factors that are
thought to influence this sensitivity include the length of the PCR fragment (150bp is
reported to be the optimal length), the position of the base substitution within the
fragment, the nature of the base substitution (transition versus transversion) and the
sequence composition of the DNA fragment. Therefore, the precise sensitivity of this
technique depends on the gene being analysed, although overall, it is reported to detect
>90% of all single base substitutions in a 200 nucleotide fragment (Hayashi et al,
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1992). A recent study using the same PCR/SSCP primers as this study but on
colorectal cancers, where both SSCP analysis and direct sequencing were employed to
detect mutated p53, indicated that 80% of p53 gene mutations can be detected by this
method (Cripps et al, 1994). Another study investigating the sensitivity of SSCP with
respect to contaminating normal tissue demonstrated that p53 mutations can be
detected even when they comprise only 5-10% of alleles (Wu et al, 1993).
3.4 p53 accumulation and gene mutation in cutaneous carcinogenesis
High levels of p53 protein are a common feature of many human neoplasms and it has
often been assumed that accumulated p53, visualised by immunocytochemistry, is
equivalent to mutated p53. Indeed, in the majority of tumours a good correlation has
been observed between the presence of immunocytochemically detectable p53 and
gene mutations as determined by direct sequencing and other methods (Iggo et al,
1990; Gannon et al, 1990; Varley et al, 1991; Bums et al, 1993; Baas et al, 1994).
However, this relationship is not absolute (Bodner et al, 1992; Wynford-Thomas,
1992). For example, false negatives may occur if both p53 genes have been deleted, if
the concentration of stabilised protein fails to rise to detectable levels or if the
configuration of the mutant protein is not recognised by the antibody. Alternatively,
false positives could occur if p53 were stabilised by other mechanisms such as a defect
in the degradative pathway or the binding of cellular or viral proteins.
In this study, SSCP analysis of exons 5 to 8 of the p53 gene detected mutations in 6/15
(40%) immunopositive (grade 2 and 3 staining by immunocytochemistry) malignancies,
indicating that factors other than gene mutation may contribute to the accumulation of
p53 during the development of at least some skin cancers. Recently, the product of the
mdm-2 gene, which is overexpressed in osteosarcomas, has been shown to bind to and
inactivate p53 (Momand et al, 1992; Oliner et al, 1992 and 1993). It is possible that
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similar proteins are present in transformed epidermal cells that bind to and inactivate
wild type p53, rendering it detectable by immunocytochemical techniques. In this
context it is of interest that a cancer family syndrome has been identified where normal
epidermal and mesenchymal cells express high levels of wild type p53 (Barnes et al,
1992). It may be that the germline mutation predisposing these cancer family patients
to early onset of malignancies and increased levels of wild type p53 also occurs
sporadically in skin cancers.
The results reported here for skin cancer are analogous to those for breast cancer
where a group of tumours have been identified that show high levels of p53 protein in
the absence of p53 gene mutations (Bartek et al, 1990a and b; Dunn et al, 1993). In an
elegant series of in vitro experiments, Vojtesek & Lane (1993) demonstrated that the
cell environment is critical in the regulation of p53 in breast cancer cell lines and not
p53 gene mutation per se. An enzyme linked immunoassay has recently shown that p53
stabilisation also occurs in some colorectal adenomas in the absence of p53 gene
mutation and there is evidence to suggest that p53 accumulation can arise due to the
activation of other genes already implicated in cancer such as c-myc and ras (Lu et al,
1992).
In this study, several distinct patterns of p53 staining were observed in cutaneous
neoplasia, a phenomenon which has been described previously (Purdie et al, 1991;
Bartek et al, 1990b; Midgley et al, 1991). In some IECs/SCCs, intense immune
precipitate was present in the majority of cells (grade 3) while others showed either
patchy, widespread staining (grade 2) or staining in occasional cells (grade 1). This
study found a direct correlation between the grade of p53 immunopositivity and the
percentage of cases exhibiting mutated p53. Therefore one hypothesis, previously
proposed by Hall & Lane (1994), is that these different immunochemical phenotypes
represent different biological mechanisms for the accumulation of p53. In those cases
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showing grade 1 staining, wild type p53 accumulation may have occurred as a natural
response to genotoxic damage. Grade 2 staining may represent stabilisation of p53 by
mechanisms other than mutation such as complex formation with viral or cellular
proteins or reduced p53 degradation, whereas p53 mutation may result in grade 3
staining. This hypothesis is supported by the observation that breast cancer cell lines
expressing high levels of wild type p53 usually show cellular heterogeneity in their
pattern of p53 expression (Bartek et al, 1990a; Vojtesek & Lane, 1993). Cells
transformed by ras and myc which exhibit increased expression of wild type p53, also
have a heterogeneous p53 staining pattern (Lu et al, 1992). Barnes et al (1993) have
recently demonstrated that the extent of p53 immunostaining is of prognostic
significance in breast carcinomas. Thus, immunocytochemistry may prove to be a good
screening method for assessing the functional status of p53 within dysplastic and
normal cells, however, further work is required to confirm the biological basis for these
different staining patterns.
In conclusion, this study demonstrated a strong association between p53
accumulation, dysplasia and neoplastic progression in cutaneous carcinogenesis
of RARs and ICPs. The prevalence and extent of p53 immunostaining was
greater in pre-malignant tumours from RARs than from ICPs which may reflect
the faster clinical rate of neoplastic progression towards invasive carcinoma of
these lesions in allograft recipients. SSCP analysis of exons 5 to 8 of the p53 gene
in cutaneous IECs and SCCs detected p53 mutations in 21% of cases. p53 gene
mutations were present in only 40% of immunopositive IEC/SCC tested
indicating that factors other than p53 mutation may be responsible for the
accumulation of p53 in some cutaneous neoplasms. It is possible that the pattern
of p53 immunostaining may reflect the biological potential of lesions.
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4: MODEL OF CUTANEOUS CARCINOGENESIS IN RENAL ALLOGRAFT
RECIPIENTS
Cancers do not arise de novo in their final form but begin as small indolent growths
that gradually acquire characteristics associated with malignancy (Sidransky et al,
1992a and b). In the skin, low grade dysplasias, such as actinic keratoses, may evolve
into more dysplastic lesions (in situ or intraepidermal carcinoma) which may eventually
become invasive (SCC) (Marks et al, 1986; Milburn et al, 1988; Johnson et al, 1992;
Ledo, 1992). It has been postulated that the neoplastic progression of low to high
grade tumours is driven by a series of genetic alterations, with each alteration
conferring a selective growth advantage over other cells (Nowell, 1976). This
hypothesis is most strongly supported by mouse skin and human colon models of
tumour progression where a number of the genetic changes occurring at different
stages have been characterised (Vogelstein et al, 1988; Bums et al, 1991). In this
study, the availability of cutaneous lesions from throughout the neoplastic spectrum
has enabled investigation into the functional roles of HPV and p53 at the different
stages of cutaneous carcinogenesis in RARs.
4.1 THE ROLF. OF HPV IN CUTANEOUS CARCINOGENESIS OF RARS
The overall finding in this study was of similar HPV prevalence throughout the
spectrum of cutaneous neoplasia in RARs. Studies of the prevalence of accurately
typed, specific HPV indicated that multiple different EV-associated, common
cutaneous and mucocutaneous HPV types are present in cutaneous lesions from RARs
with no one specific type predominating. One hypothesis to explain these results is that
HPV act as tumour promoters in cutaneous carcinogenesis of RARs. In the mouse
model of skin carcinogenesis, the phorbol ester class of tumour promoters act by
selectively stimulating the proliferation of initiated keratinocytes while inducing
differentiation of the others (Hartley et al, 1985 and 1987). Consequently, the genetic
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changes generated by initiating agents, such as chemical carcinogens or UV light, are
fixed irreversibly and expansion of the initiated cell population occurs. However,
multiple applications of promoting agent are required over a prolonged period before
papillomas develop and malignant conversion takes place. The ability to induce
keratinocyte proliferation is common to all HPV types, therefore, HPV may provide a
stimulus analogous to phorbol esters in cutaneous carcinogenesis of RARs (Figure
4.1). The role of promoter for HPV has previously been suggested by zur Hausen
(1982). In those keratinocytes with no DNA damage, HPV infection may lead to cell
proliferation, differentiation and the development of viral warts. However, the
presence of long-term immunosuppressive therapy is likely to permit viral persistence
(and therefore cell proliferation) over a prolonged period which, along with the DNA
damaging effects of UV radiation (see Section 4.4 for further discussion), may give
rise to an environment conducive to tumour induction. This hypothesis is supported by
the clinico-pathological observations that RARs frequently exhibit extensive warts and
verrucous keratoses as well as malignant tumours: these lesions form a seamless
spectrum of histological change, with many keratoses (actinic and verrucous) showing
dysplasia, and both IECs and SCCs retaining viral features. Furthermore, these
immunosuppressed patients appear to have relatively high background levels of HPV
indicated by the finding that 3 out of 21 (14%) biopsies from the apparently
uninvolved skin of RARs contained HPV DNA. HPV encourage squamous rather than
basal cell proliferation and differentiation, therefore, the finding that the usual 1:5 ratio
of SCC:BCC is reversed in RARs to 15:1 further supports a role for HPV as a tumour
promoter.
In the mouse model of skin carcinogenesis, specific genetic events are associated with
the progression of papillomas to malignant SCCs. It is likely that in RARs, the
progression from dysplastic keratoses to IECs and then SCCs involves further genetic
damage and mutation/deletion of specific oncogenes or tumour suppressor genes. HPV
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induced cell proliferation may increase the chance of these specific genetic events
occurring. Therefore, as well as tumour induction, HPV infection may also indirectly
contribute to neoplastic progression in RARs.
4.2 THE ROLE OF P53 IN CUTANEOUS CARCINOGENESIS OF RARS
The results of this study show that the largest increment in the prevalence of p53
accumulation was from keratoses to IECs in both RARs (41% for keratoses compared
to 65% for IECs) and ICPs (25% in keratoses compared to 53% in IECs).
Furthermore, in RARs this difference was statistically significant (p<0.05 by %2 test).
These data suggest that inactivation of p53 acts at the point of progression from
dysplastic keratosis to IEC in cutaneous carcinogenesis of both RARs and ICPs
(Figure 4.1). The implication of this data is that IECs evolve through clonal expansion
of cells that have previously acquired abnormal expression of p53 and therefore a
selective growth advantage. Sidransky et al (1992b) have also identified p53 as a
selectable gene and demonstrated that clonal expansion of p53 mutated cells is
associated with progression of low grade to high grade astrocytomas.
Within some immunopositive IECs and SCCs there was a marked cell to cell
heterogeneity in p53 immunostaining which may contradict the concept of clonal origin
and expansion. Evidence from this study suggests that a factors other than p53 gene
mutation are responsible for the accumulation of p53 in the majority of IECs/SCCs
exhibiting this heterogeneous staining pattern (see section 3.4 of the Discussion). One
possible explanation for the heterogeneity is that abnormal p53 accumulation, like wild
type p53, is regulated during the cell cycle and consequently only cycling tumour cells
express increased levels of p53 (Reich and Levine, 1984; Shaulsky et al, 1990; Bischoff
et al, 1990a; Steinmeyer et al, 1990; Perry & Levine, 1993). This hypothesis is
supported by the finding that p53 immunostaining was confined to the proliferative
compartment (basal cells) of well differentiated SCCs, whereas almost all the cells of
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poorly differentiated, immunopositive SCCs (where poorly differentiated keratinocytes
remain in the cell cycle), stained for p53. Increased expression of p53 in poorly
differentiated cutaneous SCCs has previously been demonstrated (Gusterson et al,
1991; McGregor et al, 1992; Ro et al, 1992; Helander et al, 1993).
There is growing evidence that p53 functions as part of a cell cycle checkpoint control
pathway (Kastan et al, 1991; El-Deiry et al, 1993 and 1994; Khanna & Lavin, 1993;
Perry & Levine, 1993). It is therefore probable that multiple genes are involved in this
pathway and that deregulation or inactivation of one (or more) of these genes may
induce accumulation of p53 at critical times during the cell cycle. It is probable that
tumours overexpressing wild type p53 have lost the growth regulatory response to the
protein so are functionally similar to those expressing the mutant protein (Vojtesek &
Lane, 1993). Therefore, this p53 accumulation may lead to increased levels of
dysplasia and progression of cutaneous neoplasms. The complex cellular environment
of chronic HPV infection and associated keratinocyte proliferation may provide
multiple opportunities for gene mutations to result in the deregulation of p53. The
identity of such genes and their roles in the accumulation of p53, and subsequent
development of dysplasia and progression to skin cancer, remain to be established.
4.3 The relationship between HPV and p53 in cutaneous carcinogf.nf.sis
E6 oncoproteins from HPV types 16 and 18 can bind to and induce rapid degradation
of wild type p53. From observations in anogenital cancers, it has been proposed that
p53 inactivation occurs either by complexing of wild type p53 with such viral
oncoproteins or, in the absence of virus, by mutational loss of gene function (Scheffner
et al, 1990, 1991 and 1992; Werness et al, 1990; Crook et al, 1991a and b and 1992).
This concept, however, remains controversial and other workers have failed to confirm
these suggestions (Busby-Earle et al, 1993; Cooper et al, 1993). Evidence from this
study suggests that, in contrast to cervical carcinogenesis, HPV contributes to skin
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carcinogenesis through viral promotion of cell proliferation. The failure to demonstrate
any relationship between the presence or absence of HPV DNA and accumulated p53
in dysplastic or frankly malignant skin lesions from RARs or ICPs is consistent with
this viral promotion hypothesis. Furthermore, accumulated p53 was demonstrated in
cutaneous neoplasia exhibiting HPV 16 DNA and p53 mutations were detected by
SSCP analysis in both HPV positive and negative malignancies. Also in keeping with
the suggestion that HPV do not contribute to cutaneous carcinogenesis by inactivating
p53, is the recent demonstration that the E6 oncoprotein from skin associated HPV
type 8 does not bind to p53, unlike its HPV 16 or 18 equivalents (Steger & Pfister,
1992). Therefore, HPV appear to contribute to cutaneous carcinogenesis by promoting
keratinocyte proliferation, which is different to the mechanism of action of anogenital
HPV types.
It is of interest that accumulated p53 was predominantly found in the basal layers of
differentiated SCC. In papillomavirus infected epithelium, low levels of E6 and E7
proteins are found in the basal and suprabasal layers, increasing in the upper
differentiated layers (Arends et al, 1990). Gusterson et al (1991) postulated that the
low levels of E6 in the basal layers bind to and inactivate p53 resulting in an increased
cell turnover and an increase in the pool of keratinocytes in which viral replication can
take place. As cells differentiate, there is competition for binding of E6 between the
p53 protein and viral DNA such that in the basal cells the equilibrium favours p53 with
resultant proliferation while in the differentiated cells, with low endogenous levels of
p53, DNA binding is favoured. The demonstration of accumulated p53 in basal cells
indicates that this hypothesis is only likely if the E6 proteins from skin associated HPV
types bind to and stabilise p53 without degradation, as is the case for SV40 large T
antigen and adenovirus E1A. Although this does not appear to be true for cutaneous
HPV types (Steger & Pfister, 1992), it would be of interest to carry out a double
immunocytochemical assay, using antibodies directed to HPV E6 and p53, to
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determine whether in those cases exhibiting HPV DNA and stabilised p53, HPV E6 is
expressed in the p53 stained or unstained cells.
4.4 THE ROLF. OF IJV RADIATION IN CUTANEOUS CARCINOGENESIS OF RARS
Epidemiological studies strongly implicate UV light in the development of many
epidermal tumours, including solar keratoses and SCCs (Blohme & Larko, 1984;
Boyle et al, 1984; Yoshikawa et al, 1990; Marks, 1992). It has been discovered that
patients with xeroderma pigmentosum (who are unable to repair UV-induced DNA
photoproducts) have a 2000 fold increase in cutaneous SCCs. This suggests that one
role of sunlight in the development of these malignancies is to induce genetic damage,
thus acting as an initiating agent (Figure 4.1) (Brash et al, 1991; McGregor et al. 1991;
Kraemer et al, 1984; Ziegler et al, 1993). Mutations due to direct absorption of UV
light by DNA are predominantly C-T transitions at dipyrimidine sites. These include
CC-TT double base mutations which are virtually pathognomonic of a UV based
aetiology (Ananthaswamy & Pierceall, 1990; McGregor et al, 1991; Vogelstein &
Kinzler, 1992). The recent demonstration of p53 mutations at dipyrimidine sites and
the unique finding of CC-TT double base changes in epidermal tumours, but not in
other common malignancies, provides further evidence that UV light may act as an
initiating agent in cutaneous carcinogenesis (Brash et al, 1991; Ziegler et al, 1993;
Campbell et al, 1993a). In this study, 5 of the 6 malignancies with mutated p53
developed on sun exposed body sites, implicating UV radiation in the genesis of these
cancers. A role for UV was confirmed in one SCC that was found to have a UV
specific (C-T) mutation at the codon 248 mutational hotspot of p53.
UV irradiation of mice induces a local and systemic immune response which is strongly
associated with UV induced promotion of murine cutaneous neoplasms (Streilein,
1991). It has recently been demonstrated that UV radiation can suppress immune
function in humans in a similar manner (Baadsgaard, 1991). Therefore, in RARs, UV
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induced immunosuppression, in addition to transplant related immunosuppressive
therapy, may allow chronic HPV infection and tumour formation and progression
where rejection would otherwise occur with an intact immune response. This
hypothesis is supported by the findings of this study that the majority of both viral
warts and skin cancers developed on sun exposed body sites in RARs and that both
types of lesion were more prevalent in patients with high sun exposure. Tilbrook et al
(1989) have previously detected HPV DNA in papillomas and in situ and invasive
SCCs of UV irradiated, hairless mice and suggested that these animals may be used as
a model for viral carcinogenesis.
4.5 A MODF.I. OF CUTANEOUS CARCINOGENESIS IN RARS
On the basis of the data from this and other studies, a model of skin carcinogenesis
may be proposed (Figure 4.1). Initially, UV radiation (or in a minority of cases,
another carcinogen) induces an irreparable genetic lesion in an oncogene or tumour
suppressor gene which results in the initiation of one or more epidermal keratinocytes.
Exposure to high or chronic levels of UV radiation also results in local immuno¬
suppression which, along with the effects of long term immunosuppressive therapy,
allows persistent infection with any one of multiple different papillomavirus types. In a
background of continuing sun exposure and immunosuppressive therapy, HPV
stimulate high level proliferation of epidermal keratinocytes which expands the
population of initiated cells and allows replication of damaged DNA without repair,
generating further genetic damage. Eventually, mutations occur to a gene(s) involved
in the regulation of p53, resulting in the accumulation and/or inactivation of wild type
p53. Selection and clonal expansion of the cell population carrying inactivated p53
leads to increased levels of dysplasia and progression from dysplastic keratosis to IEC.
Inactivation of p53 results in further uncontrolled cell proliferation and the
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Figure 4.1:- Proposed scheme of HPV induced cutaneous carcinogenesis in RARs.
HPV infection of epidermal keratinocytes causes cell proliferation, differentiation and
the development of a viral wart. Chronic sun exposure and viral induced cell
proliferation may lead to genetic damage and dysplasia of HPV infected cells within
the viral wart. Alternatively, HPV infection of an epidermal keratinocyte carrying a UV
induced initiating mutation results in proliferation of the genetically damaged cell and
thus fixation of the genetic damge. Immunosuppressive therapy and the
immunosuppressing effects of UV radiation allow viral DNA persitence and continued
cell proliferation which may allow further genetic abnormalities and increasing levels of
dysplasia. Genetic damage occurs in oncogenes or tumour suppressor genes and the


































accumulation of more genetic lesions. One such lesion(s) causes further progression
from in situ to invasive SCC.
This model of skin carcinogenesis is supported by the time scale of tumour
development in RARs and ICPs. Although HPV infection may occur prior to or just
months after transplantation, there is usually a time lapse of 5 to 10 years before the
first skin cancer appears in transplant patients. Furthermore, in contrast to RARs
where skin cancers may develop at a relatively early age, cutaneous SCCs are rarely
observed in patients under seventy years of age in the immunocompetent population. It
has been suggested that in ICPs, the initial genetic event inducing these lesions occurs
20 years prior to the development of the cancer (Kwa et al, 1992). These data suggest
that a number of events may be required prior to the development of skin malignancies.
Papillomavirus driven promotion of cell division in immunosuppressed patients may
increase the chance of these genetic events occurring, which may explain the increased
number and the early age of onset of skin tumours in RARs. In the absence of
immunosuppressive therapy and papillomavirus infection, cutaneous tumours are
probably promoted by UV radiation alone, which may explain the long time scale of
skin cancer development in ICPs
Some features of this study may be explained by the above model of cutaneous
carcinogenesis. The early acquisition of abnormal p53, through increased proliferation
of epidermal keratinocytes, may account for the increased prevalence and extent of p53
immunostaining in dysplastic skin lesions, and the increased clinical rate of progression
of such lesions, from RARs compared to those from ICPs (see Section 3.2 of the
Discussion). In a background of deregulated cell proliferation, driven initially by HPV
and subsequently by inactivation of p53, genetic damage may occur not only to the
host cell genomic DNA but also to the infecting viral DNA. This may explain why in
this study, a number of HPV were detected exhibiting deletions, amplifications and
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mutations in their genome (see Section 2.3 of the Discussion). Under these
circumstances, integration of viral DNA into the host genome may also occur as a
random event, although, this appears to be rare in skin cancers.
The initiating genetic lesion in human skin cancers is presently unknown. In the mouse
model of skin carcinogenesis, mutation of the c-Ha-ras oncogene is (in over 90% of
tumours) strongly associated with the initiated state. However, the majority of reports
suggest ras gene mutations are rare in human skin malignancies (Campbell et al,
1993c; Mukhtar & Bickers, 1993; Pierceall et al, 1991b). The presence of UV-
associated, p53 mutations in skin cancers (Brash et al, 1991; Moles et al, 1993;
Campbell et al, 1993a and b) suggests that p53 mutation may be one of the initial
events in human skin carcinogenesis, however, this study indicated that this is only true
in a minority of cases. The genetic event associated with malignant conversion of
human skin cancers has also yet to be identified. In the mouse model of carcinogenesis,
activation of the/os oncogene is associated with malignant conversion of keratinocytes
(Greenhalgh et al, 1990). However, this gene has not yet been investigated in human
skin cancers. Further investigations into early skin neoplasms (such as dysplastic
keratoses) and cutaneous SCCs are required to determine the initiating events and the
genetic events associated with malignant progression to invasive SCC in human skin
carcinogenesis.
4.6 CUTANEOUS CARCINOGENESIS IN INDIVIDUAL PATIENTS
This study identified a sub-group of patients who appeared to be particularly
susceptible to the development of skin neoplasia and consequently exhibited multiple
skin cancers over the sample collection period (see Section 1 of the Discussion).
Dysplastic and malignant cutaneous lesions from these patients were found to have an
increased HPV prevalence compared to those from RARs with single or few skin
cancers. HPV DNA was particularly prevalent in skin tumours from a 36 year old,
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female RAR (patient 20) who, despite low levels of sun exposure, developed over 10
SCCs during the sample collection period. HPV DNA, including HPV 5 and 16, was
detected in 70% of these lesions. This patient also developed multiple genital tract
neoplasms and eventually died in 1993 of cervical cancer. HPV 5 and 16 have
previously been found in some of these genital tract lesions (Alloub et al, 1989;
Rudlinger et al, 1986). These data suggest that some RARs have an increased
susceptibility to persistent HPV infection and consequently develop multiple
carcinomas of the skin, and in some female RARs, the anogenital tract. This study is
the first to demonstrate an association between the development of multiple skin
cancers and an increased prevalence of HPV. Bouwes Bavinck et al (1993b) have
recently demonstrated a strong link between HLA-Dr7, the absence of an antibody
class switch (from IgM to IgG) in response to the LI protein of HPV8 (or associated
HPV types) and an increased incidence of skin cancer in RARs. In the present study, it
is possible that some patients with multiple skin cancers may carry certain particular
MHC class II subtypes that may affect the effeciency of mounting an effective immune
response to HPV. This may exaggerate the effects of long term immunosuppressive
therapy, resulting in chronic viral infection and skin cancer development. It has also
been demonstrated that the immunosuppressive effects of UV radiation may be
genetically determined (Yoshikawa et al, 1990). Therefore, an alternative explanation
may be that RARs with multiple skin cancers have a genetic predisposition to the
immunosuppressive effects of UV radiation and consequendy develop multiple
persistent HPV infections and skin neoplasms on UV exposed sites.
4.7 FINAL CONCMISIONS
The findings of this study provide strong evidence that multiple different HPV types
contribute to cutaneous carcinogenesis of RARs most likely by promotion of cell
proliferation. At a practical level, these data challenge the necessity to systematically
type HPV DNA found in cutaneous lesions from RARs. However, they highlight the
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need for a sensitive assay to detect multiple different EV-associated and common
cutaneous HPV types. These results also indicate that an effective vaccine against
papillomavirus infection in transplant patients would have to be directed against viral
epitopes which are conserved amongst all papillomavirus types, such as the LI capsid
protein. The finding that patients who develop multiple skin cancers have an increased
prevalence of HPV infection is important. Further investigations are required to
determine the reasons for this increased susceptibility to HPV infection in order to
identify those transplant patients who may be at an increased risk of developing skin
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APPENDIX 1: ASSOCIATION BETWEEN RENAL ALLOGRAFT




1 15 98 US
2 13 140 vw
3 18 51 VW(D+)
142 US
4 9 172 US
165 MISC
5 8 121 US




7 13 211 US
8 6 102 IEC
173 AK (D+++)
174 AK(D+++)
9 12 118 US
10 8 195 US
11 9 182 vw
12 15 9 VK(D+)
10 AK(D+++)
53 VW





13 5 198 IEC
14 4 89 IEC
97 US









Patient Code Duration Of
Transplant (yrs)
Sample Code Histology







17 12 202 us
18 6C 42 AK(D++)
68 VK
69 AK
19 1 157 AK(D+++)
















21 23 128 us
22 14 141 us
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24 2 178 US
25 8 151 MISC
152 M1SC























28 9 154 VW
29 3 46 VW
47 VW
30 14 108 VW
31 11 88 VW
115 VW
32 3 57 VW




34 26 32 IEC
33 AK(D+)
213
Patient Code Duration Of
Transplant (yrs)
Sample Code Histology











35 14 94 MISC
95 AK
36 7 120 US
37 3 203 vw
38 3 204 MISC
39 9C 132 sec




41 21 164 US
42 12 107 US
43 7 81 VW
44 13 207 AK(D+)
208 AK(D+)
45 9 218 VW
46 16 135 US
47 5C 43 VW




49 25 50 AK(D+)
50 8 73 VK(D+)
79 AK
80 AK(D++)
51 3 87 MISC
117 US
52 9 199 AK(D+)




Patient Code Duration Of
Transplant (yrs)
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55 11 176 VW
177 US
56 10 153 MISC
57 15 62 VK
62A VK(D+)
58 10 93 SCC
59 1 175 BCC
214 IEC
60 20 180 VW
61 15 194 VK(D+)
62 13 15 BCC
63 3 63 VW








yrs= years; C = cardiac transplant recipient; VW = viral wart; VK = verrucous
keratosis; AK = actinic keratosis; D = mild dysplasia; D++ = moderate dysplasia;
D+++ = severe dysplasia; IEC = intraepidermal carcinoma; SCC = squamous cell
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Prevalence of human papillomavirus DNA in cutaneous neoplasms from
renal allograft recipients supports a possible viral role in tumour
promotion
L.A. Stark1, M.J. Arends1, K.M. McLaren', E.C. Benton2, H. Shahidullah2, J.A.A. Hunter2 &
C.C. Bird1
Departments of'Pathology and2Dermatology, University of Edinburgh, Edinburgh, UK.
Summary It is well established that renal allograpft recipients (RARs) have an increased incidence of viral
warts and premalignant and malignant cutaneous lesions, and the risk of their development increases in
proportion to duration of graft survival. It has been postulated that, in addition to the effects of prolonged
immunosuppression and previous sun exposure, human papillomaviruses (HPV) may also contribute to the
carcinogenic process. In this study, the prevalence of HPV DNA was examined in a range of premalignant and
malignant cutaneous tumours from 50 immunosuppressed patients (47 renal allograft recipients plus three
cardiac allograft recipients) and 56 immunocompetent patients using Southern hybridisation as a low-
stringency screening method and type-specific polymerase chain reaction (PCR) assays for eight HPV types.
The combined results for renal allograft recipients show that HPV DNA was detectable in 79% of viral warts,
42% of premalignant keratoses, 33% of intraepidermal carcinomas, 43% of invasive squamous cell carcinomas
and 16% of uninvolved skin specimens (squamous cell carcinomas/renal allograft recipients significantly
different at P <0.05 from uninvolved skin specimens/renal allograft recipients). In immunocompetent patients
the pattern of HPV DNA prevalence was 100% for viral warts; 25% for keratoses, 23% for intraepidermal
carcinomas, 22% for squamous cell carcinomas and 8% for uninvolved skin. No single HPV type
predominated in tumour specimens from either group. More tumours were found to contain HPV DNA by
Southern hybridisation analysis than PCR, indicating the presence of HPV types other than HPV 1, 2, 5, 6, 8,
11, 16 and 18 in some tumours. However, 'low cancer risk' HPV types 1, 2 and 6 as well as 'high cancer risk'
HPV types 5 and 16 were specifically detected by PCR in a small number of neoplasms. These data suggest
that multiple HPV types may contribute to cutaneous neoplasia in RARs and that they appear to act early in
the process of carcinogenesis, perhaps by functioning as tumour promoters via stimulation of cell prolifera¬
tion.
Renal transplantation is now a well-established procedure,
with many recipients surviving 20 years or more. However, a
major problem associated with long-term immunosuppression
is the increased prevalence of various malignancies, especially
in skin, anogenital tract and lymphoreticular system (Hoxtell
el al., 1977; Birkeland, 1983; Blohme & Larko, 1984; Sheil et
a/., 1985; Shuttleworth et al., 1987; Alloub et al., 1989).
Moreover, renal allograft recipients (RARs) frequently
develop a spectrum of cutaneous complications ranging from
benign viral warts (VWs), to verrucous and actinic keratoses
(Ks) exhibiting varing degrees of dysplasia, culminating in
squamous cell carcinoma (SCC) (Benton et al., 1992). The
prevalence and morbidity of such complications increases the
longer the duration of immunosuppression with a number of
long-standing RARs developing multiple skin tumours (Barr
et al., 1989). In RARs squamous cell cancers outnumber
basal cell cancers (BCCs) by a ratio of 15:1, a reversal of the
1:5 ratio normally observed in immunocompetent patients.
A number of factors have been implicated in the develop¬
ment of skin cancers in RARs. Ultraviolet (UV) radiation is
known to be of considerable importance as the majority of
tumours occur on sun-exposed skin (Blohme & Larko, 1984;
Boyle et al., 1984; Baadsgaard, 1991; Streilein, 1991). The
alteration in cell-mediated immunity brought about by pro¬
longed immunosuppressive therapy is thought to be a con¬
tributory factor and is associated with an increased incidence
of anogenital cancers and lymphomas as well as skin
tumours (Streilein, 1991). The possible association with
human papillomaviruses (HPVs) is derived indirectly from
observations in the rare, inherited skin disease epidermodys¬
plasia verruciformis (EV) (Orth el al., 1979; Orth, 1986). This
disease is characterised by the development of extensive,
Correspondence: L.A. Stark, Department of Pathology, University
Medical School, Teviot Place, Edinburgh EH8 9AG, UK.
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persistent infection with unusual HPV types and a predis¬
position to cutaneous SCC on light-exposed skin in around
one-third of patients (Pfister et a!., 1983a; Fuchs & Pfister,
1990). Although over 20 HPV types have been detected in
benign skin lesions from EV patients, in SCC HPV types 5
and 8 are consistently demonstrated (Orth et al., 1986; Fuchs
& Pfister, 1990). However, in contrast to the HPV types 16
and 18 that are usually integrated in squamous cervical
cancers, the majority of EV-associated SCCs contain HPV 5
or 8 DNA in an episomal form, with integration being a rare
event (Yabe et al., 1989).
There is also some direct evidence to suggest that HPV
may play a part in the development of skin cancers in RARs
(Blessing et al., 1989; Benton el a!., 1992). Histologically,
viral warts and keratotic lesions in RARs often exhibit vary¬
ing degrees of epidermal dysplasia, while SCCs develop on a
background of verrucous keratoses and may retain HPV-
associated features. However, the detection of HPV DNA in
the cutaneous SCC of RARs has been somewhat controver¬
sial, with EV-associated types and a variety of common
cutaneous and genital HPV types being identified in some,
but not all, studies (Lutzner et al., 1980; Van der Leest el al.,
1987; Barr et a!., 1989; Rudlinger & Grob, 1989; Dyall-Smith
et al., 1991; Soler et al., 1992).
We report here the results of an investigation in which we
determined, first, the prevalence of HPV DNA in various
cutaneous lesions from RARs and immune-competent
patients (ICPs) by Southern hybridisation analysis with
mixed probes for common cutaneous and EV-associated
HPV types. Second, using type-specific and sensitive PCR
assays we determined the prevalence of the putative
oncogenic HPV types 5 and 8, the more common cutaneous
HPV types 1 and 2 and the common genital HPV types 6, 11,
16 and 18. Finally, we considered whether the pattern of
HPV prevalence in the cutaneous lesions provided clues as to
the stage at which HPV may act in the oncogenic pro¬
cess.
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Materials and methods
Patients
Two groups of patients were investigated. The first comprised
47 immunosuppressed patients, 44 RARs plus three cardiac
allograft recipients (mean age 50 years, range 20-71 years),
all of whom received transplants between 1965 and 1992
(mean duration of transplant 10.9 years, range 1-26 years).
Prior to 1984 patients received immunosuppressive therapy
with prednisolone and azathioprine, but since then all new
allograft recipients have been treated with prednisolone and
cyclosporin A, a few subsequently being switched to azathio¬
prine. The second patient group comprised 56 immuno¬
competent individuals (mean age 66.6 years, range 22-90
years) who were referred for treatment of suspected warts or
skin malignancies. All patients were treated in the Depart¬
ment of Dermatology at the Royal Infirmary of Edin¬
burgh.
Tissue collection and DNA extraction
Therapeutic skin biopsies were collected from RARs (120 in
all) and ICPs (63). A 6 mm biopsy of uninvolved, sun-exposed,
forearm skin was also obtained from 19 RARs (some with
and others without skin tumours elsewhere) and 12 healthy
ICPs who volunteered to undergo this procedure. Immedi¬
ately following excision, each lesion was bisected
longitudinally with a sterile blade to minimise the risk of
contamination: half was snap frozen in liquid nitrogen prior
to DNA extraction while the remainder was fixed in formalin
or periodate-lysine-paraformaldehyde-dichromate (PLPD)
(Holgate et al., 1986) for histological examination. Frozen
tissue was minced in lysis buffer (50 mM Tris, 50 mM EDTA,
100 mM sodium chloride, 5 mM DTT. 1% SDS, 1.5mgml_1
proteinase K) and DNA extracted using a standard phenol-
chloroform extraction technique (Sambrook et al., 1989).
Histopathology
The cutaneous lesions were assessed for standard mor¬
phological features suggestive of actinic damage and for
degrees of dysplasia progressing to intraepidermal and
invasive carcinoma (Blessing et al., 1989). They were desig¬
nated as viral warts (VWs), actinic and verrucous keratoses
(AKs and VKs), intraepidermal carcinoma (I EC) and
squamous cell carcinoma (SCC) (Figure 1). VWs showed
architectural symmetry, hypergranulosis and koilocytosis.
Lesions showing double-layered basal budding, basal
hypermelanosis and dysplasia and loss of granular layer with
superficial parakeratosis were classified as actinic keratoses.
Lesions that showed some features suggestive of HPV infec¬
tion, but various degrees of basal budding and basal dys¬
plasia, were termed verrucous keratoses. IECs exhibited
either full-thickness dysplasia or severe dysplasia in the basal
layer. The designation of SCC was confined to lesions in
which there was evidence of dermal invasion. In some in¬
stances, the complex architecture of VKs and the variable
dysplasia made confirmation of invasion difficult so the term
SCC was used only when dermal invasion was unequivocal
(Blessing et al., 1989).
Polymerase chain reaction (PCR)
Oligonucleotide primers, situated in E6, were designed from
published sequence data (Danos et al., 1982; Fuchs et al.,
1986; Zachow et al., 1987; Hirsch-Behnam, 1990) to detect
HPV types 1, 2, 5 and 8 in type-specific assays (Table I).
Primer sequences for HPV types 6, 11, 16 and 18 were
validated in previous studies (Arends et al., 1991). Prior to
amplification with HPV primers, each sample was amplified
with control ras primers to confirm adequate preservation of
DNA (Table I). A 1 fig aliquot of genomic DNA was used as
template in a 100 pi reaction containing 1 x preprepared
reaction buffer (NBL), 200 (iM dNTPs 1 pM each primer and
0.5 U of Taq polymerase (NBL). PCR cycle conditions used
Figure I a. Viral wart exhibiting papuliferous architecture. Inset shows cell vacuolation (koilocytotic change) and cytoplasmic
inclusions at high power. I). Verrucous keratosis with the topography of a viral wart but lacking the cytological features. There is
some irregularity of the basal tongues, c. Verrucous keratosis with widespread dysplasia amounting to intraepidermal carcinoma, d.
Invasive squamous cell carcinoma arising from a surface exophytic verrucous keratosis (haematoxylin and eosin).
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Table I HPV primer sequences used to detect HPV types 1, 2, 5 and 8, and K-ras
HPV
type Primer Sequence Position" Product
1 P' AGTCTTATGAGGTACCGGAAATAGAAG 383-409
1 P2 ATGCACTCTTTCTCCGTTTGACACAACCTC 520 490 136 bp
2 P1 ATGGTTTGGAGCTAGAGGATTTGCG 159-183
2 P2 AACTAGTAATGCCTCCTTCTCCTCC 463-438 303 bp
5 Pi CTCTAATACCAAATTCTGTGGCGT 616-640
5 P2 GAGGAACGCCTGGAAGGGAATCTG 894-870 279 bp
8 Pi CGGGCAGGACAAGGCTTCATATTTAGACAC 200-230
8 p2 ACAACAACGACAACACGCAGTAACAAC 420-393 220 bp
K-ras pl GACTGAATATAAACTTGTGG 3-22
K-ras P2 CTCTATTGTTGGATCATATT 111-92 109 bp
"Position in HPV genome defined by EMBL/Genebank database.
to amplify HPV types 1, 2, 5 and 8 were as follows: One
cycle of 94°C for 5 min; 30 cycles of 58°C (55°C for HPV 1)
for 2 min, 72°C for 3 min and 94°C for 1 min; and one cycle
of 58°C (55°C for HPV 1) for 2 min and 72°C for 10 min.
Positive (1 pg of purified HPV plasmid DNA instead of
genomic DNA) and negative (template-free) controls were
included with all reactions. Amplified products were
visualised on a 2% Nusieve-Seakem (3:1) agarose gel con¬
taining 0.5 fig ml"1 ethidium bromide (Flowgen Instruments,
Kent, UK).
Southern hybridisation analysis
Genomic DNA (8-10ng) was digested using the restriction
enzyme BamH\ (NBL). Following electrophoresis on 8%
agarose gel, DNA was alkaline denatured and transferred on
to charged nylon membrane (Hybond N+, Amersham, Ayles¬
bury, UK) according to the manufacturer's instructions.
HPV probe DNA was isolated from vector DNA by diges¬
tion with the appropriate restriction enzyme followed by
electrophoresis on a 0.8% low melting temperature agarose
gel. The resulting HPV DNA was purified using Biorad
Prepagene kit (Biorad Laboratories, Richmond, UK) and
25 ng DNA of each HPV type was prepared and labelled
with 32P using the Amersham Multiprime kit as specified by
the manufacturer's instructions. Hybridisation was carried
out at Tm — 40°C (55°C) (hybridisation buffer consisted of
6 x SSC, 1% SDS and 0.1 g ml"1 dextran sulphate) using
mixed HPV probes containing 25 ng each of either HPV
types 3, 8 and 13 or HPV types 2, 4 and 12. The minimum
specific activity of all probes was 4-5 x 106c.p.m. ml"1. All
filters included positive (HPV plasmid DNA) and negative
(placental DNA) controls. Following hybridisation, filters
were washed at low stringency [2 x SSC, 1% SDS, at 55°C
for 30 min (Tm — 35°C)] and exposed to X-ray film initially
for 24 h and subsequently for 3 days. Cases positive for HPV
by this intial screen were further analysed by Southern hy¬
bridisation using the restriction enzyme Pstl. Filters contain¬
ing 50 pg of purified HPV plasmid DNA of types 1, 2, 3, 4,
5, 8, 10, 12, 13, 14, 17, 19 and 20 (Heilman et al., 1980;
Ostrow et al., 1982, 1983; Kremsdorf et al., 1983, 1984;
Pfister et al., 1983a, b; Gassenmaier et al., 1984) mixed with
lOftg of genomic DNA were also made for use in initial
optimisation experiments. The sensitivity of this technique
was investigated by performing Southern hybridisation
analyses on serially diluted HPV 16 plasmid DNA mixed
with a known concentration of genomic DNA.
Results
Prevalence screen for HPV DNA by Southern hybridisation
Initial experiments indicated that, by using Southern hy¬
bridisation with a probe cocktail containing a mixture of
HPV types 3, 8 and 13 at low hybridisation (Tm — 40°C) and
washing (Tm — 35°C) stringency, it was possible to detect
HPV types 1, 2, 3, 4, 5, 8, 10, 12, 13, 14, 17, 19 and 20. The
probe cocktail containing HPV types 2, 4 and 12 was also
extensively used, but added little extra information. The
sensitivity of Southern hybridisation analysis was found to be
5 pg of viral DNA in a background of 10 pg of genomic
DNA, equivalent to 0.1 copies per cell.
A total of 108 skin biopsies from RARs, including over 50
IEC and SCC specimens from 16 patients, together with 63
specimens from ICP were analysed by Southern hybridisa¬
tion, using the mixed probe cocktail described above to
screen for the presence of HPV DNA. As expected, detection
of HPV DNA was greatest in VWs (64%), but 25% of
keratoses, 24% of IECs and 33% of SCCs from RARs
contained HPV DNA (Figure 2 and Table II). All specimens
from normal skin were negative for HPV DNA. Lesions
from ICPs showed lower HPV DNA prevalence than those
from RARs, except for viral warts, only five of which were
examined from ICPs (Table II). Statistical comparison of the
results for each histological category between RARs, and
ICPs revealed that SCC/RAR differed significantly (/><0.05
by chi-squared test) from SCC/ICP, despite the small
number of ICPs analysed. It should be noted that the two
A B C D E F
Figure 2 Southern hybridisation autoradiograph showing three
HPV DNA-positive specimens, (A) SCC (from patient G), (D)
VW and (F) VW, compared with three HPV DNA-negative
specimens, (B) AK (from patient I who was HPV 16 positive by
PCR), (C) IEC and (E) AK. All specimens were from RARs, and
the size markers are indicated. A probe cocktail of HPV types 3,
8 and 13 was used with BamHI-digested DNA. Track A (which
was negative by PCR) shows evidence of HPV genome integra¬
tion within a DNA fragment greater than 12 kb in size. Tracks D
and F show episomal HPV genomes cleaved twice into fragments
of 6 and 2 kb.
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Table II HPV DNA prevalence detected by Southern hybridisation analysis
Number (%) of lesions positive
Patient group VW K IEC SCC US
RARs 9/14 (64) 6/24 (25) 5/21 (24) 10/30 (33) 0/19 (0)
ICPs 5/5 (100) 1/8 (13) 0/12 (0) 0/9 (0) 0/12 (0)
Chi-squared tests revealed significant differences of P <0.00001 for comparisons of
both VW/RAR with US/RAR and VW/ICP with US/ICP, P <0.025 for comparison of
either K/RAR or IEC/RAR with US/RAR, P <0.005 for SCC/RAR w US/RAR, and
P <0.05 for SCC/RAR vs SCC/ICP.
RAR, renal allograft recipient; ICP, immunocompetent patient; VW, viral wart; K,
keratosis; IEC, intraepidermal carcinoma; SCC, squamous cell carcinoma; US,
uninvolved, sun-exposed skin.
groups of patients (RARs and ICPs) could not be age mat¬
ched for IEC and SCC specimens, as these occurred mostly
in the elderly in the ICP group. However, compared with 0%
prevalence in US/RAR, HPV DNA positivities differed
significantly in SCCs (33%; P <0.005), IECs (24%;
P<0.025), Ks (25%; P<0.025) and VWs (P<0.00001)
within the RAR group.
Restriction pattern analysis suggested that HPV integra¬
tion had taken place in a dysplastic VW, an AK and an SCC
(Figure 2) in three separate RARs. When digested with the
single-cut enzyme BamHl, both cases gave multiple restric¬
tion fragments, the sum of which was greater than 8 kb, but
dissimilar to the size of multimer episomes. These banding
patterns were reproducible, providing evidence that some
RAR skin lesions contained integrated HPV DNA, but the
numbers of affected lesions were too small to determine
whether integration plays a significant role. The restriction
patterns obtained when HPV-positive cases were further
digested with Pst\ were dissimilar, indicating that different
HPV types were present in these lesions.
Detection of specific HPV types by polymerase chain reaction
The reaction conditions for all primers were optimised to
allow detection of 0.001 pg of episomal HPV DNA in a
background of lOpg of placental DNA, equivalent to 80
copies of HPV or 5 x 10~5 copies per cell. Each set of
primers was tested against a panel of cloned HPV types 1, 2,
3, 4, 5, 8, 10, 12, 14, 17, 19 and 20, and found to be
absolutely type specific.
A total of 118 specimens from RARs and 48 from ICPs,
were analysed by type-specific PCR for HPV types 1, 2, 5
and 8 (Tables III and IV). In each sample c-Ki-ra.v sequences
could be detected with appropriate ras primers (data not
shown). Relatively few specimens were positive for HPV
DNA compared with results by Southern hybridisation
analysis. In particular, HPV 5 DNA was only present in a
small number of benign and premalignant lesions from
RARs and ICPs but in no SCCs. HPV 8 DNA was found in
only one SCC from an ICP. HPV 1 and 2 DNA was found
in both benign and malignant lesions from RARs and ICPs
(Tables III and IV). A total of 102 lesions from RARs and
43 from ICPs were further tested for the common genital
HPV types 6, 11, 16 and 18 by type-specific PCR (Tables III
and IV). 'High-risk' HPV 16 DNA was detected in unin¬
volved skin from an RAR, and 'low-risk' HPV 6 DNA was
present in an SCC from an RAR. Four VWs from RARs
contained more than one HPV type (5 and 2, 5 and 6, 5 and
11, 2 and 11). Rigorous anti-contamination procedures were
followed throughout (Arends et al., 1991), and there was no
evidence to suggest that any of these positive results were due
to contamination from other sources. Overall there was no
dominant HPV type in any of the histological categories and
the distribution of types was broadly similar for immunosup-
pressed and immunocompetent patients.
Correlation ofHPV DNA detection by Southern hybridisation
and type-specific PCR
Twenty-one specimens of Ks, IECs and SCCs from RARs
exhibited HPV DNA by Southern hybridisation. However,
only three of these were HPV DNA positive by type-specific
PCR (Table V). Likewise, of the 13 specimens of Ks, IECs
and SCCs from RARs that were HPV DNA positive by
Table III HPV type prevalence by type-specific PCR in renal allograft recipients




examined I 2 5 8
Number
examined 6 11 16 18
VW 18 0 4 3 0 14 1 2 0 0
K 26 2 1 1 0 23 0 0 1 0
IEC 24 0 2 1 0 23 0 0 0 0
SCC 31 1 2 0 0 24 1 0 1 0
US 19 0 0 2 0 18 0 0 1 0
VW, viral wart; K, keratosis; IEC, intraepidermal carcinoma; SCC, squamous cell
carcinoma; US, uninvolved, sun-exposed skin.
Table IV HPV type prevalence by type-specific PCR in immunocompetent patients




examined 1 2 5 8
Number
examined 6 11 16 18
VW 6 1 1 0 0 5 0 0 0 0
K 8 0 0 1 0 8 0 0 0 0
IEC 13 2 1 1 0 11 0 0 0 0
SCC 9 0 1 0 1 7 0 0 0 0
US 12 0 1 0 0 12 0 0 0 0
VW, viral wart; K, keratosis; IEC, intraepidermal carcinoma; SCC, squamous cell
carcinoma; US, uninvolved, sun-exposed skin.
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type-specific PCR, only three were positive by Southern hy¬
bridisation analysis (Table V). A combination of both detec¬
tion assays resulted in 11/14 (79%) VWs, 10/24 (42%) Ks,
7/21 (33%) IECs, 13/30 (43%) SCCs and 3/19 (16%) USs
from RARs containing HPV DNA (Table VI). The com¬
bined results for ICPs gave HPV prevalences of 5/5 (100%)
for VWs, 2/8 (25%) for Ks, 3/13 (23%) for IECs, 2/9 (22%)
for SCCs and 1/12 (8%) for USs. No statistically significant
differences by the chi-squared test were found comparing
HPV prevalence in each histological group between ICPs and
RARs. However, SCCs from RARs showed a significantly
higher HPV prevalence (P<0.05) than uninvolved skin from
RARs. Overall, HPV DNA was detected with greater fre¬
quency by Southern hybridisation analysis than by type-
specific PCR (Tables II, III and IV). Some patients showed a
high susceptibility to developing multiple malignant tumours
exhibiting different HPV DNA content (Table V), but there
was no specific pattern of combination of HPV types in these
lesions.
Discussion
Prevalence of HPV DNA in the spectrum of cutaneous
neoplasia in RAR
Compelling evidence exists of a contributory role for 'high-
risk' genital HPV types 16 and 18 in the development of SCC
of the genital tract (Arends et al., 1990, 1991, 1993; zur
Hausen, 1991; Lorincz et al., 1992). Similarly, in EV the role
of HPV 5 and 8 in the aetiopathogenesis of cutaneous SCC is
suggested by their presence in over 90% of cancers (Orth et
al., 1979; Orth, 1986). Furthermore, HPV types 5, 8, 16 and
18 can cooperate with activated ras to transform rodent cells
(Watts et al., 1984; Iftner et al., 1988; Fuchs & Pfister, 1990).
By contrast, investigation of the relationship between HPV
and cutaneous cancers in RARs has been inconclusive with
regard to both prevalence and type of HPV DNA detected.
This may be the result of differences in sample size studied or
differences in sensitivity and specificity of the detection
Table V Clinicopathological details of HPV-positive lesions from renal allograft recipients
Patient Graft HPV type identified
Age (years)/ duration Histological Southern
Code sex (mjf) (years) type of lesion Site hybridisation PCR
A 56m 6 AK (D + +) Face pos uk neg
B 49m 17 SCC Scalp pos 2
B SCC Ear pos uk neg
C 57m 12 AK (D + +) Finger pos uk neg
C SCC Hand pos uk neg
C IEC Ear pos uk neg






E 36f 21 IEC Presternal pos 5
E VK Thigh ND 5
E SCC Neck neg 16
E SCC Chest neg 2




E SCC Forearm neg 6
F 52m 10 IEC Upper
back
pos uk neg
F SCC Neck pos uk neg




F SCC Shoulder pos 1
G 44m 26 IEC Scalp neg 2
G SCC Forearm pos uk neg
G SCC Scalp pos uk neg
G I EC Scalp pos uk neg
G SCC Chest pos uk neg
H 59m 13 IEC Scalp neg 2
62m 8 AK (D + +) Forearm neg 16
VK Forearm pos uk neg








VK Forearm pos uk neg
VK (D +) Thigh neg 2
AK, actinic keratosis; D +, mild dysplasia; D + + , moderate dysplasia; D + + + , severe dysplasia;
SCC, squamous cell carcinoma; IEC, intraepidermal carcinoma; VK. verrucous keratosis: ND, not
done; uk, unknown; neg, negative. "The Pst\ and Hind\\\ restriction digest of this lesion gave identical
restriction fragment patterns to HPV 10 by Southern hybridisation analysis.
Table VI Combined HPV prevalence by Southern hybridisation analysis and
type-specific PCR assays
Number (%) lesions positive
Patient group VW K IEC SCC US
RARs 11/14 (79) 10/24 (42) 7/21 (33) 13/30 (43) 3/19 (16)
ICPs 5/5 (100) 2/8 (25) 3/13 (23) 2/9 (22) 1/12 (8)
Chi-squared tests revealed significant difference of P<0.05 for comparisons of
SCC/RAR with US/RAR, and P = 0.00003 for both VW/RAR vs US/RAR and VW/ICP
vs US/ICP.
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methods employed (Lutzner et al., 1980, 1983; Rudlinger el
al., 1986; Jablonska et al., 1987; Van der Leest, 1987; Barr el
al., 1989; Blessing et al., 1989; Rudlinger & Grob, 1989;
Euvrard et al., 1991). An additional factor in some studies
may be the inclusion of a large proportion of patients who
seem to be at exceptionally high risk of developing multiple
and widespread premalignant and malignant cutaneous
lesions with increased HPV DNA content (Barr et al., 1989).
To overcome some of these problems we have studied a
large, unselected series of RARs using both Southern hy¬
bridisation and type-specific PCR techniques.
The prevalence of HPV DNA was closely similar through¬
out the spectrum of cutaneous neoplasia in RARs: 42% of
keratoses, 33% of IECs and 43% of SCCs contained HPV
DNA, but only 16% of uninvolved skin was positive (Table
VI), not dissimilar to some other reports (Soler et al., 1992).
This pattern differs from that found in cervical neoplasia in
which the prevalence of HPV (of specific 'high-risk' types)
increases throughout the cervical intraepithelial neoplasia
spectrum (Stanley, 1990; Arends et al., 1991, 1993; Lorincz et
al., 1992). These findings suggest that, if HPV play a role in
cutaneous neoplasia of RARs, this must involve the early
stages of the neoplastic process. One hypothesis is that HPVs
may act as tumour promoters by stimulating cell prolifera¬
tion. Thus, HPV may provide a stimulus analogous to that
of phorbol esters in traditional rodent skin carcinogenesis
models, in which promotion of cell proliferation fixes irrever¬
sibly any genetic mutations induced by initiating agents such
as chemical carcinogens or UV light. The role of promoter
for HPV was previously suggested by zur Hausen (1982), and
the ability to induce keratinocyte proliferation is common to
the many different types of common cutaneous and EV-
associated HPV, as evidenced by the variety of warts that
they cause. This hypothesis is supported by the clinico-
pathological observations that RARs frequently exhibit
extensive warts and verrucous keratoses, as well as malignant
tumours: these lesions form a seamless spectrum of his¬
tological change, with many keratoses (actinic and verrucous)
showing dysplasia, and both IECs and SCCs retaining viral
features. Furthermore, these immunosuppressed patients
appear to have relatively high background levels of HPV,
indicated by our findings that 3 out of 19 (16%) biopsies
from the apparently uninvolved skin of RARs contained
HPV DNA, in two cases HPV 5 DNA and in one HPV 16
DNA. Such a background level of HPV infection of skin, in
the presence of long-term immunosuppression that is likely to
permit viral persistence over a prolonged period, together
with sun-induced DNA damage, may give rise to conditions
conducive to tumour induction. Moreover, the usual 1:5
ratio of SCC BCC is reversed in RARs to 15:1, suggesting
that HPVs encourage squamous rather than basal cell neo¬
plastic differentiation.
Specific HPV types found in cutaneous neoplasms in RAR
In this study we were not always able to characterise fully the
HPV types found by Southern hybridisation analysis. How¬
ever, the results of type-specific PCR analysis indicate that
only a small proportion of lesions contained HPV 5 or 8
DNA. This is in contrast to previous findings from SE
Scotland (Barr et al., 1989), where 15 out of 25 SCCs were
found to contain HPV5 or 8 DNA. That study used mostly
dot blotting to detect HPV 5 or 8 DNA, which does not
exclude the possibility of cross-hybridisation with other EV-
associated HPV types. Moreover, all 15 positive specimens in
that study came from four patients at exceptionally high risk
of development of cutaneous lesions, each of whom had
multiple SCCs. The balance of evidence now suggests that
HPV 5 and 8 DNA is found relatively infrequently in
tumours from RARs (Lutzner et al., 1980, 1983; Rudlinger et
al., 1986; Van der Leest, 1987; Soler et al., 1992).
It is of interest that we found both HPV 1 and 2 DNA by
PCR in a small number of SCCs in this series. These HPV
types were previously considered to be non-transforming, and
usually associated with benign skin warts. Recent work has
also emphasised the importance of extending investigations
of HPV content to include the anogenital HPV types (Ostrow
et al., 1987, 1989; Stone et al., 1987; Rudlinger et al., 1989;
Eliezri et al., 1990; Ashinoff et al., 1991). Two positive SCCs
in the present study, one containing HPV 6 and the other
HPV 16 DNA, both came from a female RAR who in
addition to multiple cutaneous SCCs has developed SCCs of
cervix, vulva and anal canal. HPV 16 DNA has also been
detected in her genital tumours. Overall, from the present
investigation using both Southern hybridisation and PCR,
the emerging pattern of HPV type prevalence is one of
involvement by multiple HPV types.
Some cases found to contain HPV sequences by PCR
could not be confirmed by Southern hybridisation analysis,
indicating that in many cases copy numbers of HPV genomes
were too low to be detected by Southern analysis. Not sur¬
prisingly, the absolutely type-specific PCR assays for HPV 1,
2, 5, 6, 8, 11, 16 and 18 did not detect other HPV types
found by Southern hybridisation. In a pilot study applying a
consensus PCR assay (Manos et al., 1989), primarily
designed to detect genital HPV types, the common cutaneous
and EV-associated HPV types were poorly detected even
when using cloned HPV plasmid DNA as template (unpub¬
lished data). Thus, it is possible that this and other studies
have underestimated the true HPV prevalence in cutaneous
neoplasms in RARs, owing to a combination of a wide
variety of HPV types involved and low copy number of HPV
genomes.
The overall pattern found in this study is of similar HPV
prevalence throughout the spectrum of cutaneous neoplasia
in RARs. Furthermore, studies of the prevalence of
accurately typed specific HPV have shown that no single
HPV type predominates in cutaneous lesions in RARs with
multiple HPV types being detected. At a practical level, these
data challenge the necessity to systematically type HPV DNA
found in cutaneous lesions in RARs. Our observations are
consistent with the hypothesis that in RARs multiple HPV
types play a role in carcinogenesis by promotion of cell
proliferation, and this hypothesis merits further testing.
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and Cancer Research Campaign for funding this research, Robert
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Accumulation of p53 is associated with tumour progression in cutaneous
lesions of renal allograft recipients
L.A. Stark1, M.J. Arends1, K.M. McLaren1, E.C. Benton2, H. Shahidullah2, J.A.A. Hunter2 &
C.C. Bird'
'Department of Pathology, Edinburgh University Medical School, Teviot Place, Edinburgh, UK; 2Department of Dermatology.
Royal Infirmary of Edinburgh, Lauriston Place, Edinburgh, UK.
Summary Renal allograft recipients suffer from a markedly increased susceptibility to premalignant and
malignant cutaneous lesions. Although various aetiological factors have been implicated, little is known of the
associated genetic events. In this study we initially employed immunocytochemical techniques to investigate the
prevalence and localisation of accumulated p53 in over 200 cutaneous biopsies (including 56 squamous cell
carcinomas) from renal allograft recipients and immunocompetent controls. In renal allograft recipients
accumulated p53 was present in 24% of uninvolved skin samples, 14% of viral warts, 41% of premalignant
keratoses, 65% of intraepidernial carcinomas and 56% of squamous cell carcinomas [squamous cell carcinoma
and intraepidermal carcinoma differed significantly from uninvolved skin (P<0.005) and viral warts
(f <0.01)]. A similar trend was revealed in immunocompetent patients (an older, chronically sun-exposed
population) but with lower prevalence of p53 immunoreactivity: 25% of uninvolved skin samples, 0% of viral
warts, 25% of keratoses, 53% of intraepidermal carcinomas and 53% of squamous cell carcinomas. These
differences were not statistically significant. Morphologically, p53 immunoreactivity strongly associated with
areas of epidermal dysplasia and the abundance of staining correlated positively with the severity of dysplasia.
These data suggest that p53 plays a role in skin carcinogenesis and is associated with progression towards the
invasive state. No correlation was observed between accumulated p53 and the presence of human papil¬
lomavirus (HPV) DNA in any of the lesions. Single-strand conformational polymorphism analysis (exons 5-8)
was used to determine the frequency of mutated p53 in 28 malignancies with varying degrees of
immunopositivity. p53 mutations were found in 5/9 (56%) malignancies with p53 staining in >50% of cells,
reducing to 1/6 (17%) where 10-50% of cells were positively stained and none where <10% of cells were
stained. These data imply that factors other than p53 gene mutation play a part in accumulation of p53 in skin
cancers.
The p53 gene encodes a 53 kDa phosphoprotein that acts as
a transcription factor and has tumour-suppressor functions.
The wild-type gene product also has the ability to induce
growth arrest and/or apoptosis in response to DNA injury,
preventing replication of genomes that have suffered DNA
damage (Kastan et ah, 1991; Hartwell, 1992; Lane, 1992,
1993; Unger et al., 1992; Clark et al., 1993; Hall et al., 1993).
Mutations in the p53 gene are considered to play a significant
part in the development of many human malignancies: a high
frequency of mutation is observed in most of the common
forms of human cancer and there are elevated rates of malig¬
nancy in patients with Li-Fraumeni syndrome (in which
there is an inherited p53 gene mutation) and in genetically
engineered, p53-deficient mice (Baker et al., 1989; Nigro et
ah, 1989; Srivastava et ah, 1990; Hollstein et al., 1991;
Donehower et al., 1992; Purdie et al., 1994). A number of
oncogenic viral proteins can also form complexes with wild-
type p53, initiating gene inactivation by mechanisms other
than mutational loss of function (Scheffner et al., 1990; Yew
& Berk, 1992; Debbas & White, 1993; Moran, 1993). Most of
the mutations observed in p53 are thought to induce confor¬
mational changes in the protein product, increasing its half-
life and rendering it detectable by immunocytochemical
techniques (Milner & Cook, 1986; Gannon et al., 1990;
Milner & Medcalf, 1991; Montenarh, 1992; Wynford-
Thontas, 1992).
Renal allograft recipients (RARs) manifest a greatly in¬
creased susceptibility to cutaneous malignancy, with squam¬
ous cell carcinoma (SCC) occurring commonly, especially in
patients with long graft life or high sun exposure (Shuttle-
worth et al., 1987; Alloub et al., 1989; Benton et al., 1992).
These malignancies, however, form part of the wider spect¬
rum of cutaneous disease observed in RARs that includes
viral warts (VWs) and keratoses (K.s) displaying varying
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degrees of epidermal dysplasia and topographical continuity
with intraepidermal carcinoma (IEC) and invasive SCC (Bles¬
sing et al., 1989; Benton et al., 1992). Although a number of
putative aetiological factors have been implicated in the
development of these malignancies, including ultraviolet
(UV) radiation (Blohme & Larko, 1984; Boyle et ah, 1984),
decreased cell-mediated immunity (Streilein, 1991) and
human papillomavirus (HPV) infection (Rudlinger et al.,
1986; Barr et al., 1989; Benton et ah, 1992; Stark et al.,
1994), little is known of the associated genetic events and
whether these may differ in RARs and immunocompetent
patients (ICPs). To our knowledge, there have been no major
studies in which the role of p53 in the development of
cutaneous lesions in RARs has been considered, although
p53 mutations have been reported to occur in lECs and
SCCs from ICPs (Brash et al.. 1991; Gusterson et al., 1991;
Pierceall et al., 1991; McGregor et al., 1992; Burns et al.,
1993; Campbell et al., 1993a, b).
In this study we have employed immunocytochemical tech¬
niques to compare the prevalence of p53 accumulation in
premalignant and malignant cutaneous lesions from both
RARs and ICPs. Single-strand conformational polymor¬
phism (SSCP) analysis was also employed to determine the
relationship between positive immunocytochemistry and p53
gene mutations. The relationship between p53 expression and
the HPV satus of the lesions was also considered since it has
been reported that viral oncoproteins may play a part in p53
inactivation in other HPV-associated malignancies (Scheffner




Sixty RARs (mean age 49 years, range 20-71 years) and 83
ICPs (mean age 68 years, range 12-94 years) were investi¬
gated. All SCCs came from 10 RARs and 17 ICPs. RARs
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received transplants between 1965 and 1992 (mean duration
of transplant 10.8 years, range 1-26 years). Prior to 1984,
prednisolone and azathioprine were the main immunosup¬
pressive drugs used, but thereafter most patients received
prednisolone and cyclosporin A. ICPs all presented to the
Dermatology Department in Edinburgh Royal Infirmary for
treatment of viral warts or skin tumours. Most of these
patients were elderly with lesions on sun-exposed sites.
Tissue collection
One hundred and thirty-five and 68 cutaneous lesions were
collected from RARs and ICPs respectively. These included
56 SCCs and 62 IECs. Six millimetre punch biopsies of
normal (sun-exposed), forearm skin were also collected from
21 RARs and 12 ICPs. Biopsy samples were bisected longi¬
tudinally; half were placed immediately in PLPD (periodate-
lysine-paraformaldehyde-dichromate) (Holgate et a/., 1986),
or 10% formalin and fixed for 24 h at 4°C before paraffin
embedding. Histological assessment and immunohistochemi-
stry were carried out on sections prepared from paraffin-
embedded material. The other half were snap frozen in liquid
nitrogen and stored at — 70°C to await DNA extraction and
virological investigation.
DNA extraction and HPV detection
Frozen tissue was minced in lysis buffer (50 mM Tris, 50 mM
EDTA, 100 mM sodium chloride, 5 mM DTT, 1% SDS
1.5mgml_1 proteinase K) then incubated at 37°C overnight.
DNA extraction was carried out using a standard
phenol-chloroform extraction technique (Sambrook et al.,
1989). Two methods were employed to screen for the pre¬
sence of HPV DNA (Stark et al., 1994). Southern analysis,
using mixed HPV probes at low hybridisation (Tm — 40°C)
and washing stringency (Tm— 35°C), was used to detect com¬
mon cutaneous and epidermodysplasia verruciformis (EV)-
related types. The polymerase chain reaction (PCR) was used
to detect specific HPV types 1, 2, 5, 8, 6, 11, 16 and 18
(Arends et al., 1991; Stark et al., 1994).
Histopathology
The skin lesions were classified as follows: viral warts (VWs)
exhibited symmetry, papuliferous architecture and koilocytic
change; verrucous keratoses (VKs) displayed the architecture
of warts but lacked definitive cytological features of viral
infection; actinic keratoses (AKs) showed basal budding and
basal hypermelanosis (degrees of dysplasia were assessed in
both types of keratosis); intraepidermal carcinoma (IECs)
showed either full-thickness dysplasia or severe dysplasia and
acantholysis of the basal layer, invasive squamous cell car¬
cinoma (SCC) showed dermal invasion (Blessing et al., 1989).
Immunocytochemistry
Immunocytochemistry was performed on 3 pm sections of
PLPD- and formalin-fixed tissue using the mouse anti-p53
monoclonal antibodies MAb Do-7 (Vojtesek et al., 1992) and
PAb 1801 (Banks et al., 1986) and a standard ABC horse¬
radish peroxidase (HRP) technique (Dako, High Wycombe,
Bucks, UK) as previously described (Purdie et al., 1991).
Formalin-fixed tissue was treated with MAb Do-7 (1:100
dilution, overnight incubation) only, whereas PLPD-fixed
material was treated with MAb Do-7 and PAb 1801 (1:100
dilution, 1 h incubation). Each section was scored by two
independent observers and the extent of staining recorded on
the following graded scale: 1 = < 10%, 2 = 10-50% and
3 = > 50% of cells in a lesion showing positive nuclear stain¬
ing. Sections were recorded as positive when immune pre¬
cipitate was visible in > 10% of cells in the lesion, i.e. grades
2 and 3 only. Lesions with grade 1 score were considered to
be negative. The histological localisation of accumulated p53
within each lesion was also noted.
Single-strand conformational polymorphism (SSCP) analysis
and direct DNA sequencing
Twenty-eight tumour samples and 12 normal skin samples
from RARs and ICPs underwent SSCP analysis. PCR was
performed on 0.1-1 pg of genomic DNA using primers
specific for p53 exons 5, 6, 7 and 8. SSCP analysis was based
on the protocol of Cripps et al. (manuscript in preparation).
The 100 pi PCR reaction was purified using a standard
chloroform extraction technique. A 5-10 pi volume of the
purified product was alkali denatured (80 pM sodium hydrox¬
ide. 10 pM EDTA, at 48°C for 5 min), 10 pi of stop solution
added (10 mM EDTA, 0.1% bromophenol blue, 0.01%
xylene cyanol) and the whole sample loaded onto a 5%
glycerol, 0.5 x MDE Hydrolink gel. Following electro¬
phoresis (25°C, 20 W, for 2-3 h) the DNA was visualised by
silver staining (BioRad kit). SSCP mutations were detected as
bands of altered mobility. In one sample showing an exon 7
mutation by SSCP analysis, sequencing was performed using
the Sequenase (II) kit (United States Biochemical) with
cloned double-stranded DNA.
Results
Immunocytochemical demonstration of p53
Experiments were initially carried out to determine the
specificity and sensitivity of MAb Do-7 and PAb 1801 stain¬
ing in PLPD- and formalin-fixed material. No statistically
significant difference in the number of positive cases was
detected in formalin- or PLPD-fixed material (data not
shown), permitting results from both fixatives to be com¬
bined. In 74 lesions tested with both MAb Do-7 and PAb
1801 the number of positive cases was identical, and within
each section both antibodies reacted with similarly located
cells. Overall, MAb Do-7 gave a more intense precipitate
than PAb 1801, although some minor variation in intenstiy
occurred between assays.
Accumulated p53 in cutaneous lesions from RARs and ICPs
A total of 156 biopsies from RARs and 80 from ICPs were
screened for the presence of accumulated p53 using MAb
Do-7 (Table I, Figures 1 and 2). In both populations, over
50% of SCCs exhibited p53 immunoreactivity in >10% of
cells (grades 2 and 3). Overall, the number of lesions
exhibiting accumulated p53 and the grade of staining within
these lesions correlated positively with the degree of dysplasia
present. In RARs, significantly more IECs and SCCs demon¬
strated accumulated p53 than either uninvolved sun-exposed
skin (US) (r test, P<0.05) or VWs (f test, PCO.Ol). A
similar trend was revealed in ICPs, although a lower propor¬
tion of cases were stained positive for p53. However, the
differences between SCCs or IECs and US in ICP were not
statistically significant.
Distribution of accumulated p53
In both RARs and ICPs, immunostaining of lesions was
confined to nuclei of dysplastic epithelial cells and was most
Table I Prevalence of accumulated p53 in cutaneous lesions from
RAR and ICPs
No. of lesions (%) demonstrating accumulated p53"
Patients US VWs Ks IECs SCCs
RARs 5/21 (24)b 3/21 (14)' 17/41 (41) 22/34 (65)bc 22/39 (56)bc
ICPs 3/12 (25) 0/7 (0) 4/16 (25)15/28 (53) 9/17 (53)
"Sections with staining in >10% of nuclei in the lesion (grades 2 and
3) were scored as positive. RAR, renal allograft recipient: ICP,
immunocompetent patient: VW, viral wart; K, verrucous and actinic
keratosis; I EC, intraepidermal carcinoma; SCC, squamous cell car¬
cinoma; US, uninvolved, sun-exposed skin. bP<0.05 using f test.
'XO.OI using ■/} test.
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abundant in areas of severe dysplasia (Figure 2a). Within K
and IEC lesions, staining was generally strongest in basal
epithelial layers, particularly at sites of basal budding where
dysplastic changes were most severe (Figure 2a and b). This
was particularly notable in Ks exhibiting actinic features. In
dysplastic Ks and IECs, acantholysis and suprabasal clefting
were also observed to correlate with strong p53 staining. In
tissue sections that contained skin appendages, the specialised
lining cells were always negative and staining was confined to
the surrounding dysplastic cells (Figure 2c). While the
majority of SCCs showed accumulated p53, there was a
tendency for greater positivity to occur in less well-
differentiated lesions (Figure 2d) and adjacent normal epider¬
mis remained unstained. Occasionally, p53 was detected in
dysplastic basal cells and overlying IECs but not in con¬
tiguous tongues of invasive carcinoma. The positive staining
in non-lesional, sun-exposed skin was light in intensity and
predominantly basal in location in cells exhibiting only mild
dysplastic change.
HPV status and presence of accumulated p53
One hundred and twenty-six biopsies from RARs and 75
from ICPs were also screened for the presence of HPV DNA
using low-stringency Southern hybridisation with a cocktail
of HPV probes, and type-specific PCR for HPV types 1, 2, 5,
8, 6, 11, 16 and 18 (Table II). The details of these results are
reported elsewhere (Stark et al., 1994). Overall, no relation¬
ship was observed between the presence of accumulated p53
and HPV DNA in premalignant or malignant cutaneous
lesions from RARs or ICPs. The prevalences of the specific
HPV types 1, 2, 5, 8, 6, 11, 16 and 18 were also too low to
determine whether any correlation existed between these
HPV types and p53 immunoreactivity.
ICP Histology RAR
Figure 1 Extent of p53 staining in cutaneous lesions from RARs
and ICPs. Grade 1 ( W//A )= <10% of cells, grade 2 ( @83 ) =
10-50% of cells, grade 3 (■) = >50% of cells in a lesion
showing positive nuclear staining by immunocytochemistry; neg
( [Z3 ) = negative by immunocytochemistry; US, uninvolved, sun-
exposed skin; VW, viral wart; K, keratosis; IEC, intraepidermal
carcinoma; SCC, squamous cell carcinoma.
SSCP analysis ofp53 immunopositive and immunonegative
lesions
SSCP analysis of exons 5-8 of the p53 gene was performed
on 28 IECs/SCCs from RARs and ICPs. Fifteen of these
were immunopositive (grades 2 and 3) and 13 were immuno¬
negative (including seven with grade 1 staining) (Table III
and Figure 3). Overall, SSCP mutations (SSCPs) were
detected in 6/28 (21%) malignancies [3/15 (20%) SCCs and
3/13 (23%) IECs]. However, the incidence of mutation was
related to the grade of p53 positivity detected by immuno¬
cytochemistry with 5/9 (56%) grade 3, 1/6 (17%) grade 2 and
no grade 1 lesions showing SSCPs. Three of the SSCPs were
in exon 7 (all grade 3), two in exon 5 (one grade 3, the other
grade 2) and one in exon 8 (grade 3). In our series, no SSCPs
were detected in immunonegative cancers or matched normal
skin samples and there was no difference in the number of
SSCPs present in RARs and ICPs. Direct DNA sequencing
of one SCC with a SSCP mutation in exon 7 revealed a C-T
transition at codon 248 (Figure 3). SSCPs were detected in
Figure 2 Histological distribution of accumulated p53. a. Severely dysplastic keratosis (left) is associated with strong p53
immunostaining as compared with negative normal epidermis (right), b, p53 immunostaining is localised to the dysplastic basal cells
in actinic keratosis, c, Dysplastic basal cells are positive for p53 while the specialised cells in appendages are negative, d. Nuclear
localisation of p53 in an invasive squamous cell carcinoma from a RAR. p53 immunocytochemistry was performed using PAb
Do-7 and a standard ABC/horseradish peroxidase technique.
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Table II Correlation between presence of HPV DNA and accumulated
p53 in cutaneous lesions from RARs and ICPs
RARs ICPs
HPV+ HPV— HPV+ HPV—
Histology p53 + °' p53- p53 +" p53- p53 + ° p53— p53 +" p53-
US 0/3 3/3 5/16 11/16 1/1 0/1 2/11 9/11
VWs 1/10 9/10 0/5 5/5 1/5 4/5 1/1 0/1
Ks 4/10 6/10 6/19 13/19 0/3 3/3 3/H 8/11
lECs 8/12 4/12 13/20 7/20 2/4 2/4 13/24 11/24
SCCs 7/15 8/15 10/16 6/16 3/5 2/5 4/10 6/10
"Sections with staining in > 10% ofnuclei in the lesion (grade 2 and 3)
were scored as positive. RAR, renal allograft recipient; ICP,
immunocompetent patient; US, uninvolved, sun-exposed skin; VW,
viral wart; K, keratosis; I EC, intraepidermal carcinoma; SCC,
squamous cell carcinoma
Table III SSCP analysis of immunopositive and immunonegative
tumours from RARs and ICPs
No. of ICC positive and negative lesions
exhibiting SSCPs

























ICC, immunocytochemical; SSCPs, p53 mutations as detected by
SSCP analysis; grade 1, <10%, grade 2, 10-50%; grade 3, Ss 50% of
cells in a lesion showing positive nuclear staining; RAR, renal allograft
recipient; ICP, immunocompentent patient, SCC, squamous cell car¬
cinoma; IEC, intraepidermal carcinoma.
three HPV-positive malignancies and one HPV-negative
malignancy.
Exon 5 a Exon 5
Wt 16 Wt 36
Sample 1
G C A T
/ * *
Figure 3 a. Examples of SSCP mutations in exons 5 and 7 of
p53 in cutaneous malignancies from RARs and ICPs. Using
SSCP analysis, a single base change, such as a point mutation, is
visualised as a band of altered migration (as indicated by arrows)
in a polyacrylamide gel. Samples 1 and 16 = squamous cell
carcinomas from renal allograft recipients, both with grade 3
staining by immunocytochemistry (ICC); sample 36 = an intra¬
epidermal carcinoma from an immunocompetent patient with
grade 2 staining by ICC. b, Direct DNA sequencing of exon 7





p53 accumulation and progression in cutaneous carcinogenesis
In this study we have demonstrated the presence of accumu¬
lated p53 in over 50% of cutaneous SCCs from both RARs
and ICPs suggesting that p53 may play a role in skin car¬
cinogenesis in both populations. This detection level is in
broad agreement with previously reported results for SCC in
ICPs in which it has ranged from 15% to 56% of lesions
(Gusterson et a/., 1991; McGregor et al., 1992; Ro et al.,
1992). A striking feature of our study was the increase in
prevalence and extent of staining which occurred as lesions
progressed through the histological spectrum of neoplasia.
Indeed, there was a close correlation between the extent of
staining in these lesions and the severity of dysplasia. These
results strongly suggest that in skin carcinogenesis, in both
RARs and ICPs, accumulation of p53 represents an impor¬
tant step in malignant progression. This hypothesis is sup¬
ported by recent studies of skin carcinogenesis in p53 null
mice, in which inactivation of p53 specifically associates with
progression of benign papillomas to SCCs (Kemp et al.,
1993). It is important to note, however, that the occurrence
of p53 immunoreactivity does not always equate with ac¬
quisition of the malignant state since in ICPs accumulated
p53 can be demonstrated in solar keratoses, of which only a
small proportion progress to invasive carcinoma (Marks et
al., 1986). Clearly, other genetic events must contribute to the
development of invasive skin malignancies. In this context it
is also of interest that we found a small number of SCCs
showing p53 staining in superficial dysplastic epidermis and
adjacent areas of IEC but not in contiguous tongues of
invasive SCC. One possible explanation for this may be that
gross chromosomal deletions, involving 17p, have occurred in
more invasive malignant elements, abolishing all p53 gene
expression.
HPV and p53 in cutaneous lesions from RARs and ICPs
E6 oncoproteins from HPV types 16 and 18 can bind to and
induce rapid degradation of wild-type p53 (Scheffner et al.,
1990; Werness et al., 1990). From observations in anogenital
cancers it has been proposed that p53 inactivation occurs
either by complexing of wild-type p53 with such viral onco¬
proteins or, in the absence of virus, by mutational loss of
gene function (Crook et al., 1991, 1992; Scheffner et al., 1991,
1992). This concept, however, remains controversial, and
other workers have failed to confirm these suggestions
(Busby-Earle et al., 1993; Cooper et al., 1993). We have
recently reported the prevalence of HPV in cutaneous lesions
from RARs (Stark et al., 1994) and suggested that the
mechanism by which HPV contributes to skin carcinogenesis
may differ from that proposed for anogenital cancer. The
present study confirms our previous findings in that we have
failed to demonstrate any relationship between the presence
or absence of HPV DNA and accumulated p53 in dysplastic
or frankly malignant skin lesions from RARs or ICPs.
Moreover, p53 mutations were detected by SSCP analysis in
both HPV-positive and -negative malignancies. Recently, it
has also been demonstrated that the E6 oncoprotein from
skin-associated HPV type 8 does not bind to p53, unlike its
HPV 16 or 18 equivalent (Steger & Pfister, 1992). Therefore,
if HPV is involved in cutaneous carcinogenesis, it must be
presumed to act by a different mechanism from that found in
anogenital cancer.
p53 mutations in cutaneous carcinogenesis
In this study SSCP analysis was used to demonstrate muta¬
tions in the p53 gene. Although the precise sensitivity of this
technique is presently unknown, a recent study in our
laboratory involving human colorectal cancer, in which both
SSCP analysis and direct sequencing were performed, indi-
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cates that approximately 80% of p53 mutations can be de¬
tected by SSCP analysis (Cripps el al., manuscript in
preparation). The detection of p53 mutations in 21% of
SCCs/IECs in our series is in agreement with previous
reports for cutaneous cancer (Pierceall et al., 1991; Ro et al.,
1992; Campbell et al., 1993a, b). With one exception, these
mutations occurred in exons 5 and 7, in keeping with the
suggestion that these exons contain mutational hotspots for
most human malignancies (Brash et al., 1991; Hollstein et al.,
1991; Pierceall et al., 1991; Campbell et al., 1993a; Levine,
1993). Molecular analysis of p53 mutations has previously
suggested that the pattern of nucleotide alterations may be
tissue dependent and related to the type of mutagenic agent
involved (Harris, 1991; Vogelstein & Kinzler, 1992). For
instance, CC to TT double-base changes are almost exclus¬
ively associated with UV-induced DNA damage (Brash et al.,
1991). It is of interest, therefore, that the SCC in our series
that was sequenced was found to contain a C-T transition at
the codon 248 mutational hotspot, implicating UV radiation
in its genesis.
p53 immunocytochemical detection and gene mutations
Immunocytochemistry has been proposed as a rapid and
simple means of identification of p53 gene mutations. In the
majority of tumours, good correlation has been observed
between the presence of immunocytochemically stable p53
and gene mutations determined by sequencing or other
methods (Gannon et al., 1990; Iggo et al., 1990; Bodner et
al., 1992). However, it is also recognised that immuno¬
cytochemically detectable levels of wild-type p53 may occur
in response to DNA injury, and that some p53 mutations do
not result in immunocytochemical demonstration of p53 pro¬
tein (Bodner et al., 1992; Oliner et al., 1992; Wynford-
Thomas, 1992; Hall et al., 1993, Lane, 1993). In this study,
SSCP analysis of exons 5-8 detected mutations in 6/15
(40%) immunopositive malignancies, with most mutations
occurring in tumours with the largest number of positive cells
(grade 3 lesions). This indicates that immunocytochemical
detection of p53 does not always signify the presence of p53
gene mutations in skin cancers, particularly where there are
relatively few positive cells. While the possibility remains that
mutations may have occurred in exons other than 5-8, our
own experience and that of others studying other common
cancers suggests that this is likely to account for only a small
proportion of cases. This implies that additional factors may
contribute to the accumulation of p53 during the develop¬
ment of at least some skin cancers. Recently, the product of
the mdm-2 gene, which is overexpressed in osteosarcomas,
has been shown to bind to and inactivate p53 (Momand et
al., 1992; Oliner et al., 1992). It is possible that similar
proteins may be present in transformed epidermal cells, com-
plexing with wild-type p53 and rendering it detectable by
immunocytochemical methods. The identity of such proteins
and their role in the accumulation of p53 and subsequent
development of skin cancer remain to be established.
We would like to thank the Scottish Home and Health Department
for funding this research, Robert Morris and John Lauder for tech¬
nical advice and Jill Bubb and Andrew Wyllie for useful discus¬
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